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In this PhD thesis, I investigate the importance of inflammatory cytokines for activation 
of adrenal activity, and couple this with the use of a novel microdialysis system to assess the 
response of the hypothalamic-pituitary-adrenal axis in children undergoing cardiac surgery. 
The thesis is structured in three parts. 
 
Following the recent demonstration that there is an increased sensitivity of the adrenal 
cortex to ACTH in adults undergoing cardiac surgery, I investigated whether this could be 
mediated by cytokines. In the first part of my thesis, I describe a novel co-culture model to 
investigate the local, immune-adrenal crosstalk and its impact on steroidogenesis. I 
demonstrate that in the adrenocortical cell line ATC-7 the expression of pro-inflammatory 
cytokines after LPS stimulation is dependent on the ratio of adrenal and immune cells, that the 
presence of immune cells can modulate steroidogenesis and that this interaction can be further 
modulated by ACTH stimulation. In the second part, I discuss the current evidence and 
knowledge gaps behind the practice of glucocorticoid administration in paediatric heart 
surgery. I also report the results of a national survey showing a considerable variation in 
glucocorticoid administration within and between units.  
 
The above findings set the scene for the third part of this dissertation, that reports a 
study protocol for the basic understanding of the HPA axis function in children undergoing 
paediatric heart surgery the - Peacock Study. By using our novel automated tissue microdialysis 
system, I successfully measured tissue cortisol and cortisone levels in children of various ages 
without reducing their circulating blood volume. I also report the preliminary results of the 
study on 36 children undergoing surgery or catheter procedures. Firstly, I demonstrate that 
cortisol secretion in children is secreted with a pulsatile pattern, suggesting single-point cortisol 
testing is obsolete. Furthermore, I found marked changes in the perioperative cortisol to 
cortisone ratio. Neonates had a distinct response in that they had lower cortisol to cortisone 
rations presumably related to differential 11 β-HSD isoenzymes activities. Also, I show that 
the release of CBG and cytokines is dependent on the age of the child, the type of procedure 
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8 CHAPTER 1 INTRODUCTION 
 
 ‘‘Constancy and stability of the internal environment 
 is the condition that life should be free and independent’’  
Claude Bernard  
 
8.1 The stress response – a brief historical note 
The concept of biological stress is undoubtedly related to the name of the so-called 
three “old masters”. The first one is the famous physiologist,  Claude Bernard (1813-1878) 
who introduced the concept of the ability of the human organism to maintain a constant internal 
environment (“milieu interieur”) independent of the external challenges (Le Moal 2007; 
Goldstein and Kopin 2007). Later, Walter Cannon (1871-1945) introduced the concept of 
“homeostasis” that described the capability of the human body to maintain its function within 
acceptable physiological ranges. He is also known for the so-called “fight or flight” response 
and advocated the activation of the sympathetic nervous system to control the adrenal response 
during stress to restore homeostasis. However, the concept of biological stress was introduced 
by Hans Selye (1907-1982). He used the term “stress” adapted from the Physics field, where 
this describes the force necessary to produce a deformity within a material. He advocated the 
concept of the nonspecificity of the stress response and described the three stages of the 
“General Adaptation Syndrome”: the initial alarm phase, the stage of adaptation and the 
exhaustion phase. In his experimental work, he found a pathological triad of adrenal 
enlargement, atrophy of the lymphoid tissue in thymus and spleen, and gastrointestinal ulcers 
as a result of injection animals with a variety tissue extracts or formalin. Later, he demonstrated 
that these changes are related to the activation of the hypothalamic-pituitary-adrenocortical 




The current, modern, concepts of stress challenge the non-specificity of the stress 
response and argue that there is a degree of specificity depending on the challenge to the 
homeostasis. Furthermore, the concept of “allostasis” was proposed to replace 
“homeostasis”(McEwen 1998). This concept refutes homeostasis, which suggests constancy of 
values and ranges during stress, and broadly refers to an adaptative process to maintain 
homeostasis. There is now an increased understanding of the impact of psychobiology and 
psychosocial factors on the mechanism of stress during disease (Le Moal 2007).  
My PhD thesis is aimed at understanding the HPA axis physiology by using the stress 
model of paediatric heart surgery.  
 
8.2 The stress of cardiac surgery  
 
In the third chapter of my thesis, I study the paediatric HPA axis function using the stress model 
of paediatric heart surgery. Certainly, cardiac surgery is a major stressor of the body. Firstly, 
anaesthesia itself requires sedation and intubation of the patient. Further stress is added in the 
anaesthetic room by obtaining intravenous access, arterial access (for invasive blood pressure 
monitoring) and central venous access. To access the heart, a sternotomy is usually performed 
that involves the division of the bony chest wall and retraction of the musculoskeletal tissues. 
Furthermore, to perform open-heart surgery, the patient is attached to the cardiopulmonary by-
pass system that is essentially a non-self-extracorporeal circuit that further exacerbates the 
stress response. At times, the circulation is completely stopped (deep hypothermic circulatory 
arrest) to perform certain operative steps. The duration of the cardiopulmonary by-pass and the 
by-pass temperature are other determinants of the magnitude of the stress response. In the 
postoperative period, the extubation time or other complications such as bleeding or infection 




in low weight babies and operations with a long CPB runs, results in haemodilution and 
pulmonary oedema with ultimately organ dysfunction. 
 
8.3 The systemic inflammatory response to cardiac surgery  
 
Similar to adult cardiac surgery, the combination of anaesthesia, the access to the heart 
(sternotomy) and use of the CPB evoke a systemic inflammatory response that contributes to 
the HPA axis activation (Brix-Christensen 2001). According to in vivo studies (Brix-
Christensen et al. 2001), the sternotomy itself elicits inflammatory stress; however, the addition 
of the cardiopulmonary by-pass increases the magnitude of the inflammatory reaction. By 
extrapolation to adult cardiac surgery, a patient undergoing off-pump coronary artery bypass 
grafting has a lower inflammatory response than a patient undergoing coronary artery surgery 
with the use of CPB (Ascione et al. 2000).  The extracorporeal circuit contributes to the 
systemic inflammatory response by (1) immune cell activation in contact with the circuit, (2) 
mechanical shear stress, (3) haemodilution and (4) hypothermia. Furthermore, this reaction is 
augmented in children due to the disparity between the surface of the circuit and the surface of 
the circulatory system. This results in a greater proportion of blood coming into contact with 
the circuit or cardiotomy suction. Therefore, the systemic activation of immune cells such as 
polymorphonuclear cells or platelets results in the production of cytokines. The cytokine 
production is further exacerbated by the ischaemia-reperfusion injury of key organs that are 
essentially turned off during cardiopulmonary (mainly the heart and the lungs) that results in 
endothelial activation. Finally, the cardiopulmonary by-pass circuit also results in significant 
complement activation (C3a, C3d, C5a) that simulates both the endothelial activation and the 
activation of the immune cells.  It is believed that the balance between the production of pro-




antagonist) influences the outcomes after cardiac surgery. In addition to these systemic 
activations, it is believed that a great deal of mortality and morbidity also results from 
multiorgan dysfunction (heart, lung, kidneys, brain) that results from pooling/accumulation of 
activated immune cells within these organs (Brix-Christensen 2001; Laffey, Boylan, and 
Cheng 2002).  
 
8.4 Key receptors and inflammatory cell signalling pathways.    
 
As discussed earlier, the systemic inflammatory response results from cellular 
activation by the by-pass activations that promote further inflammation by the production of 
cytokines and chemokines.  
One class of receptors that are activated during this systemic inflammation are the 
germline-encoded pattern-recognition receptors (PRRs) that are expressed in both immune and 
non-immune cells. One class of PRRs are the Toll-like receptors (TLRs) for examples. Some 
of PRRs are capable of recognising disrupted or damaged cells called danger-associated 
molecular patterns (DAMPS) in the absence of microbial structures (Chen et al. 2018). Further 
inflammation signalling also occurs via the various specific cytokine receptors. The major pro-
inflammatory cytokines (IL-1, IL-6, TNFα) signal via type I transmembrane cytokine receptors 
with specific structures (Turner et al. 2014).  
Receptor activation triggers activation of three main intracellular signalling pathways: 
(1) the mitogen-activated protein kinase (MAPK), (2) nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), (3) Janus kinase (JAK)- signal transducer and activator 
of transcription (STAT) pathways.  
The MAPK pathway is activated by various cellular stressors and various cytokines 




expression of inflammatory cytokines. The JAK-STAT pathway is activated by IL-6, leading 
to activation of other cytokines (Chen et al. 2018).  
Of importance to the in vitro inflammatory stress model described in the first chapter 
of my thesis is the LPS/TLR4 signal transduction pathway (Figure 1). Briefly, the LPS is an 
essential structure of gram-negative bacterial all. As discussed earlier, the TLRs are expressed 
by cells of the innate immune systems that are capable of recognising structural motifs 
expressed by bacteria, viruses or fungi called pathogen-associated molecular patterns 
(PAMPs).  
LPS activation of various mammalian cells occurs via complex extracellular and 
intracellular interactions. Firstly, the LPS binds to the LPS binding protein (LBP), a shuttle 
protein, that facilitates the associated between the LPS and cluster of differentiation 14 (CD14). 
CD-14 is a glycosylphosphatidylinositol-anchored protein that helps the transfer of the LPS to 
the TLR4/MD-2 receptor complex and facilitates its recognition. Downstream, the TLR4 
signalling pathway occurs via a myeloid differentiation primary response 88 (MyD88)-
dependent and MyD88-independent pathways [TIR-domain-containing adapter-inducing 
interferon-β (TRIF) dependent]. The MyD88 dependent pathway activates the interleukin-1 
receptor (IL-1R) associated kinase (IRAK) (IRAKs)/ TNF receptor-associated factor (TRAF) 
6 as well as the transcription factors NF-κB, activator protein 1 (AP-1) and interferon 
regulatory factor 5 (IRF-5) further downstream and induce the expression of pro-inflammatory 
cytokine genes. The MyD88 independent pathway involves signalling via Type I interferons 
that recruit TRAF3 and receptor-interacting protein 1 (RIP1) to activate transcription factor 






















8.5 The HPA axis: basic control mechanisms  
 
The human body’s acute stress response comprises sympathetic nervous system 
activation, an endocrine response and an immunological and haematological reaction 
(Desborough 2000). The hypothalamic-pituitary-adrenal (HPA) axis regulates the primary 
neuroendocrine response that is activated to produce glucocorticoids (corticosterone in rodents 
and cortisol in humans) for adequate homeostatic regulation (Spiga et al. 2014). The stressors 
are integrated by the brain stem and limbic areas, and inputs to the hypothalamic 
paraventricular nucleus are thus generated. The paraventricular nucleus (PVN) projects to the 
median eminence where corticotropin realising hormone is produced. The corticotropin-
releasing hormone (CRH) then reaches the anterior pituitary via the portal circulation to 
activate the adrenocorticotrophic hormone (ACTH) secretion in the venous circulation. The 
ACTH activates both the production and release of cortisol from the zona fasciculata of the 
adrenal gland cortex (Spiga et al. 2014; B. Gibbison, Angelini, and Lightman 2013) (Figure 2). 
Within the HPA axis, there is a negative feedback control exerted by cortisol at the pituitary 
and hypothalamic level. Therefore, cortisol regulates its own production by inhibition of the 
production and release of the ACTH from the anterior pituitary and inhibition of the CRH by 
direct action on the PVN and other hippocampal structures that modulate the PVN (amygdala 












Figure 2.  HPA axis control 
 
8.6 Adrenal steroidogenesis  
Due to their lipophilic nature, glucocorticoids cannot be stored in granules and need to 
be synthesised de novo in the adrenal cortex in response to ACTH stimulation (Figure 3). 
Binding of ACTH to its specific receptor, the melanocortin type-2 receptor (MC2R) leads to 
activation of the protein kinase A (PKA) pathway, which, in turn, results in the secretion of 
glucocorticoid as well as steroidogenic gene expression, via non-genomic and genomic 
pathway, respectively (reviewed in (Miller and Auchus 2011)). While the non-genomic 
pathway includes the phosphorylation, thus activation, of steroidogenic proteins including the 
rate-limiting protein steroidogenic acute regulatory protein (StAR) (Arakane et al. 1997; 
Stocco and Clark 1996; Strauss et al. 1999), the genomic pathway regulates the transcription 
of steroidogenic proteins and its transcriptional regulators. This includes transcription of the 




a protein that regulates MC2R expression (Metherell et al. 2005) as well as the orphan nuclear 
receptor – steroidogenic factor (SF-1) (Sugawara et al. 1996) and the transcriptional inhibitor  
(the dosage-sensitive sex reversal, adrenal hypoplasia congenital critical region on the X 
chromosome, gene 1) DAX-1 (Zazopoulos et al. 1997; Iyer and McCabe 2004) (Figure 3). This 
brief overview is necessary because in Chapter 2 of the thesis I will explore the effect of LPS 
stimulation on both the inflammatory pathway and steroidogenic pathway in isolated adrenal 
cells or adrenal cells co-incubated with immune cells.   
 
Figure 3 Adrenal Steroidogenesis (Adapted from F. Spiga et al.) 
 
 
8.7 The glucocorticoid receptor and its development  
Glucocorticoids exert their physiological and pharmacological effects by acting on the 
glucocorticoid receptor. The glucocorticoid receptor (GR) is a member of the nuclear receptor 
superfamily of ligand-dependant transcription factors (Oakley and Cidlowski 2013). Due to its 
lyophilic nature, cortisol traverses the cell membrane and binds to the GR complex. This 
complex is made up of the GR receptor in combination with heat shock protein 90 and p23 that 




recycled while the Cortisol-GR complex dimerises and is to be transported in the nucleus via 
nuclear pore special complex. At the nuclear level, the activated GR binds to the glucocorticoid 
responsive elements (GRE) of the DNA to control transcription. In some cells, the membrane-
bound GR (mGR) exerts its effects via non-genomic pathway (Figure 4) (B. Gibbison, 
Angelini, and Lightman 2013).  
The GR receptor is expressed in almost all tissues. In adults, the GR effect can vary 
considerably in the different tissues of and an individual (Oakley and Cidlowski 2013). A 
pertinent question to my thesis is how the GR receptor expression develops by age, and how 
does this affect the physiological and pharmacological actions of steroids give to children of 
various ages?  
The development of the GR receptor has been studied extensively in the brain. In vitro 
studies by Meaney et al. (Meaney, Sapolsky, and McEwen 1985) have shown low levels of the 
GR receptor in brain rat cells perinatally with an increase in the levels at the end of the first 
week of life that paralleled the increase of the circulating corticosterone. This suggests a lack 
of GR autoregulation that is seen in adults where increases in corticosterone levels result in a 
decrease in the GR receptor.  
Glucocorticoids have a significant role in the development of several tissues apart from 
the brain such as the lung, intestine, neural retina or the HPA axis. It has been shown that the 
GR receptor is present in the above tissues in the fetus but only at a minimal level. However, 
there is a general agreement that adult GR receptor levels are reached between 5 and 15 
postnatal days (Kalimi 1984). Therefore, we to keep in mind that the differential expression of 









Figure 4 Glucocorticoid signal transduction via GR (From (B. Gibbison, Angelini, 










8.8 1.1 Cortisol regulation at the tissue level: the role of the 11 β-hydroxysteroid 
dehydrogenases 
 
Apart from the regulation of the glucocorticoid actions in the target tissues by the density 
of GR receptor, an important role is played by the intracellular metabolism of cortisol at tissue 
level (Chapman, Holmes, and Seckl 2013). The crucial regulators are the two isoenzymes of 










Figure 5 The 11β-hydroxysteroid dehydrogenase type 1 and 2 action (from Chapman 




The 11β-HSD1 is a reductase that catalyses the regeneration of active cortisol. It is widely 
expressed in liver, adipose tissue, muscle, pancreatic islets, adult brain, inflammatory cells 
(mainly macrophages), and gonads. The expression is highest in the liver. Interestingly the 11β-
HSD1 is expressed late in gestation mainly in liver and lung where the glucocorticoid action is 
required for maturation of these organs. In the context of inflammation/immunity, the 11β-
HSD1 is highly expressed in macrophages activated by LPS as compared to the monocytes 
(undifferentiated cells) where levels are quite low (Chapman, Holmes, and Seckl 2013). Hence, 
in the context of systemic activation of the immune cells, the 11β-HSD1 can exert a pro-
inflammatory effect.  
The 11 β-HSD2 is a dehydrogenase that inactivates the cortisol to inert cortisone. In 
contrast to 11β-HSD1, the 11 β-HSD2 is not expressed in immune cells except in some human 
rheumatological conditions such as rheumatoid arthritis. The expression of the 11 β-HSD2 in 
the kidney, inactivates cortisol to cortisone and ensures that the only agonist of the MR receptor 
is aldosterone (see the relevance in the Discussion chapter 11.6.14). The 11 β-HSD2 is highly 
expressed in the fetal and placental tissues where the glucocorticoid inactivation essentially 
prevents the premature maturation of the fetal tissues and protects against developmental 







1 During foetal development the environmental influences can shape the developing organism structure 
and function in such a manner that these effects persists for the lifespan. In the context of the maternal stress 
model discussed above, early exposure of the foetus to maternal glucocorticoids can influence the prevalence of 




8.9 HPA axis rhythms 
 
HPA axis pulsatility is present in various species studied to date, including the: rat, 
monkey, hamsters, horse, sheep, goat and human (Stafford L. Lightman et al. 2008). The 
secretion of ACTH and cortisol display a dynamic, circadian pattern. Underlying the circadian 
rhythm, there is an ultradian rhythm of fine pulses (Figure 6). Studies by our group have 
demonstrated that the feedforward - feedback in the pituitary-adrenal system is enough to 
produce the oscillations of the ultradian rhythm. (Walker, Terry, and Lightman 2010). 
Further forcing by the SCN above superimposes the circadian rhythm on top of this. 
Thus, the highs of the circadian rhythm are produced by large-amplitude pulses and the lows 
by little or no pulsatility.  Hormone pulsatility is necessary for accurate regulation of target 
genes by the glucocorticoid receptor (GR) (Conway-Campbell et al. 2010; Stavreva et al. 
2009). It has been shown that circadian and ultradian rhythms show variation according to sex 
(Seale et al. 2004), genetic background (R. J. Windle et al. 1998), age (S L Lightman et al. 
2000) and reproductive cycle (Richard J. Windle et al. 2013). Furthermore, rats exposed to 
early stress during neonatal period display a change in their pulsatility in adult life, a 
phenomenon called neonatal programming (Shanks et al. 2000).  During disease, changes in 
pulsatility were demonstrated in models of chronic stress in the rat (R. J. Windle et al. 2001; 







8.10 The ACTH-Cortisol Dissociation  
 
According to this “traditional” model, any increase in ACTH secretion to acute stress 
would result in concomitant increase cortisol. However, during surgery and critical illness, a 
so-called “ACTH-cortisol dissociation” occurs (Boonen, Bornstein, and Van den Berghe 
2015). After the stress stimulus (surgery) there is an initial rise in ACTH followed by cortisol 
increase, then, the ACTH falls, but the cortisol remains elevated. This finding is a matter of 
debate and can be explained by several mechanisms (Figure 7) including altered cortisol 
metabolism (Boonen et al. 2013), saturation of CBG (Roth-Isigkeit, Dibbelt, and Schmucker 
2000; Wald et al. 2011b), splanchnic nerve activity (Ulrich-Lai, Arnhold, and Engeland 2006) 
increased sensitivity of the adrenal cortex to ACTH (Ben Gibbison et al. 2015) and local, 
adrenal “tissue” mechanisms (Boonen, Bornstein, and Van den Berghe 2015).  
Figure 6 Profiles of serum cortisol concentrations (nmol/L) in a healthy volunteer. Rapid 
(10-minute) automated sampling demonstrates the circadian profile and the underlying 
ultradian rhythm (from Henley, D. E., Leendertz, J. A., Russell, G. M., Wood, S. A., 
Taheri, S., Woltersdorf, W. W., & Lightman, S. L. (2009). Development of an automated 
blood sampling system for use in humans. Journal of Medical Engineering and 





Figure 7 ACTH-Cortisol dissociation factors 
 
To support the concept of an adrenal, local inflammatory mechanism responsible for 
this so-called dissociation, the systemic intravenous injection of LPS in the rat reproduces the 
ACTH-cortisol dissociation observed in adults undergoing heart surgery. This is opposed to 
the finding that an ACTH subcutaneous injection in the rat results in a return of both cortisol 
and ACTH to basal  (Ben Gibbison et al. 2015).  
 
8.11 Cortisol binding globulin 
 
Cortisol is relatively insoluble in plasma; hence, most of the hormone in the plasma is 
bound to its main protein carrier - cortisol binding globulin (CBG). CBG is mainly produced 
in the liver but also in the lung, kidney and testis (Hammond et al. 1990). The binding capacity 
of CBG is finite, and in adults, it occurs at cortisol levels of approximately 400-500 nmol per 




Cortisol levels that exceed this threshold result in a disproportionate amount of free 
cortisol and any pulses that exceed this level lead to large swings of free active cortisol. 
Furthermore, the CBG’s affinity to cortisol can be affected by temperature (Cameron et al. 
2010; D.E. Henley and Lightman 2011) and neutrophil activity (Hammond et al. 1990). 
Granulocytes from septic patients incubated with CBG destroy the steroid-binding activity 
(Hammond et al. 1990), and fever or external temperatures releases cortisol from CBG 
(Cameron et al. 2010; D.E. Henley and Lightman 2011). All these findings suggest that cortisol 
delivery can be increased in areas of inflammation because of reduced affinity for CBG. 
Cameron et al. used recombinant human CBG to assess the binding to cortisol depending on 
temperature and pH. At 37 C degrees for example, the fall of pH from 7.4 to 6.8 does not 
modify the binding affinity of cortisol  to CBG however it does affect the binding of cortisol 
to other protein such as albumin (Cameron et al. 2010; D.E. Henley and Lightman 
2011).Therefore, CBG is both a reservoir and regulator of cortisol (B. Gibbison, Angelini, and 















8.12 Cortisol pulsatility during adult cardiac surgery – Gibbison et al. studies  
 
Gibbison et al. (Ben Gibbison et al. 2015) characterised the pulsatile nature of ACTH 
and cortisol during and after cardiac surgery (coronary artery by-pass grafting - CABG) in 
adults by using blood measurements every 10 minutes. Then, the authors used a translational 
rat model where they have replicated the same ACTH/cortisol pattern after LPS injection and 
looked at the changes in the adrenal steroidogenic pathway.   The main findings of the study 
were (1) maintenance of ACTH-cortisol ultradian pulsatility across the entire peri-operative 
period and (2) increased adrenal sensitivity to ACTH (Figure 8). This maintenance of ACTH-
cortisol pulsatility is contrary to previous studies that advocate a dissociation (Vermes et al. 
1995; Mackie et al. 2011; Roth-Isigkeit, Dibbelt, and Schmucker 2000).   
   
 
8.13 Justification of my three lines of research 
This PhD thesis is built around three main lines of investigation (Figure 9). The first 
direction was to try to understand the local adrenal mechanisms responsible for the ACTH-
cortisol dissociation. This led us to develop a novel co-incubation model to explore the 
Figure 8 Twenty-four-hour cortisol profile of a patient undergoing CABG (from 




immune-adrenal cross talk (Chapter II). Building from the adult cortisol studies, the second 
line of research was aimed at understanding the basic HPA axis response in children 
undergoing heart surgery (Chapter III and IV). Why study the HPA axis function in children? 
The interest in this area of research resulted from how little we know about the paediatric stress 
response. This limited understanding of paediatric HPA axis physiology is undoubtedly 
reflected in a lack of consensus around the use of synthetic glucocorticoids administered 
perioperatively. Therefore, a significant part of my PhD was dedicated to understanding the 
evidence for giving glucocorticoids perioperatively (Chapter III). Finally, I focused on trying 
to understand the basic stress response in children by using a novel approach that allows 
recording the dynamic HPA function during and after surgery (The Peacock Study) (Part IV).  
 
 













9 CHAPTER 2 THE ROLE OF THE IMMUNE-ADRENAL CROSS 
TALK DURING INFLAMMATORY STRESS 
 
“The body is a community made up of its innumerable cells or inhabitants.” 
Thomas A Edison 
9.1 Introduction  
 
9.1.1 The immune-adrenal crosstalk 
As discussed in chapter 1, one of the aims of my research was to understand how the 
local adrenal mechanisms affect intraadrenal cytokine expression and the activation of the 
steroidogenic pathway during inflammatory stress. As seen later, I focus initially on 
understanding the response of isolated on adrenal cells to inflammatory stress (LPS 
stimulation) and then I further hypothesise that an immune-adrenal cross talk can occur. By 
using a co-culture model, I explore the cellular interaction between the adrenal cells and the 
surrounding immune cells (Figure 10). This cross-talk can occur via cytokines produced by 
adrenal cells themselves or by the neighbouring immune cells to regulate steroidogenesis 
(Bornstein, Rutkowski, and Vrezas 2004). The above hypotheses are supported by several 
studies. In an in vivo study in rats, lipopolysaccharide infusion induced systemic inflammation 
that was accompanied by infiltration of leukocytes in the adrenal gland (Kanczkowski, 
Chatzigeorgiou, et al. 2013). In a model of sepsis, induced by caecal ligation and puncture in 
mice, the non-survivors had a significant increase of interleukin-6 (IL-6), interleukin-1β (IL-
1β), and tumour necrosis factor-α (TNFα) in adrenal protein extracts (Jennewein et al. 2016). 
It is also possible that the local modulation of the adrenocortical cell function can occur 




including lipopolysaccharide (LPS), and that are expressed in adrenocortical cells (Bornstein 
et al. 2004), or via circulating cytokines activating the adrenal cytokine receptors. However, it 
remains unclear if the plasma level of immune-derived cytokines is high enough to regulate 
directly the adrenocortical steroidogenesis or if they have to be locally, intra-adrenally secreted 
(Ehrhart-Bornstein et al. 1998). 
Nevertheless, the adrenal cells produce a variety of cytokines such as IL-1, interferon-
gamma inducing factor (IGIF), IL-6 and TNFα. Moreover, steroidogenesis has been shown to 
be influenced directly by IL-1α, IL-1β, interleukin IL-2, IL-6, TNFα, interferon-alpha (IFNα) 
in several in vitro experiments (Ehrhart-Bornstein et al. 1998). A previous study using primary 
cultures of human adrenocortical cells co-cultured with human monocytes has shown a 
significant increase in cortisol production by the adrenal cells. In this study, the monocyte 
induced cortisol increase was much higher compared to the direct IL-1 stimulation (Whitcomb 
et al. 1988).  





9.1.2 Development of the ATC7-THP1 cells model 
 
During my in-vitro project, a great deal of effort was invested in trying to obtain a 
significant expression of pro-inflammatory cytokines in immortalised adrenal cells 
(adrenocortical tumour cell lines - ATC cells). This lack of success made me understand that 
the adrenal response might be dependent on the presence and activation of immune cells. 
Therefore, the current thesis describes a novel co-incubation model of ATC with complete zona 
fasciculata (ZF) cell phenotype (Ragazzon et al. 2006; Hazell et al. 2019) and macrophage-
derived from THP1 monocytes (a human monocytic cell line derived from an acute monocytic 
leukaemia patient) (Tsuchiya et al. 1980). Using this model, I explored the effects of an 
immunological stimulus (lipopolysaccharide, LPS) on the expression of the pro-inflammatory 
cytokine IL-6, as well as the expression of genes involved in steroidogenesis in ATC7 cells, 
both in basal conditions and under ACTH stimulation. Synthetic glucocorticoids are still widely 
used in clinical practice to modulate the immune and adrenal response to acute stress observed 
during sepsis or surgery, however, their use and mechanism of action remain a matter of intense 
debate in this setting (D. P. Fudulu, Schadenberg, et al. 2018; D. P. Fudulu, Gibbison, et al. 
2018; D. P. Fudulu, Lightman, et al. 2018).   Therefore, in this study, I also investigated the 
temporal effects of glucocorticoid treatment on ATC7 cells responses to LPS (see the section 
below). 
 
9.1.3 The bimodal effect of glucocorticoids 
 
Glucocorticoids are well known for their anti-inflammatory effects, but less well known 
are their possible proinflammatory effects initially suggested by Ingle in 1952 and Selye in 




Since the ‘80s a bimodal, permissive-suppressive model (Figure 11) is being researched and 
advocated by several groups (Yeager, Guyre, and Munck 2004; Yeager et al. 2016; 2009; 
Sapolsky, Romero, and Munck 2000). These antagonistic effects seem to be influenced by the 
temporal relation between the inflammatory insult and glucocorticoid exposure. According to 
this model, at basal concentrations, in the absence of a stressor, glucocorticoids are permissive 
by supporting the metabolic and inflammatory processes. The absence of this activity leads to 
the well-known Addisonian crisis. However, when glucocorticoids are present in higher 
concentration, in the context of concurrent exposure to stress stimulus, they exert an anti-
inflammatory action by preventing the damaging effect of excessive inflammation. 
Interestingly, when there is exposure to a high concentration of glucocorticoids that is followed 
by no stimulation and return of glucocorticoid levels to normal, preparatory effects are noticed. 
These changes are phenotypic and transcriptional and were noted in immunocompetent cells 
(Yeager et al. 2016). Subsequent exposure to inflammatory exposure results in a pro-
inflammatory effect that is meant to increase the organism resistance to subsequent injury.  
 
Figure 11 Pro-anti-inflammatory model (adapted from Yeager et al. 2016) 
 
For example, Johnson et al. (Johnson et al. 2002) showed that prior exposure of rats to 
inescapable tail shock followed by LPS injection resulted in a more rapid and pronounced 
expression of the inflammatory cytokines compared to the non-stressed rats and this 
phenomenon was demonstrated to be GR dependent since adrenalectomy or GR receptor 





9.2 Hypothesis and aims 
 
The starting point of this work was to explore the local adrenal mechanisms responsible 
for the increased adrenal sensitivity to ACTH demonstrated by Gibbison et al. (Ben Gibbison 
et al. 2015) The initial focus was to use isolated adrenal cells (ATC7 cells) that were exposed 
to inflammatory stress to study the expression of adrenal inflammatory cytokines and the 
impact on steroidogenesis. Besides, I have also tried to test if glucocorticoids have a bimodal 
effect (e.g. pro- and anti-inflammatory) on isolated adrenal cells.  However, despite much 
effort, I could not induce a significant expression of inflammatory cytokines after LPS 
stimulation within the isolated adrenal cells. Therefore, the central hypothesis shifted towards 
testing if the expression of the adrenal cytokines is dependent on the presence of immune-
competent cells. This required the development of a co-incubation model of adrenal cells and 
immune cells. Using this novel model, I investigated the effect of LPS, glucocorticoids and 
ACTH on the expression of adrenal cytokines (IL-6 mRNA and the changes in the key 
steroidogenic genes.   
 
In this chapter, the following hypotheses have been tested: 
1) Stimulation of isolated adrenal cells (ATC7 cells) with LPS induces the 
expression of the pro-inflammatory cytokines IL-6 mRNA; 
2) The presence of immune cells (THP1 cells) influences the LPS induced pro-
inflammatory cytokines IL-6 mRNA and steroidogenic gene expression; 
3) Glucocorticoids exert a bi-modal effect on the expression of adrenal IL-6 




4) The ACTH induced adrenal IL-6 mRNA expression, and the steroidogenic 
pathway is influenced by the temporal administration of LPS and 
glucocorticoids (pre- or co-treatment)    
Furthermore, the aims of this chapter are shown as following: 
1) To test the effect LPS on IL-6 mRNA expression in the isolated ATC cells 
(ATC1 and ATC7 cells); 
2) The determine the optimal co-incubation ratio of ATC7 cells and THP1 cells;  
3) To determine the optimal LPS stimulation dose pf ATC7-THP1 co-culture;  
4) To assess the time course of LPS incubation on IL-6 mRNA expression and 
steroidogenic gene expression. 
5) To assess the effects of co-incubation with the synthetic glucocorticoid 
dexamethasone (DEX) on LPS induced IL6-mRNA expression. 
6) To investigate the effect of DEX pre-treatment on LPS induced IL6-mRNA 
expression. 
7) To investigate the effect of LPS on ACTH- induced IL-6 mRNA and 















9.3.1 Single-cell type culture, trans-well co-culture and cell treatments 
 
Murine adrenocortical tumour ATC7 cells (from Dr Pierre Val, Université Clermont 
Auvergne, Clermont-Ferrand, France), were cultured on poly-L-lysine-coated 75cm2 tissue 
culture flasks in a 1:1 mixture of Dulbecco's Modified Eagle's Medium (DMEM) and Ham’s 
F-12 medium (DMEM-F12) at 37°C in a 5%CO2-95% air atmosphere. The medium was 
supplemented with insulin (10 mg/ml), transferrin (5.5 mg/ml), and selenium (5 ng/ml) (ITS), 
L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 µg/ml), 2.5% horse serum, and 
2.5% fetal bovine serum. Cells were passaged every 3-4 days, and the culture medium changed 
every 2-3 days. For all the experiments, cells were seeded 2-3 days before experimentation into 
poly-L-lysine-coated 6-well plates at 5-7 x105 cells/well. Human monocytic THP1 cells 
(Sigma, Gillingham, UK) were cultured in suspension in 75cm2 tissue-culture flasks in DMEM 
at 37°C in a 5%CO2-95% air atmosphere. The medium was supplemented with 20% horse 
serum penicillin (100U/ml) and streptomycin (100ug/ml). Cells were passaged every 3-4 days, 
and culture media changed every 2 days. Differentiation of THP1 cells was achieved by 
resuspending THP1 cells in medium containing 100nM PMA (Sigma) in 6 wells plate 
polycarbonate cell culture inserts (TC inserts, Sarsted, Nümbrecht, Germany). Cells were left 
to differentiate for 72 hours then washed twice with 1x PBS (phosphate-buffered saline, pH 
7.4, ThermoFisher, Waltham, MA USA). The insert containing THP1 cells was then transferred 
into a six wells plate containing ATC7 cells and incubated in serum-free media 
(DMEM/F12/0.1% BSA). The ratio ATC7:THP1 was kept at 1:2 for all experiments except on 
the ratio experiment in which different ratio ATC7:THP1 were tested. Both ATC7 and THP1 




16-24 hours before the start of each experiment. ATC7 or ATC7+THP1 cells were incubated 
with: LPS (Lipopolysaccharides from Escherichia coli O111:B4; Sigma, UK), 
proinflammatory cytokines (mouse IL-1β, IL-6 and TNFα, Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany), dexamethasone (DEX, Dexamethasone 21-phosphate disodium salt; 
Sigma); ACTH (adrenocorticotropic hormone from porcine pituitary, Fragment 1-39; Sigma) 
as described in detail for each experiment in the result section. At the end of each experiment, 
cells were washed with ice-cold phosphate-buffered saline (PBS), and then sodium dodecyl 
sulfate (SDS)-lysis buffer (2% SDS, 50mM Tris pH 6.8, 10% glycerol) was added to each well. 
Cells were scraped off, and the lysate was collected in two aliquots and stored at -20C until 
processing for RNA and protein extraction as described below. 
 
9.3.2 Quantitative RT-PCR 
For RNA quantification, cells were lysed in RNA lysis buffer, and total RNA was 
purified using Ambion Pure-Link kit (Invitrogen, ThermoFisher Scientific). The cDNA 
template was reverse transcribed from 1000ng of total RNA using Cloned AMV First-Strand 
cDNA synthesis kit (Invitrogen, ThermoFisher Scientific). RTqPCR was performed using 
Power SYBR green PCR mix (Applied Biosystems, ThermoFisher Scientific) and a 4 ng cDNA 
template. Samples were amplified by an initial denaturation at 50 °C for 2 min, 95 °C for 10 
min and then cycled (40-50 times) using 95 °C for 15 s and 60 °C for 1 min. Genes were 
normalised to GAPDH mRNA as determined in a separate real-time PCR reaction.  RTqPCR 
primers (Table 1) were used at a final concentration of 200nM and designed to span an exonic-








Gene target Forward Reverse 




StAR mRNA TCGTGAGCGTGCGCTGTACC CTTCGGCAGCCACCCCTTCAG 
MC2R mRNA CCAAGGCCCTTCTAAGCCAG CTTGCGGTGTCATTGGTGTG 
MRAP mRNA AGTCATGGCCAACGGGACCG GGGACTGTGCCTCATCTGTGGGG 
SF-1 mRNA AGGAGGAAAGGACGATCGGA ACCTTGTCACCACACATGG 
DAX-1 mRNA ACCGTGCTCTTTAACCCAGA CCGGATGTGCTCAGTAAGG 
Table 1  RTqPCR primers sequence 
 
9.3.3 Western immunoblotting 
For protein quantification, cells were lysed in SDS lysis buffer (2% SDS; 50 mM Tris 
pH 6.8; 10% glycerol) and Western immunoblotting performed as described in Hazell et al. 
(Hazell et al. 2019)  In brief, all membranes were blocked with 1% BSA in Tris-buffered 
saline/0.05% Tween 20 (TBS/T) and probed with primary rabbit antibodies directed to StAR 
(1:1000; Santa Cruz Biotechnology, USA), pCREB (1:1000; Cell Signalling Technology, Inc., 
USA), followed by horseradish peroxidase-conjugated donkey α-rabbit secondary antibody 
(1:5,000; Santa Cruz Biotechnology). Vinculin (Goat α-vinculin primary (1:5,000) followed 
by a Donkey α-Goat secondary (1:5,000) (both Santa Cruz Biotechnology) was used as a 
loading control as previously shown (Hazell et al. 2019). Protein bands were visualised with 
Luminata Forte Western HRP substrate (Millipore Corporation, Billerica, MA, USA) using a 
G BOX (Syngene, Cambridge, UK) and densitometry was determined using Image J 
























Figure 12 Diagram of the experiment plan. The ATC7 cells and the THP1 cells are first 
cultured separately (1) then are co-incubated using a transwell system and undergo 
various treatments with LPS, DEX or cytokines (2). At the end of treatment, the well 
containing the THP1 cells is removed, and the ATC7 cells only are collected for further 
processing for mRNA and protein measurement by RT-qPCR and western 




Graph Pad Prism version 7.00 (Graph Pad Software, La Jolla, CA, USA) and SPSS 
version 24 (IBM Corp., Armonk, NY, USA) was used for data graphing and statistical analysis, 
respectively. All data are expressed as mean ± SEM. For all experiments, one-way, two-way 
or three-way analysis of variance (ANOVA) was used. When a significant effect of main 
factors or interactions were found, a Tuckey (One-way and two-way ANOVA) or Fisher’s LSD 







9.4 Results  
 
9.4.1 Effects of LPS stimulation of isolated ATC cells 
 
The rationale of these initial experiments was to understand if isolated adrenal cells 
express IL-6 mRNA after LPS stimulation. First, I proved that the TLR4 mRNA is expressed 
in the adrenocortical cell lines. Analysis of the adrenal TLR4 mRNA revealed no effect of LPS 
stimulation dose and time course of treatment (1-hour and 6-hour treatments). I then moved to 
(1) to asses which cell lines are more responsive to LPS stimulation (ATC1 or ATC7), (2) the 
optimal dose of LPS, (3) the optimal time of LPS stimulation. I found that stimulation with 
LPS 10µg/mL for 24 hours achieved the most pronounced IL-6 mRNA response; however, this 
did not reach statistical significance (Figure 13) Furthermore, the ATC7 cells displayed a more 
pronounced response than the ATC1 cells.   
 
 
Figure 13 ACT7 cells were treated with LPS (10 μg/mL) for 1, 6, 24 and 48 hours. 
Relative levels of Il-6mRNA were measured by RTqPCR, and IL-6 mRNA expression 
was normalised to GAPDH. Data are mean ± SEM of three separate experiments and 
are expressed as fold induction of untreated ATC7 cells. Data were analysed using 





Because the IL-6 mRNA response remained modest, I explored (1) the effect of age of 
adrenocortical cells passage (“young” vs “old” cells) on the IL-6 mRNA expression, (2) the 
effect of changing the LPS batch used for stimulation, (3) the effect of ACTH co-incubation 
on IL-6 mRNA expression, however, I found no significant effect on any of the hypothesis 
tested. In the macrophage murine cell line, RAW 264.7, IFN-γ was shown to increase the 
affinity and number of GR receptor (Salkowski and Vogel 1992; Smyth et al. 2004). To my 
knowledge, the effect of IFN-γ on the expression of the pro-inflammatory cytokines in adrenal 
cells has not been studied; therefore, I hypothesised that co-treating the cells with IFN-γ could 
increase the responsiveness of the ATC7 cells, but again I found no significant effect (Figure 





Figure 14 Effect of IFN-γ and LPS on IL-6 mRNA in ATC7 cells. ACT7 cells were 
treated with LPS (10 μg/mL) and/or IFN-γ (100u or 1000u) for 1 and 6 hours. Relative 
levels of IL-6 mRNA were measured by RTqPCR, and the IL-6 expression was 
normalised to GAPDH. Data are mean ± SEM of three separate experiments and are 
expressed as fold induction of untreated ATC7 cells. Data were analysed using 






9.4.2 LPS stimulation of ATC7 cells co-cultured with THP1 cells induces the expression 
of adrenal IL-6 mRNA 
 
My preliminary experiments demonstrated no significant changes in the expression of 
IL-6 mRNA in response to LPS stimulation, either alone or co-incubated with IFN-γ. Because 
resident macrophages are found in basal unstimulated conditions in the adrenal cortex in vivo, 
I hypothesised that ATC7 cells would require the presence of activated immune cells for LPS 
to be able to affect the expression of pro-inflammatory cytokines and steroidogenic genes. 
Therefore, in this experiment, I tested the effect of co-culturing ATC7 cells with of THP1 
derived macrophages (referred to as THP1) cells at various ratios, as well as the effect of 
treatment with various doses of LPS for 24 hours (Figure 15). Two-way ANOVA showed a 
significant effect of LPS (P<0.0003), but no effect of THP1 co-culture, nor interactions, was 
observed on Il-6 mRNA (Figure 15 A). Although higher levels of IL-6 mRNA could be 
observed in co-cultured ATC7 cells co-cultured with THP1 cells treated with LPS, post hoc 
test did not detect any specific difference between experimental groups. Next, I evaluated the 
dose-response effect of 24-hour LPS stimulation on ATC7 cells co-cultured with THP1 cells 
co-cultured at 1:2 ATC7 cells co-cultured with THP1 cells ratio. One-way ANOVA revealed 
a significant effect of LPS on IL-6 mRNA expression (p=0.0032;  Figure 15 B), with a 
significant increase observed in cells treated with LPS at the dose of 1.25 µg /ml and 5 µg /ml 





Figure 15 Effect of LPS on adrenocortical ATC7 cells IL-6 mRNA expression. ATC7 
cells were co-cultured with THP1 cells and/or treated with LPS (5μg/mL) for 24-h. 
Relative levels of Il-6 and steroidogenic gene mRNA were measured by RTqPCR and 
the expression of each target gene was normalised to GAPDH. (A) Effect of increasing 
ATC7:THP1 cells ratio and LPS treatment on IL6-mRNA expression in ATC7 cells. 
Data are the mean ± SEM of four separate experiments and are expressed as fold 
induction of untreated ATC7 (1: 0) cells. Data were analysed by two-way ANOVA 
followed by Tukey’s multiple comparison test. (B) Effect of increasing doses of LPS in 
ATC7-THP1ATC7 cells co-cultured with thp1 cells (1:2 ratio) on IL6 mRNA expression 
in ATC7 cells. Data are the mean ± SEM of four separate experiments and are 
expressed as fold induction of untreated ATC7-thp1ATCatc7 cells co-cultured with thp1 
cells (Ctrl). Data were analysed by one-way ANOVA followed by Tukey’s multiple 
comparison test. *P<0.05; **P<0.01 vs Ctrl. 
 
 
9.4.3 Effect of increasing ratio of THP1 co-culture and LPS stimulation on steroidogenic 
gene expression in ATC7 cells. 
 
Significant effects of ACT7-THP1 cells co-culture and LPS treatment were also found 
on the expression of key steroidogenic genes (Figure 16). Specifically, there was an overall 
effect of LPS on StAR mRNA (P=0.021; Figure 16 A) and an overall effect of THP1 co-culture 
on MC2R mRNA levels (P=0.001; Figure 16 B). As observed for Il-6 mRNA, post hoc analysis 
did not reveal any significant differences between groups, however, StAR mRNA levels 




untreated ATC7 cells co-cultured with THP1 cells, and MC2R mRNA levels were elevated in 
ACT7-THP1 cells with low THP1 ratio (0.25 and 0.5), compared to single ATC7 cells (Figure 
16 B). No effects of co-culture, nor LPS, were found on MRAP mRNA (Figure 16 C) or SF-1 
mRNA (Figure 16 D). However, a significant effect of THP1 (P<0.0001), as well as a 
significant effect of THP1xLPS interaction (P=0.048), was found on DAX-1 mRNA (Figure 
16 E). Post hoc testing revealed a significant decrease of DAX-1 mRNA in ATC7 cells co-
cultured with THP1 cells treated with either LPS or vehicle. Interestingly, in ATC7 only cells, 
there was a trend of increase in the expression of DAX-1 mRNA in response to LPS stimulation 













Figure 16 Effect of increasing THP1 cells ratio and LPS stimulation on steroidogenic gene expression in ATC7 cells. ACT7 cells were co-
cultured with THP1 and/or treated with LPS (5μg/mL) for 24-h. Relative levels of Il-6 and steroidogenic gene mRNA were measured by 
RTqPCR and the expression of each target gene was normalised to GAPDH. Data are mean ± SEM of four separate experiments and are 
expressed as fold induction of untreated ATC7 cells (1: 0); data were analysed by two-way ANOVA followed by Tukey’s multiple 





9.4.4 Dose-dependent effects of LPS on the expression of steroidogenic genes in ATC7 
cells co-cultured with THP1 cells. 
 
In this experiment, I evaluated the dose-response effect of 24-hour LPS stimulation on 
the expression of steroidogenic genes in ATC7 cells co-cultured with THP1 cells at a 1:2 ATC7 
to THP1 cells ratio (Figure 17). Two-Way ANOVA showed a significant effect of LPS on 
StAR mRNA (P<0.0001; Figure 17 A) and DAX-1 mRNA (P<0.0001; Figure 13 E). Compared 
to controls, StAR mRNA expression was significantly decreased in cells treated with LPS at 
doses between 0.05 and 5µg/mL, (p<0.0001; Figure 17 B), whereas a significant decrease in 
DAX-1 was observed in cells treated with LPS at doses between 0.5 and 5µg/mL (Figure 13E). 
Consistent with the previous experiment, there was no effect of LPS on MC2R, MRAP and 
SF-1 mRNA (Figure 17 B-D). In accordance with the mRNA data, analysis of StAR protein 
showed a significant effect of LPS (P<0.0001; Figure 17 F), with a significant decrease in cells 















Figure 17 Effect of LPS on ATC7 cells steroidogenic pathway. ATC7 cells were co-cultured with THP1 at 1:2 ratio and treated with LPS 
(5μg/mL) for 24-h. (A-E) Effect of LPS on steroidogenic genes mRNA expression. Relative levels of Il-6 and steroidogenic genes mRNA 
were measured by RTqPCR, and the expression of each target gene was normalised to GAPDH. (F) Effect of LPS on StAR protein 
expression in ATC7-thp1ATCatc7 cells co-cultured with thp1 cells. Relative levels of StAR protein were measured by western 
immunoblotting, and data were normalised to vinculin. Data are mean ±SEM of four separate experiments and are expressed as fold 
induction of untreated ATC7-thp1ATCatc7 cells co-cultured with thp1 cells (Ctrl); data were analysed by one-way ANOVA followed by 





9.4.5 Effects of dexamethasone and LPS co-treatment on Il-6 and steroidogenic gene 
mRNA levels in ATC7 cells co-cultured with THP1 cells. 
 
In the following sets of experiments, I tested the hypothesis that the effects of LPS on 
IL-6 mRNA and steroidogenic gene expression can be modulated by treatment with the 
synthetic glucocorticoid dexamethasone (DEX). Firstly, I investigated the effect of 24-hour co-
treatment with DEX and LPS on the expression of IL-6 mRNA and steroidogenic genes mRNA 
in ATC7 cells co-cultured with THP1 cells (Figure 18). I found a significant overall effect of 
LPS (P<0.0001) on IL-6 mRNA, but no significant effect of DEX nor interactions (Figure 5 
A). Post hoc testing revealed a significant increase in IL-6 mRNA in cells treated with 5 µg/mL 
LPS (P=0.0009) compared to control ATC7 cells co-cultured with THP1 cells, and this effect 
was prevented by both 1nM and 10nM DEX, but not by 100nM DEX (P=0.0037) compared to 
control ATC7 cells co-cultured with THP1 cells ((Figure 18 A). I did not observe any effect of 
the lower dose of LPS (0.05µg/mL LPS), nor an effect of DEX alone or in the presence of 
5µg/mL LPS.  
Analysis of the effects of DEX and LPS on steroidogenic gene expression revealed a 
significant effect of DEX (P<0.0001) and a significant DEX x LPS interaction (P=0.0009) on 
StAR mRNA (Figure 18 B). StAR mRNA levels were decreased in cells treated with 5µg/mL 
LPS (P=0.0037), compared to control ATC7 cells co-cultured with THP1 cells, and these 
effects were prevented by 1 nM DEX, but not by 10 and 100nM DEX. I also observed a 
significant decrease in StAR mRNA in cells treated with both 1nM DEX and 0.05µg/mL LPS 
(P=0.0116) compared to control ATC7 cells co-cultured with THP1 cells, suggesting a 
synergistic effect of DEX and LPS at low doses. There was also a significant effect of DEX 




post hoc analysis did not reveal any significant effect of LPS or DEX alone, but a trend of 
decrease in DAX-1 mRNA levels was found in cells treated with 1nM DEX and 0.05µg/mL 
LPS and in cells treated with 100nM DEX and 5µg/mL LPS (P=0.0887 and P=0.0800, 
respectively, compared to control ATC7 cells co-cultured with THP1 cells). Co-treatment with 






Figure 18 Effect of dexamethasone and LPS on ATC7 cells IL-6 and steroidogenic genes mRNA expression. ATC7 cells co-cultured with 
thp1 cells  were treated with dexamethasone (DEX, 1, 10 and 100 nM) and/or LPS (0.05 and 5 µg/mL) for 24-h. Relative levels of Il-6 and 
steroidogenic genes mRNA were measured by RTqPCR, and the expression of each target gene was normalised to GAPDH. Data are the 
mean ±SEM of six separate experiments and are expressed as fold induction of untreated Ctrl cells; data were analysed by two-way ANOVA 
followed by Tukey’s multiple comparison test. *P< 0.05; **P< 0.01 vs untreated Ctrl; ^P<0.05; ^^P<0.01 vs untreated cells from the same 





9.4.6 Effects of dexamethasone pre-treatment on LPS-induced changes in IL-6 and 
steroidogenic gene mRNA levels in ATC7 cells co-cultured with THP1 cells. 
 
My previous experiment has shown that, in ATC7 cells co-cultured with THP1 cells, 
treatment treated with DEX prevents some of the effects of LPS on IL-6, StAR and DAX-1 
mRNA, but only at the lower doses of 1nM and 10nM. In this experiment, I have tested if 
glucocorticoids exert a bimodal effect (See chapter 9.13) on the expression of adrenal IL-6 
mRNA and the changes in the steroidogenic gene pathway. In this experiment, I aimed to test 
whether pre-treatment with 100nM DEX was able to prevent LPS-induced effects on gene 
transcription in ATC7 cells co-cultured with THP1 cells. Twenty-four hours treatment with 
DEX was followed by 24-hours treatment with LPS (at the dose of 0.05 of 5 µg/mL) alone or 
in combination with DEX (Figure 19). Three-way ANOVA revealed a significant effect of LPS 
on IL-6 mRNA (P<0.00001) but no effect of DEX pre-treatment, DEX co-treatment, nor 
interactions (Figure 19 A). IL-6 mRNA levels were significantly higher in cells treated with 
5nM LPS, and this effect was prevented in cells pre-treated with DEX, but not in cells both 
pre- and co-treated with DEX. Three-way ANOVA also revealed a significant effect of LPS 
on StAR (P<0.0001; Figure 19 B) and DAX-1 mRNA (P<0.0001; Figure 19 F), but no effect 
of DEX pre-treatment, DEX co-treatment, nor interactions on either gene. LPS treatment 
decreased StAR mRNA levels and neither pre- nor co-treatment with DEX prevented these 
effects. Similarly, LPS treatment decreased DAX-1 mRNA levels, but this effect was prevented 
in cells treated with 0.05µg/mL LPS pre- and co-treated with DEX. I also observed an overall 
effect of LPS on MC2R mRNA, (P=0.0180; Figure 19 C); however, a significant decrease in 
MC2R mRNA was only observed in cells treated with 5µg/mL LPS and pre-treated with DEX. 








Figure 19 Effect dexamethasone pre-treatment on dexamethasone and LPS effects on 
ATC7 IL6 and steroidogenic genes mRNA expression. ATC7-THP1ATC7 cells co-
cultured with THP1 cells were pre-treated with dexamethasone (100 nM) for 24-h, and 
then co-treated with LPS (0.05 or 5 µg/mL) and/or dexamethasone (100 nM) for 24-h. 
Relative levels of Il-6 and steroidogenic genes mRNA were measured by RTqPCR, and 
the expression of each target gene was normalised to GAPDH. Data are mean ±SEM 
of six separate experiments and are expressed as fold induction of untreated Ctrl; data 
were analysed by three-way ANOVA followed by Fisher’s LSD post hoc test. ***P< 
0.001; ****P< 0.0001 vs LPS-untreated Ctrl; ^P<0.05; ^^P<0.01 ^^^P<0.001; 
^^^^P<0.0001 vs Ctrl cells from the same LPS±DEX treatment. The closed bars denote 






9.4.7 Effect of LPS on ACTH- induced IL-6 mRNA and steroidogenic gene expression in 
ATC7 and ATC7 cells co-cultured with THP1 cells  
 
Studies in humans and rodents have shown that LPS-induced glucocorticoid secretion 
can occur through its effects on the HPA axis (George P. Chrousos 1995). In addition to 
regulating the secretion of CRH in the hypothalamus, and of ACTH in the pituitary, LPS 
administration directly activates the adrenal gland steroidogenic pathway and can potentiate the 
effects of ACTH on glucocorticoid synthesis (Kanczkowski, Sue, and Bornstein 2016). 
Therefore, I decided to investigate the effects of LPS treatment on Il-6 and steroidogenic genes 
mRNA in both ATC7 alone and ATC7 cells co-cultured with THP1 cells (Figure 20). In these 
experiments set, ATC7 and ATC7 cells co-cultured with THP1 cells were treated with LPS 
5µg/mL for 24 hours and then treated with ACTH 10nM for up to 2h.  
 
Three-way ANOVA analysis of Il-6 mRNA data showed a significant effect of ACTH 
(P<0.0001), LPS (P<0.0001), THP1 (P=0.02) as well as ACTH x THP1 (P=0.007), LPS x 
THP1 (P<0.0001) and ACTH x LPS (P=0.011) interactions (Figure 20 A). Interestingly, I found 
that ACTH alone increased IL-6 mRNA levels in ATC7 cells, and this effect was potentiated 
by pretreatment with LPS. Interestingly, ACTH alone did not increase Il-6 mRNA in ATC7 
cells co-cultured with THP1 cells, whereas a significant increase was observed when ATC7 
cells co-cultured with THP1 cells were treated with LPS. 
Analysis of StAR mRNA showed a significant effect of ACTH (P<0.0001), LPS 
(P=0.001) and THP1 (P<0.0001) as well as a significant ACTH x THP1 interaction (P=0.005) 
(Figure 20 B). As expected, StAR mRNA levels were increased in ATC7 cells treated with 
ACTH, and LPS did not affect such effect. However, the increase in StAR mRNA induced by 




potentiated by LPS. A significant effect of ACTH (P<0.0001) and THP1 (P=0.021), as well as 
THP1 x LPS interaction (P=0.049),  was also observed on MC2R mRNA levels (Figure 20 C). 
However, while there were no significant changes in ATC7 cells treated with ACTH, even 
following pre-treatment with LPS, MC2R mRNA levels were higher in ATC7 cells co-cultured 
with THP1 cells treated with ACTH only, when compared to ATC7 cells. DAX-1 mRNA levels 
were also affected by both ACTH (P=0.031) and THP1 (P<0.0001), with a significant effect of 
ACTH x THP1 interaction (P=0.024), whereas only a trend of the effect of LPS was observed 
(P=0.082) (Figure 20 F). DAX-1 mRNA levels were decreased in ATC7 cells treated with 
ACTH±LPS at 2h, compared to time 0, whereas a significant decrease was observed in ACT7-
THP1 cells prior to ACTH treatment, and no further decrease was observed after ACTH 
treatment, nor LPS treatment had any further effect. Only a trend of effect of ACTH was 
observed on MRAP (figure 16D), while a significant effect of THP1 (P<0.0001), and a trend 
of effect of LPS (P=0.09), was found on SF-1 mRNA levels, with a significant overall decrease 
in ATC7 cells co-cultured with THP1 cells treated with LPS (Figure 20 E). 
To evaluate whether the decrease in ACTH-induced StAR mRNA in ATC7 cells co-
cultured with THP1 cells was associated with a decreased activation of CREB, I measured the 
levels of pCREB using Western immunoblot (Figure 20 G). Although there was no significant 
effect of ACTH, LPS or THP1, a significant ACTH x LPS interaction was detected (P=0.024). 
Post hoc analysis revealed that while ACTH increased pCREB levels in ATC-7 cells pretreated 
with vehicle (P=0.02), only a trend of effect was found in ATC-7 cells pre-treated with LPS 









Figure 20 Effect of LPS on ACTH-induced IL6 mRNA and steroidogenic pathway activity. ATC7 and 
ATC7-THP1ATC7 cells co-cultured with THP1 cells were incubated with LPS (5 µg/mL) and then 
treated with ACTH for up to 2 h. (A-F) Il-6 and steroidogenic genes mRNA levels were measured by 
RTqPCR and data from each target gene were normalised to GAPDH. (G) Relative levels of 
phosphorylated CREB (pCREB) was measured by western immunoblotting, and data were normalised 
to vinculin. Data are mean ±SEM of four separate experiments and are expressed as fold induction of 
untreated ATC7 cells; data were analysed by three-way ANOVA followed by Fisher’s LSD post hoc test. 
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 vs same treatment ATC7 or ATC7 cells co-cultured 
with THP1 cells at time 0; ^^P<0.01; ^^^P<0.01; ^^^^P<0.01 vs untreated ATC7 or ATC7 cells co-




9.5 Discussion  
 
Recent research has demonstrated the role of HPA axis-independent, intra-adrenal 
mechanisms in regulating glucocorticoid release during acute inflammatory stress (Boonen, 
Bornstein, and Van den Berghe 2015). Such mechanisms could likely complement or augment 
the well-known HPA axis activation during critical illness states. The adrenal tissue 
microenvironment contains a variety of cells, including neural cells, adipocytes, endothelial 
and immune cells, that could indeed regulate adrenal steroidogenesis (Boonen, Bornstein, and 
Van den Berghe 2015). The interaction of steroidogenic cells with immune cells is of particular 
importance because several studies have shown that the generalised inflammation that 
accompanies acute stress is associated with an infiltration of the adrenal cortex by immune 
cells (Jennewein et al. 2016; Kanczkowski, Chatzigeorgiou, et al. 2013). This immune-
steroidogenic crosstalk could occur either following activation of resident macrophages or/and 
by the intervention of circulating immune cells that are recruited in the adrenal cortex. One 
study suggested that systemic immune cells, rather than the adrenal cells, are the primary 
regulator of the TLR-mediated adrenal activation (Kanczkowski, Alexaki, et al. 2013). It is 
undoubtedly the case that the adrenals glands, like the thyroid gland, have the highest blood 
supply per gram of tissue in the body, and the adrenal tissue will likely be flooded by immune-
effector cells during acute inflammatory stress.  
The current study reports the characterisation of a novel co-culture model to investigate 
these interactions. The use of the adrenocortical tumour ATC7 cell line with complete zona 
fasciculata cell phenotype enabled us to assess the effect of an inflammatory stimulus on the 
expression of the pro-inflammatory cytokine IL-6 mRNA and the expression of key 
steroidogenic genes. Rat and human adrenal cells do express a variety of pro-inflammatory 




1997; Bornstein, Rutkowski, and Vrezas 2004). I have chosen to measure the expression of IL-
6 because it can be induced by inflammation directly as well as in response to IL-1. 
Furthermore, several studies have shown that IL-6 can affect adrenal steroidogenesis either 
directly or via activation of the CRH-ACTH axis (G P Chrousos, Branch, and Development 
2015; Bethin, Vogt, and Muglia 2000; Bornstein, Rutkowski, and Vrezas 2004). In humans, 
the presence of IL-6, IL-6 receptor and IL-6 mRNA in the adrenal cortex suggests that IL6 
could play a paracrine or autocrine role in the immune adrenal cross-talk (Gonzalez-hernandez 
and Scherbaum 2016; Päth et al. 1997). I decided to use the THP1 cell line because this is a 
broadly used model to study the monocyte/macrophage functions (Tsuchiya et al. 1980). THP1 
cells have been used before in other co-culture models including vascular smooth muscle cells 
(Zhang et al. 2008; Li et al. 2006) , adipocytes (Spencer et al. 2010) , T-lymphocytes (Azenabor 
et al. 2011), platelets (Aslam et al. 2007) and intestinal cells (Watanabe et al. 2004). 
Furthermore, THP1 cells, and particularly the matured macrophages, are known to secrete 
several pro-inflammatory cytokines as a result of LPS stimulation including TNFα, IL-1β, IL-
6, IL-8 and IL-10 (Schildberger et al. 2013; Wehrhahn et al. 2010; Palacio, Markert, and 
Martínez 2011).  
In the present study, I show a significant increase in IL-6 mRNA expression in ATC7 
cells in response to LPS only when these cells are co-cultured with the THP1 cells, suggesting 
that the expression of adrenal pro-inflammatory cytokines in response to inflammatory stress 
is dependent on the presence of immune cells. Because LPS had no effect on ATC7 alone, I 
hypothesise that, in our co-culture experimental model, LPS induces the secretion of a cytokine 
mix by THP1 macrophages which then acts on the adrenal cells resulting in the expression of 
IL-6 mRNA. I have also found that the effects of LPS on Il-6 mRNA is dependent on the ATC7 




inflammatory cytokines during acute stress could occur by increased recruitment of immune 
cells within the adrenal cortex.  
I have also assessed the effect of glucocorticoids on immune-adrenal interactions. This 
approach is novel since, to my knowledge, the effects of glucocorticoids on the HPA axis 
responses to inflammation has only been investigated at a system level, and not directly in the 
adrenal gland cells. I found a significant effect of a high dose of LPS on the increase of IL-6 
mRNA expression. This increase was suppressed by low and medium DEX doses. A similar 
dose-dependent suppression was noted in the StAR mRNA expression as a result of LPS 
stimulation. Furthermore, I found a significant effect of DEX on DAX-mRNA response to LPS 
stimulation, whereas we noted a trend in a decrease of DAX-1 mRNA expression dependent 
on LPS and DEX dose co-stimulation. Gummow et al. investigated the direct effect of 
dexamethasone on the steroidogenic gene expression in primary adrenocortical cells, and they 
found an increase in DAX-1 mRNA expression and a decrease in StAR mRNA expression that 
was mediated by glucocorticoid receptor activation (Gummow et al. 2006).  In my experiments, 
I did not find any effect of dexamethasone co-incubation on steroidogenic gene expression in 
ATC7-THP1 cells in the absence of LPS co-stimulation. Nevertheless, my data further support 
a direct effect of glucocorticoids on the steroidogenic network activity. This suggests that 
during acute inflammatory stress, systemic administration of glucocorticoids can modulate the 
steroidogenesis directly, without the pituitary inputs (e.g. in HPA axis independent manner). 
I also investigated the temporal relation between glucocorticoid and LPS stimulation in 
regulating the expression of IL-6 and steroidogenic genes. Despite traditional views according 
to which glucocorticoids are considered uniformly anti-inflammatory, research in the last 
decade has suggested that glucocorticoids can have a bimodal action: both pro-inflammatory 
and anti-inflammatory (Sorrells et al. 2009; Sapolsky, Romero, and Munck 2000). This 




inflammatory stress stimulus. A pro-inflammatory effect of glucocorticoids has been 
demonstrated in immune-competent cell lines (macrophages) (Smyth et al. 2004) and in the 
central nervous system (hippocampal microglia) (Frank et al. 2007). I investigated whether this 
effect occurs within the isolated adrenal cells depending on the time of glucocorticoid 
administration in relation to the inflammatory stress (LPS stimulation). I found that DEX pre-
treatment prevented the LPS-induced IL-6 mRNA when compared to pre- and co-treated DEX 
cells. Therefore I can conclude that the so-called bimodal effect of steroids (anti- and pro-
inflammatory) that was noted in immune and neural cell lines does not apply to adrenal cells, 
at least within the experimental conditions used in our studies. (Yeager, Guyre, and Munck 
2004; Horowitz and Zunszain 2015). 
Because ACTH plasma levels increase in response to inflammatory stress, I also 
investigated the effects of ACTH treatment on Il-6 and steroidogenic genes mRNA in both 
ATC7 alone and in ATC7 cells co-cultured with THP1 cells. To my surprise, I found that 
ACTH alone was able to induce IL-6 mRNA in ATC7 cells, and this effect was potentiated by 
pretreatment with LPS. Interestingly, the effect of ACTH on Il-6 mRNA was not observed in 
ATC7 cells co-cultured with THP1 cells in the absence of LPS, suggesting that anti-
inflammatory cytokines secreted by THP1 cells in basal conditions may protect the adrenal 
cells from a non-inflammatory immune activation mediated by ACTH. A recent study has 
shown that ACTH treatment dynamically increases the expression of steroidogenic genes in 
ATC7 cells (Hazell et al. 2019). My present data confirmed these previous findings, but also 
show that the dynamic effect of ACTH is disrupted in ATC7 cells co-cultured with THP1 cells, 
with a smaller effect on StAR mRNA, which was further decreased by pre-treatment with LPS, 
and complete suppression of DAX-1 mRNA. These effects were associated with a decrease in 
pCREB levels, suggesting that the effects of co-culture with THP1 cells may occur at the levels 




including MC2R, MRAP and SF-1 were not affected by co-culture with THP1 cells, nor by 
pre-treatment with LPS. The effect of ACTH on IL-6 mRNA and steroidogenic genes was 
significantly different in the presence of THP1 cells. IL-6 mRNA and phosphorylation of 
CREB appeared enhanced by ACTH in the presence to THP1 cells and LPS, while the 
suppression of STAR mRNA and DAX-1 mRNA was more pronounced in the LPS-treated 
cells, compared to vehicle-treated ATC-THP1 cells. A link between an increase in CREB 
phosphorylation and progesterone levels in response to IL-1b has been shown in granulosa 
cells (Dang et al. 2017). Therefore, it is tempting to speculate that the effects of immune 
stimulation in adrenocortical cells may occur by a similar mechanism. Overall my results 
suggest that immune-adrenal crosstalk may be integrated with the hormonal response of the 
HPA axis during acute stress.  
 
9.6 Conclusions  
 I have shown that stimulation of isolated adrenal cells does not induce a 
significant expression of IL-6 mRNA. Therefore, I have developed a novel co-culture model 
suitable for assessing immune-adrenal interactions in the context of inflammatory stress. Using 
this system, I was able to demonstrate that the expression of pro-inflammatory adrenal 
cytokines after LPS stimulation is dependent on the ratio of adrenal and immune cells. I have 
also noted that the presence of THP1 cells can modulate the response of the steroidogenic gene 
network to LPS activation, and this is further modulated by ACTH stimulation and 
glucocorticoid incubation.  
 
9.7 Suggestions for future work 
The directions for future work should focus on a better understanding of the crosstalk 




cytokines and macrophage-specific cytokine in the media followed by stimulation of isolated 
ATC7 cells with the cytokines of interest. Furthermore, it would be useful to assess if the rest 
of mRNA expression results are verified in terms of translation to protein levels. Finally, a 
further direction is to concentrate on the changes that occur within the THP1 cells during the 

























10 CHAPTER 3  THE UTILITY OF GLUCOCORTICOIDS IN 
PAEDIATRIC HEART SURGERY  
 
“The absence of proof does not constitute the proof of absence.” 
Rudolf Virchow 
 
Sections 10.1.1 to 10.1.5 of this chapter are largely taken from a published narrative 
review in Frontiers in Pediatrics (D. P. Fudulu, Schadenberg, et al. 2018). The author's 
contributions were the following: Daniel Fudulu - literature review, writing, design, 
supervision; Ben Gibbison, Thomas Upton, Serban Stoica, Massimo Caputo and Stafford 
Lightman - the writing of manuscript sections and revision; Gianni Angelini - writing, design 
and supervision. 
 
10.1  Corticosteroids in Paediatric Heart Surgery: Myth or Reality 
10.1.1 Background  
The introduction of the CPB circuit in the mid-1950s made the surgical treatment of 
intracardiac lesions possible and led to rapid progress in the field of cardiac surgery (Cooley 
and Frazier 2000). However, the CPB circuit is also known to provoke a systemic inflammatory 
response syndrome (SIRS) due to the contact of the blood to the extracorporeal circuit, the 
ischemic reperfusion injury of the heart or endotoxemia due to increased gut permeability. This 
systemic activation is beneficial because it triggers immune priming of the body that could 
prevent infection and promote healing, but if excessive, can also prove detrimental and thus 
result in organ dysfunction and even death (Laffey, Boylan, and Cheng 2002). Therefore, since 




inflammatory response to improve clinical outcomes. Such strategies include the use of 
glucocorticoids, aprotinin, antioxidants, miniaturised or heparin-coated circuits (D. Fudulu and 
Angelini 2016). Furthermore, in paediatric heart surgery, the modulation of SIRS is of greater 
importance because it is believed that the inflammatory response is augmented by the surface 
of the extracorporeal circuit relative to the reduced circulating blood volume, the more frequent 
use of the deep hypothermic circulatory arrest (DHCA) and the more pronounced 
haemodilution (Kouchoukos et al. 2012).  Historically, the use of corticosteroids in cardiac 
surgery dates back to the 1960s (Replogle, Gazzaniga, and Gross 1966) and according to 
several current surveys of clinical practice, corticosteroids are still widely used in paediatric 
heart surgery with the use of CPB (P. A. Checchia et al. 2005; Allen et al. 2009). This contrasts 
with adult heart surgery where prophylactic corticosteroids are no longer widely used because 
of no clear evidence of a beneficial effect on clinical outcomes. The DECS trial (Dieleman et 
al. 2012) recruited 4494 adult patients undergoing surgery with the use of CPB and found no 
impact, of a single dexamethasone dose 1mg/kg given intraoperatively, on the composite 
endpoint (death, myocardial infarction, stroke, renal failure and respiratory failure at 30 days). 
However, in the secondary outcomes, dexamethasone was associated with reductions in 
postoperative infection, duration of mechanical ventilation and length on intensive care and 
hospital stays. The SIRS trial (Whitlock et al. 2015) remains the largest trial of corticosteroids 
versus placebo in adult cardiac surgery to date. In this trial, 7507 were randomly assigned to 
methylprednisolone 250 mg at anaesthetic induction and 250 mg at the initiation of CPB or 
placebo. Corticosteroids had no impact on the risk of death or significant morbidity including 
infection, length of the hospital, intensive care stay, respiratory or renal failure. The 
prophylactic use of corticosteroids in the paediatric cardiac surgery population continues to be 
a matter of debate likely due to the lack of such well-designed, large randomised controlled 




morbidity. However, corticosteroids with (mineralocorticoid effects) are also given in 
paediatric heart surgery to protect against the so-called relative adrenal insufficiency that can 
accompany the acute stress of surgery (Boonen, Bornstein, and Van den Berghe 2015; Green 
and Koch 2012). Due to a lack of basic understanding of hypothalamic-pituitary axis 
physiology during and after paediatric heart surgery, the evidence is limited in this area 
(Graham and Bradley 2017). Finally, another potential use of corticosteroids in paediatric heart 
surgery is their neuroprotection effect during DHCA surgery.  In this chapter, I will discuss the 
evidence and controversies around these three main indications of steroid use in paediatric 
heart surgery (Figure 21).  
 
Figure 21 The three main glucocorticoid indications 
 
10.1.2 Corticosteroids, inflammation and clinical outcomes 
 
Many studies have tried to measure various markers of inflammation after 
glucocorticoid administration and attempted to correlate these changes to clinical outcomes. 
(Tennenberg et al. 1986; Bronicki et al. 2012; Varan et al. 2002; Schroeder 2003; Lindberg et 
al. 2003; Gessler et al. 2005; Grosek et al. 2007; Graham et al. 2011; Bocsi et al. 2011; Lerzo 
et al. 2011; Heying et al. 2012; Abbasi Tashnizi et al. 2013; Keski-Nisula et al. 2013; Byrnes 




challenging to characterize and modulate. Therefore, measuring only a few cytokines might 
not be accurate enough given the array of pro-inflammatory and anti-inflammatory cytokines 
that are released during SIRS and interact in a complex manner (Jaffer, Wade, and Gourlay 
2010). Secondly, while glucocorticoids can blunt inflammation; this does not necessarily 
translate into better short term clinical outcomes(Lindberg et al. 2003; Amanullah et al. 2016; 
Keski-Nisula et al. 2013). Moreover, a study by Gessler et al. found no impact of glucocorticoid 
administration on markers of inflammation (Gessler et al. 2005). Graham et al. in an RCT of 
68 children undergoing surgery with the use of CPB found no effect single versus 2-dose  
corticosteroids on inflammation (Graham et al. 2014). Finally, there is some evidence that the 
host inflammatory response plays an important role, and it might be essential to approach SIRS 
in a personalised rather than standardised manner. Huber et al. (Huber et al. 2017)  in a study 
of 37 children undergoing heart surgery with the use of CPB demonstrated that the neutrophil 
phenotype signature could predict end-organ dysfunction associated with SIRS.  
There are several small-sized randomised controlled trials (RCTs) that focus on the 
effect of corticosteroids on clinical outcomes, too (Table 2). Most of these trials measure 
inflammation parameters, and the clinical data is measured either as a primary or secondary 
outcome. All have in common the small sample size and the variability in the type of steroid 
and the regimens used. The first randomised controlled trial of steroid (47 children) versus 
placebo (48 children) was published by Toledo-Pereyra et al. and dates to 1980. The authors 
found a benefit in survival in patients that had methylprednisolone 30 mg/kg: 1 hour 
preoperatively, five minutes pre-CPB and every 6 hours for 24 hours, however,  there was no 
correlation with other biochemical markers (Toledo-Pereyra et al. 1980). Bronicki et al. in an 
RCT of 28 children, found dexamethasone given 1mg/kg, 1 hour before CPB, to result in the 
lower fluid requirement, lower alveolar-arterial gradients, lower fluid requirement and less 




the dose-effect of 30 mg/kg of methylprednisolone intravenous infusion to 2 mg/kg 
methylprednisolone intravenous infusion pre-CPB. There was no difference in the clinical 
outcomes between the two groups (ventilation times, intensive care unit stay or oxygenation) 
(Varan et al. 2002).  Later, Lindeberg and colleagues in an RCT of 40 children found no effect 
of dexamethasone 1mg/kg after anaesthesia induction on oxygenation, fluid balance, critical 
care stay or ventilation time (Lindberg et al. 2003). Schroeder et al. in an RCT of 29 children, 
compared the effect of 30 mg/kg of methylprednisolone double-regimen (pre-operatively and 
intraoperatively) to a single dose (30 mg/kg) intraoperatively. The double-dose steroid 
recipients had better oxygenation, lower body temperature and reduced fluid requirements. 
Checchia et al. reported in an RCT of 28 children no effect dexamethasone 1 mg/kg, given 1-
hour pre-CPB on sternal dehiscence rates, reoperation for bleeding, or gastrointestinal bleeding 
(P. a Checchia et al. 2003). Ando et al. in small RCT of 20 patients found a benefit of 
hydrocortisone administration in terms of reduced body oedema, improved oxygenation and 
reduced duration of ventilation (Ando et al. 2005). Graham et al. randomised a total of 76 
patients to either single (intraoperative) or double dose methylprednisolone (8-hour pre-
operative and intraoperative). The two-dose steroid group had a higher serum creatinine and 
poorer postoperative diuresis (Graham et al. 2011). There was no difference in the incidence 
of low cardiac output syndrome, inotropic requirement, duration of mechanical ventilation, 
ICU or hospital stay. Heying et al. evaluated the effect of dexamethasone 1 mg/kg 4 hours pre-
CPB in 20 neonates undergoing arterial switch and found no effect of corticosteroids in terms 
of postoperative cardiac parameters (heart rate, mean arterial pressure, central venous 
pressure), diuresis, oxygenation. However, there was a reduced dobutamine requirement, 4 
hours post-CPB. (Heying et al. 2012). Keski-Nisula and colleagues, in an RCT of 40 neonates 
undergoing surgery with use of CPB, found no effect of 30 mg/kg of methylprednisolone given 




duration of ventilation or survival; however, the steroid arm had significantly increased blood 
glucose (Keski-Nisula et al. 2013). The same group investigated in a three-arm RCT of 45 
children, the effect of 30 mg/kg methylprednisolone after induction versus 30 mg/kg 
methylprednisolone in prime versus placebo. There were no differences between the three 
groups, in terms of lactate, inotropic score, duration of ventilation and intensive care stay but 
the steroid arms had higher blood glucose compared to placebo (Keski-Nisula et al. 2015). 
Amanullah et al. in RCT of 152 children investigated the effect of dexamethasone 1mg/kg 
given at three time-points (induction, pre-CPB and 6 hours from last dose) versus placebo 
(Amanullah et al. 2016). There was no difference between the two arms in terms of ventilation 
times, urine output, mean systolic and diastolic pressure, central venous pressure, inotrope 
score at 6 hours and fluid requirement.  
The largest RCT to date in neonates was recently published by Graham et al. (Graham 
et al. 2019) In this double-blinded RCT, the authors randomised 190 patients to either 
methylprednisolone (30 mg/kg) or a placebo after the induction of anaesthesia. The primary 
endpoint of the study was a morbidity-mortality composite that included any of the following 
events following surgery before discharge: death, mechanical circulatory support, cardiac 
arrest, hepatic injury, renal injury, or rising lactate level (>5 mmol/l). In the overall analysis, 
there was no statistically significant difference in reaching the primary endpoint between the 
groups (odds ratio [OR]: 0.63; 95% confidence interval [CI]: 0.31 to 1.3; p = 0.21). However, 
in the analysis by type of procedure (corrective versus palliative), methylprednisolone was 





Table 2 Randomized controlled trials of steroid use in children. 

















Methylprednisolone 30 mg/kg IV  pre-op, pre-CPB, post 
CPB, every 6 hours for 
24 hours 
not assessed Increased survival Benefit 





Dexamethasone 1 mg/kg IV  1-hour pre-CPB eightfold decrease 
in interleukin-6 levels and a greater 
than a threefold decrease in tumour 
necrosis factor- 
α levels after CPB 
less supplemental fluid during 
the first 48 hours, lower 
alveolar-arterial oxygen 
gradients during the first 24 
hours, less mechanical 
ventilation 
Benefit 








Methylprednisolone 30 mg/kg vs 2 
mg/kg 
IV  30 minutes IV infusion 
pre-CPB 
no difference in serum IL-6, IL-8, 
CRP and polymorphonuclear 
leukocyte counts 
No effect No benefit 





Dexamethasone 1 mg/kg IV  post anaesthesia 
induction 
a decrease in CRP but no change in 
von Willebrand factor antigen and 
S100B  
No effect No benefit 









Methylprednisolone 30 mg/kg IV  2 dose (4 hours before 
bypass and in bypass 
prime) vs 1 dose 
(intraoperative)   
2 dose reduced myocardial mRNA 
expression for IL-6, MCP-1, and 
ICAM-1 both before and after 
bypass and had lower serum IL-6 
and increased IL-10 at end-bypass 
vs 1 dose 
combined steroid reduced fluid 
requirements, lower body 
temperature, and lower 
arteriovenous oxygen difference 
Benefit 





Dexamethasone 1 mg/kg IV  pre-CPB not assessed no effect No benefit 








0.18 mg . kg-1 
for 3 days, 
0.09 mg . kg-1 . 
hr-1 for 2 days 
and 0.045 mg . 
kg-1 for 2 days. 
IV  post-CPB not assessed less fluid retention, better 

























Dexamethasone 1 mg/kg 
(maximum 
dose 12 mg) 
IV at the induction of 
anaesthesia – pre-
operatively; at the time 
of initiation of CPB – 
intraoperatively; and 6 
hours after the second 
dose – postoperatively 
IL-6 was lower at 6 and 24 hours 
post-operatively and IL-10 levels 
were higher 6 hours post-operatively 
in the steroid group 
No effect No benefit 









Methylprednisolone 30 mg/kg IV 
and 
prime 
8 hours pre-CPB, IV 
and in prime versus 8 
hours preoperative only  
preoperative interleukin-6 was 
reduced by 2-fold in the 2-dose 
steroid group 
two-dose methylprednisolone 
was associated with higher 
serum creatinine and poorer 
postoperative diuresis 
Harm 
Heying et al.  2012 20 
neonates 
 
Dexamethasone 1 mg/kg IV  4 hours pre-CPB a decrease in myocardial expression 
of IL-6, IL-8, IL-1β, and TNF-α 
messenger RNA and decrease in 
protein synthesis of TNF-α; serum 
IL-6 significantly lower, IL-10 
significantly higher in steroid-
treated patients; lipopolysaccharide-
binding protein significantly higher 
postoperatively pretreated patients 
steroid recipients had a lower 
dobutamine requirement 
Benefit 





Methylprednisolone 30 mg/kg IV  after induction of 
anaesthesia 
a decrease in IL-6 and IL-8 and 
raised levels of anti-inflammatory 
IL-10 in steroid-treated patient 
blood glucose higher in the 
steroid-treated patient 
No benefit 







Methylprednisolone 30 mg/kg IV vs 
prime 
after induction versus in 
prime 
patients receiving steroids at 
induction had lower IL8 levels on 
weaning and 6 hours post-CPB 
versus placebo 
blood glucose higher in the 
steroid-treated patient 
No benefit 





Methylprednisolone 30 mg/kg IV after induction of 
anaesthesia 
not assessed overall, no significant difference 
in the primary endpoint of the 
study (composite) death, 
mechanical circulatory support, 
cardiac arrest, hepatic injury, 
renal injury, or rising lactate 








Another larger RCT of 1200 neonates is currently recruiting patients 
https://clinicaltrials.gov/ct2/show/NCT03229538.  
Some studies measured the effect of glucocorticoids on markers of myocardial injury 
(P. a Checchia et al. 2003; Malagon et al. 2005; Heying et al. 2012; Keski-Nisula et al. 2013; 
2015; Pesonen et al. 2017)   However, the markers of myocardial injury during cardiac surgery 
are difficult to interpret and correlate to the effect on clinical outcomes (see Table 3).  If we 
look at the adult population, the large SIRS trial demonstrated that the steroid arm had an 
increase in myocardial injury measured by elevation of the CK-MB enzyme (Whitlock et al. 
2015). 
Given the limitations in the existing RCT evidence discussed above, the available meta-
analyses should be interpreted with caution. The Cochrane meta-analysis by Robertson-Malt 
and colleagues demonstrated that corticosteroids do not significantly reduce postoperative 
complications as measured by the length of stay in ICU, peak core temperature and duration of 
ventilation (Robertson-Malt and El Barbary 2008). The most recent meta-analysis by Scrascia 
et al. demonstrated no significant effect of corticosteroids on mortality, mechanical ventilation 
time or ICU length of stay. Based only on 15 patients, the authors found a reduced prevalence 
of renal dysfunction associated with the use of steroid (13 versus 2 patients)  (Scrascia et al. 
2014). 
Despite the small-sized randomized trials, there are several large observational studies 
in children that are worthy of discussion here (Table 4). The Pasquali et al. (Pasquali et al. 
2012; 2010) studies provide us with the largest sample despite their retrospective design. In a 
large registry database study of 46730 children, of which 54% received perioperative 
corticosteroids, there was no difference in mortality or ventilation times; however, steroid use 
was associated with increased length of stay, more infection and greater use of insulin. In the 




morbidity associated with steroid use was more evident in the lower risk categories (e.g. 1 to 
3) (Pasquali et al. 2010). Later, the same group published a multicentre database study focused 
on 3180 neonates and found corticosteroids to be associated with increased infection across all 
regimens in the lower-risk groups. (Pasquali et al. 2012). A smaller observational study by 
Mastropietro et al. on 76 children undergoing complex heart surgery found that greater 
cumulative duration of steroid administration is associated with postoperative infection 
(Mastropietro et al. 2013). 
Indeed, neonates were the focus of multiple studies because they are considered to be 
the most vulnerable to the CPB insult due to both the immaturity of the HPA axis (Green and 
Koch 2012) but because they also appear to display a distinct inflammatory response compared 
to older age groups (Alcaraz et al. 2002). A recent best evidence topic review by our group 
could not find a clear clinical benefit in steroid use mainly due to the limitations in the available 
evidence, earlier discussed (D. Fudulu et al. 2016).  
Dreher et al. (Dreher et al. 2015) in a retrospective single centre database study, 
compared the effect of methylprednisolone administration in 303 children undergoing heart 
surgery during the six months before discontinuation of steroid use with a cohort of 222 
children were no steroid was used. Overall, the steroid group had more wound infection and 
more respiratory failure requiring tracheostomy. There were no differences in the rest of the 
clinical outcomes (early mortality, ventilation time, renal failure, etc.). In the neonate subgroup 
analyses, no difference in clinical outcomes was detected. Using datasets from a clinical trial 
(the Paediatric Heart Network’s Single Ventricle Reconstruction trial), on neonates that had 
the Norwood procedure, Elhoff et al. (Elhoff et al. 2016) compared the effect of steroid 
administration in 498 intraoperative steroid recipients with 51 non-recipients. In the 
multivariate analysis, the authors found no effect of steroid on lengths of stay but a trend 




the authors have also looked at the neurodevelopment outcomes at 14 months and found no 
difference. A significant limitation in the current studies of the impact of corticosteroids on the 
clinical outcomes paediatric heart surgery is the lack of long-term follow-up of the effect of 
early steroid administration on late neurocognitive outcomes. In other patient groups (preterm 
infants), the early administration of corticosteroids had detrimental effects. In an RCT of 262 
infants with severe respiratory distress syndrome requiring mechanical ventilation, 
dexamethasone 0.25 mg/kg given every 12 hours for one week was associated with adverse 
effects on the neuromotor and cognitive function at school age. (Yeh et al. 2004). However, 
we must acknowledge that the findings of this study cannot be fully extrapolated to the 
paediatric surgical population, because these pre-term infants received glucocorticoids during 
a different stage in brain development as compared to term infants or older children where 
steroids can be less detrimental (e.g. not administered during the critical period of brain 
development).  
In conclusion, most of the studies demonstrated that corticosteroids could dampen the 
systemic inflammatory response to surgery; however, the correlation to the effect on clinical 
outcomes remains unclear. The effect of corticosteroids on clinical outcomes was studied in 
several small-sized randomised controlled trials. This evidence is conflicting, with some 
studies showing a beneficial effect on clinical outcomes such as ventilation, oxygenation or 
renal function parameters while in other, the use of corticosteroids had no effect at all. Apart 
from being small sample-sized, these studies used various types of steroid and regimens; 
therefore, it is difficult to draw any valid conclusions. A few large registry studies raised 
concerns about the association of steroid administration with infection; however, their results 




Table 3 Studies of the effect of steroids on markers of myocardial injury. 




Study design Type of steroid Dose 
mg/kg 
Route Regimen Cardiac 
marker 
Effect on myocardial injury 
markers 
Effect on Clinical 
outcomes 
Cardioprotective  




IV  1-hour pre-CPB cardiac troponin 
I (cTnI) 
cTnI reduces 24 hours 
postoperatively in the 
dexamethasone group 
No effect  Yes 
Malagon et al.  2005 RCT 
steroid vs 
placebo 








T (cTnT)  
decrease in cTnT 8 h after 
admission 
No effect  Yes 
Heying et al.  2012 RCT 
steroid vs 
placebo 
20 neonates Dexamethasone 1 
mg/kg 
IV 4-hour pre-CPB cardiac troponin 
T (cTnT)  
cTnT lower in patients 
dexamethasone treated patients, 1 




Keski-Nisula et al.  2013 40 
neonates 








T (cTnT)  
No effect No effect  No 
Keski-Nisula et al.  2015 45 children RCT IV steroid 











T (cTnT)  
cTnT lower in patients in both at 
induction and in prime steroid 
recipients versus placebo, 6 hours 
post-CPB wean 
higher blood 




Pesonen et al 2017 45 children RCT of steroid 













binding protein and TnT 
decreased 6 hours post-op in both 
steroid regimens  




Table 4Retrospective studies of the effect of steroids on clinical outcomes 




Study design Type of steroid Dose  Route Regimen/timing Effect steroids 
on 
Inflammation 




Pasquali et al. 2010 46 730 
children 





no data no 
data 
on the day before or day 
of surgery 
Not assessed Corticosteroids were 
associated with longer length 
of stay, greater infection, 
greater use of insulin, 
increased morbidity was 
most prominent in RACHS-1 
categories 1 through 3 (lower 
risk groups) 
Harm 
Pasquali et al. 2011 3180 
neonates 
Retrospective,  methylprednisolone no data no 
data 
methylprednisolone on 
the day before surgery 
and day of surgery, day of 
surgery only and day 
before surgery only 
Not assessed in a lower surgical risk 
group, there was a significant 
association of 
methylprednisolone with 
infection consistent across all 
regimens  
Harm 
Mastropietro et al.  2013 76 
children 
Retrospective methylprednisolone,  all methylprednisolone 
30 mg/kg, 
hydrocortisone 1 mg/kg 
(48%), dexamethasone 
0.5 mg/kg (86%) 
IV methylprednisolone 
before surgical incision, 
hydrocortisone 6 hours for 
hemodynamic instability, 
periextubation 
dexamethasone every 6 
hours  
Not assessed greater cumulative duration 
of corticosteroid exposure 
was independently 
associated with postoperative 
infection 
Harm 







cohort, 6 months 
prior steroid 
discontinuation) 
methylprednisolone,  30 mg/kg up to a 




in prime Not assessed steroids group had more 
postoperative wound 




Elhoff et al.  2016 549 
neonates 
Retrospective no data no data no 
data 
intraoperative Not assessed improved hospital survival in 






10.1.3 Relative Adrenal Insufficiency 
 
Another justification for the use of corticosteroids is the so-called relative adrenal 
insufficiency or adrenal cortex exhaustion, originally described during critical illness or sepsis.  
According to this definition, the concentration of plasma cortisol is not high enough to cope 
with the stress of surgery (Nair and Bonneau 2006; Annane 2000). Therefore, it is thought that 
perioperative steroid supplementation could cover for this potential deficit. However, defining 
relative adrenal insufficiency during critical illness remains a matter of debate, and very few 
studies have attempted to characterise the HPA axis physiology during surgery or critical 
illness in children. The most commonly used diagnostic criteria are the ACTH stimulation test 
described by Annane et al. (Annane 2000) In this test, synthetic ACTH (e.g. tetracosactrin) is 
given intravenously (Table 5). Cortisol is measured before and after the ACTH injection at 30 
and 60 minutes. Plasma cortisol was measured by enzyme-linked fluorescent assay. In 189 
consecutive adult patients with septic shock,  the authors found that an incremental cortisol 
response to ACTH (defined as the difference between the basal cortisol and the highest value 
between cortisol measured at 30 minutes and 60 minutes) of < 9 µg/dL (248.2  nmol/L) or a 
high baseline cortisol concentration (>34 µg/dL or >937.9 nmol/L) were of good prognostic 
value for identifying patients at risk of death (Annane 2000). However, this test is based on a 
few time-point value measurements of cortisol. Therefore, this could prove inaccurate in the 
context of a dynamic, pulsatile cortisol secretion that was described in both healthy volunteers 
or adults undergoing heart surgery (Ben Gibbison et al. 2015; R. C. Bhake et al. 2013). The 
major limitation of the current literature aimed at understanding the HPA axis function during 
pediatric heart surgery, trying to correlate the findings of the ACTH test with the measures of 




cortisol levels, the variability in the dose use for ACTH testing and most importantly the 
concomitant use of glucocorticoids at induction that obscures the assessment of the HPA axis 
(Gajarski et al. 2010; Garcia et al. 2010; Mackie et al. 2011; Wald et al. 2011b; Graham and 
Bradley 2017; Crawford et al. 2017; Teagarden and Mastropietro 2016; Maeda et al. 2016b; 
Mastropietro et al. 2014; Crow et al. 2014b; Bangalore et al. 2014; Schiller et al. 2013; Verweij 
et al. 2012; Sasser et al. 2012; Green and Koch 2012).  
 
Kucera et al. measured the plasma cortisol at 6-time points in 24 children of various 
ages (ranging from 2 months to 15 years): the day before surgery, at the end of surface cooling, 
at the lowest temperature during CPB, 10 minutes after rewarming, at the end of CPB and on 
the 8th day, postoperatively (Kucera, Hampl, and Stárka 1986). Serum cortisol was measured 
using radioimmunoassay, and the haematocrit was determined in each sample so that the 
cortisol was corrected to the actual haemodilution. They found the cortisol levels to be in the 
range of the normal laboratory values with a trend toward increased during rewarming. Anand 
et al. measured cortisol levels at 7 timepoints, in 15 neonates: pre-operatively, pre-CPB, during 
DHCA, at 6 hours, 12 hours and at 24 hours. Plasma cortisol was measured using 
radioimmunoassay techniques. The peaks in cortisol secretion were recorded before CPB, and 
at the end of the operation, then, the cortisol levels fell below preoperative values at 12 hours 
(Anand, Hansen, and Hickey 1990). Gajarski et al. measured cortisol at ten time-points in 58 
children: baseline - preoperative, time of surgery and every 6 hours up to 48 hours. They have 
stratified the cortisol profiles by patient groups: control (non-bypass or non-cardiac surgery 
procedures), CPB only (no DHCA), DHCA (no steroid used), and DHCA with steroid 
administration. The cortisol and ACTH peaked within 2 hours of surgery but without 
differences between the groups. In 9 patients, not from the DHCA-steroid group, they noted an 




(Gajarski et al. 2010). Plasma cortisol was measured using a radioimmunoassay kit. In 21 
neonates undergoing heart surgery with the use of CPB, Garcia and colleagues (Garcia et al. 
2010) assessed the HPA axis with a low dose ACTH stimulation test (1 µg) on day one 
postoperatively. The patients that had a significant serum cortisol increase after ACTH test 
(>50 µg/dL or >1379.3 nmol/L) also had a higher mean arterial blood pressure at 48 hours 
postoperatively. Serum cortisol levels were measured with a standardised chemiluminescent 
immunoassay. All patients included in the study had dexamethasone 0.5 mg/kg midnight before 
surgery and at induction. In 38 neonates undergoing complex heart surgery, Mackie et al. 
measured serum cortisol at 3 time-points: preoperatively, at 24 hours and 48 hours 
postoperatively. They found the higher cortisol levels to be associated with greater atrial filling 
pressure and lower cardiac index. Again, all patients received methylprednisolone (30mg/kg at 
induction) (Mackie et al. 2011). Wald et al. (Wald et al. 2011a), in 51 children undergoing 
surgery with the use of CPB, measured total cortisol and corticosteroid-binding globulin levels 
pre- and postoperatively and after an ACTH test (subjects bellow two years received 125 µg 
while subjects > 2 years received 250 µg). The decreased CBG and increased free cortisol (> 
6 µg/ml or >165.5 nmol/L) correlated with worse clinical outcomes (longer length of stay, 
longer ventilation time, increased fluid requirement). Total serum cortisol was measured using 
a chemiluminescent immunoassay. The authors found that only 17.6% of the patient had a low 
baseline total cortisol and all had a normal ACTH stimulation test. They concluded that total 
cortisol is not a good measure of HPA axis function in this setting. All patients received 1 
mg/kg of dexamethasone before CPB. Verweij et al.(Verweij et al. 2012) in a retrospective 
analysis of 62 patients with low cardiac output post paediatric heart surgery, found no effect of 
hydrocortisone administration in patients with insufficiency (defined as having basal plasma 
cortisol was  <100 nmol/l). Sasser et al. (Sasser et al. 2012) in a retrospective analysis of 41 




associated with worse clinical outcomes (lactate measurements, inotropic score, fluid 
requirement, arteriovenous saturation difference, mean blood pressure, mean CV, mean heart 
rate or ventilation time) and no difference in steroid responsiveness compared to the cortisol > 
10 µg/dL (275.8 nmol/L) group . Schiller et al.(Schiller et al. 2013) in a prospective analysis 
of 119 children undergoing heart surgery measured cortisol levels pre-operatively and at 18 
hours after surgery. The authors defined adrenal insufficiency as a measured postoperative 
cortisol level of less than 18.1 µg/dL (499.3 nmol/L) or a delta cortisol (e.g. the difference 
between postoperative cortisol and preoperative cortisol measurements) value of < 9 µg/dL 
(248.2 nmol/L). Plasma cortisol was measured using a solid-phase competitive 
chemiluminescent enzyme immunoassay. There was no significant correlation between 
patients that had adrenal insufficiency and the procedure complexity (low or high). 
Furthermore, the postoperative course (ICU stay ventilation time, lactate, urine output) of 
children with adrenal insufficiency, was not different from the ones without adrenal 
insufficiency. All patients included had methylprednisolone (30mg/kg) at induction. A study 
by Bangalore and colleagues (Bangalore et al. 2014) assessed postoperative serum cortisol 
levels at three time-points: immediately after surgery and in the first and second postoperative 
mornings. Serum cortisol was measured using a competitive immunoassay. The cortisol fell 
significantly over the first 24 hours. Higher postoperative cortisol measurements were 
associated with increased morbidity. All patient had methylprednisolone (30mg/kg) at 
induction. Crow et al.(Crow et al. 2014a) measured serum cortisol, and dexamethasone blood 
levels after 1 mg/kg of dexamethasone were administered pre-CPB in 32 infants undergoing 
cardiac surgery. Blood cortisol was measured by liquid chromatography-tandem mass 
spectrometry. They noted significant variability in dexamethasone levels and grouped the 
patients into high dexamethasone (>15 µg/dL or 413.7 nmol/L ) or low dexamethasone (<15 




higher dexamethasone levels had more pronounced suppression of cortisol levels 
postoperatively compared to basal levels, this did not translate into any impact on clinical 
outcomes. Teagarden et al. worked on 24 patients that underwent surgery for congenital heart 
disease(Teagarden and Mastropietro 2016) found that lower pre-hydrocortisone cortisol was 
associated with improved haemodynamics after hydrocortisone administration. Serum cortisol 
was measured using a radioimmunoassay technique. Maeda et al. (Maeda et al. 2016a) 
classified 32 neonates undergoing heart surgery into patients with adrenal insufficiency 
(baseline cortisol < 15 µg/dL ( 413.7 nmol/L) or incremental increase after testing of <9 µg/dL 
(248.2 nmol/L) and baseline total cortisol of 15-34 µg/dL or 413.7-937.9 nmol/L) and a group 
with normal adrenal function, after ACTH test (3.5 µg/kg of tetracosactide acetate). All patients 
received 1mg/kg hydrocortisone perioperatively every 6 hours up to 18 hours from first 
hydrocortisone dose. Only the patients diagnosed with adrenal insufficiency exhibited a 
significant increase in mean blood pressure and urine output as response to hydrocortisone 
administration. A recent study by Crawford et al. (Crawford et al. 2017) was aimed to correlate 
relative adrenal insufficiency to clinical outcomes in 40 neonates undergoing complex heart 
surgery. Like the studies discussed above, all patients received preoperative 
methylprednisolone. The authors defined adrenal insufficiency as <9 µg/ml (248.2 nmol/L) 
increase in cortisol at 30 min post ACTH test (cosyntropin 1 mcg). Serum cortisol was 
measured using an immunoassay. Five per cent of the patients had adrenal insufficiency post-
CPB, and this was significantly associated with increased serum lactate and higher inotrope 
requirement.  
We still do not have an accepted definition for adrenal insufficiency in children 
undergoing heart surgery; hence it is difficult to draw conclusions about the effect of 
corticosteroids on the adrenal function and clinical outcomes. Most of the studies so far used 




received corticosteroids at induction, therefore, making an accurate assessment of the HPA axis 
almost impossible.  
Another question that arises from this literature review is what the best method of 
measuring cortisol is? Most of the studies have used a radioimmunoassay method.  One 
limitation of this technique is the use of specific antibodies that can cross-react with other 
endogenous or exogenous steroid, thus providing inaccurate.  Furthermore, the current assays 
that measure total cortisol (bound and unbound). This implies that any conditions that affect 
the concentration of the binding proteins can provide inaccurate results. For example, cortisol 
concentration can be falsely low in liver conditions or very unwell patients that are associated 
with low binding protein concentration. On the other hand, pregnancy or use of oral 
contraceptives can result in a higher cortisol concentration.  The mass methods such as gas 
chromatography-mass spectrometry (GC-MS) or LC-MS (liquid chromatography-mass 
spectrometry) outperform radioimmunoassay methods in terms of specificity and sensitivity 





Table 5 Studies aimed at understanding the hypothalamic-pituitary adrenal axis function in children. 
First 
author 




Frequency of cortisol 
measurement  
ACTH test ACTH test dose Definition of adrenal 
insufficiency used in the 
study 
Correlation to clinical outcome Main finding 
Kucera 
et al  
1986 24 children Observational  no data 6 1 time-point day before 
surgery, 4 time-points 
day of surgery and 1 
timepoint 8th day of 
surgery 
no NA none not assessed cortisol levels to be in 
the range of the normal 
laboratory values with a 




1990 15 neonates Observational  no  7 pre-op, pre-CPB, 
during DHCA, end of 
the operation, 6 hours, 
12 hours and 24 hours.  
no NA none survival rate non-survivors (n=4) 
had higher 
concentrations of 
cortisol than survivors 
Gajarski 
et al.  
2010 58 children Observational  10 patients in the 
DHCA arrest 
group 
10 before surgery, after 
surgery, 6, 12, 18, 24, 






NA ACTH/ serum cortisol ratio 
cut-off of >15 
Peak cortisol level did not correlate 
with simultaneous inotrope score; 
nine patients had increased 
ACTH/cortisol ratios in association 
with elevated inotrope requirement 
(none of these patients had steroids) 
cortisol peaked within 2 
hrs of surgery; ACTH 
inversely correlated 
with bypass time in 
patients with DHCA 




2010 21 neonates Retrospective All patient’s 
dexamethasone 
0.5 mg/kg before 
surgery 









1 μg basal serum cortisol level ≤ 
20 mg/dL and a post-
stimulation serum cortisol 
increase ≥ 9 mg/dL 
all neonates with haemodynamic 
instability had low basal serum 
cortisol; 48 hours post-surgery the 
mean arterial pressure in the groups 
with a serum cortisol increase after 
ACTH stimulation (<30 mg/dL 
vs>50 mg/dL) was significantly 
different 
cortisol level cut-off of 
≤20 mg/dL may not be 




et al.  
2011 38 neonates Observational  all patients had 
Methylprednisolo
ne, 30 mg/kg, IV 
at anaesthetic 
induction 
3 preoperative, at 24 
hours and 48 hours 
post-surgery 
no NA none Higher cortisol levels were 
associated with greater atrial filling 
pressures and a lower cardiac index 
cortisol levels were low 
in most subjects 
Wald et 
al  
2011 52 children Observational  all patients had 
received 1 mg/kg 
dexamethasone 
before CPB, not 
to exceed a 10-mg 
total dose 
2 pre - and postoperative no cosyntropin: 250 
μg for children >2 
yrs. of age and 
125 μg for 
children < 2 years 
reference range for normal 
total plasma cortisol was 3–
21 µg/dL. Free cortisol in 
critical illness was defined as 
>2.0 g/dL. A normal free 
cortisol value after 
cosyntropin test was defined 
as > 3.1 g/dL and total serum 
cortisol increase ≥ 9 mg/dL 
nine patient had low total cortisol 
(<3 µg/dL) baseline but normal 
ACTH stimulation test). Patient 
with free cortisol increase 
difference of > 6 μg/dL had a 
longer length of stay, higher 
inotrope scores, greater fluid 
requirement, longer ventilator times 
using total cortisol to 
investigate adrenal 
















Frequency of cortisol 
measurement  
ACTH test ACTH test dose Definition of adrenal 
insufficiency used in the 
study 
Correlation to clinical outcome Main finding 
Verweij 
et al. 




Retrospective all patients 
dexamethasone 
0.5 mg/kg before 
surgery 
1 basal cortisol no NA bassline value of total 
cortisol of <100 nmol/l and 
a similar effect of hydrocortisone in 
the groups with low or normal basal 
cortisol levels  
baseline value of total 
cortisol of <100 nmol/l 
not adequate to define 
adrenal insufficiency 
Schiller 
et al.  




ne, 30 mg/kg to a 
maximum dose of 
300 mg/kg, at 
induction 
2 before and 18 hours 
after surgery 
no NA postoperative cortisol level 
<18.1 µg/dL or delta cortisol 
(postoperative cortisol - 
preoperative cortisol) <9 
µg/dL 
normal adrenal function (NAF) 
subgroup had greater inotropic 
support at 12, 24, and 36 h after 
surgery and a higher lactate level at 
12 and 24 h after surgery; no 
differences in outcomes between 
patients with adrenal insufficiency 
and normal adrenal function in the 
first 36 hours, no correlation 
between adrenal insufficiency and 
procedure complexity 
adrenal insufficiency 
does not translate into 
worse clinical outcomes 
Bangalor
e et al.  
2014 33 neonates Observational  all patients 
methylprednisolo
ne, 20 mg/kg, at 
induction 
3 day 0 (after intensive 
care unit admission); 
day 1 (first morning of 
surgery), day 2 (second 
morning of surgery) 
no NA basal cortisol of less than 16 
μg/dL, with a change in 
cortisol of less than 9 μg/dL 
after cosyntropin 
Higher cortisol was associated with 
greater morbidity, including the 
need for preoperative ventilation, 
increased total duration of 
ventilation, duration of inotropic 
support, and hospital length of stay 
high postoperative 









7 after anaesthesia 
induction, after CPB, 
after intensive care unit 
(ICU) arrival, and 4, 8, 







NA NA no difference in clinical outcomes 
between patients with high 
dexamethasone levels (≥ 15 mg/dL) 
and low dexamethasone levels ( ≤ 
15 mg/dL); cortisol levels remained 
low throughout the first 24 
postoperative hours even after 
dexamethasone levels neared zero 
dexamethasone levels 
are highly variable 
despite a standardised 
administration protocol 
Teagard
en et al.  
2016 24 patients 
















no NA Favourable responders were 
defined as patients in whom, 
at 24 hours after 
hydrocortisone initiation, 
either (1) systolic blood 
pressure was increased or 
unchanged and vasoactive- 
inotrope score was decreased 
or (2) systolic blood pressure 
increased by ⩾10% of 
baseline and the vasoactive-
inotrope score was 
unchanged 
serum cortisol obtained before 
initiation of hydrocortisone was 
significantly lower in patients who 
responded favourably 
total serum cortisol 
may, therefore, be 
helpful in identifying 
children recovering 
from cardiac surgery 













Frequency of cortisol 
measurement  
ACTH test ACTH test dose Definition of adrenal 
insufficiency used in the 
study 
Correlation to clinical outcome Main finding 
Maeda et 
al.  
2016 32 neonates Retrospective Hydrocortisone 1 
mg/kg, was given 
every 6 hours 
immediately after 
ACTH test 
3 baseline and at 30 and 
60 minutes after the 
tetracosactide 
stimulation 
yes 3.5 μg/kg of 
tetracosactide 
acetate 
baseline cortisol <15 μg/dL 
or incremental increase after 
testing of <9 μg/dL 
one-fifth of infants developed 
adrenal insufficiency, steroid 
administration in these patients 
resulted in a significant increase in 
blood pressure and urine output 
steroid replacement 
therapy improved 
hemodynamic only in 
the subgroup with 
adrenal insufficiency 
Crawfor
d et al.  
 
40 neonates Retrospective methylprednisolo
ne 10mg/kg 8 h 
and 1 h 
 
basal and 30 minutes 






1 μg cosyntropin 




ne; and the second 
1 h after 
separation from 
CPB 
AI was defined as <9 μg/dL 
increase in cortisol at 30 min 
post ACTH test 
32.5% had adrenal insufficiency 
post CPB, AI was associated with 
increased median colloid 
resuscitation, higher serum lactate 
adrenal insufficiency 
determined by a low 
dose ACTH test occurs 
in one-third of the 
patients is not affected 






10.1.4 Corticosteroids and cerebral protection 
 
Cardiac surgery with the use of deep hypothermic circulatory arrest2 is known to be 
associated with impaired cerebral oxygen metabolism and cerebral oedema (Langley et al. 
2000; Greeley et al. 1991). Corticosteroids are used to treat cerebral oedema secondary to brain 
tumours (Koehler 1995) but are were previously used in the context of head trauma (Olldashi 
et al. 2004). Therefore, by extrapolation, another justification for the use of corticosteroids in 
deep hypothermic circulatory arrest (DHCA) surgery. However, if we look at the large CRASH 
trial, this showed an increase in death at two weeks and six months with steroid use (Baigent 
et al. 2005; Olldashi et al. 2004). The evidence of the impact of corticosteroids on brain 
protection during the use of DHCA has not been studied extensively. This evidence is limited 
to in vitro studies (Schmitt et al. 2006) and in vivo experiments on piglets (Schubert et al. 2005; 
Langley et al. 2000) and the results are quite conflictive.  
 
Schmitt and colleagues investigated the effect of deep hypothermic circulatory arrest 
on an in vitro model of mouse neonatal astrocytes, neurons and BV-2 microglia cells. The 
effect of methylprednisolone (100 nM) was tested in cells that were incubated according to a 
protocol that mimics the temperature changes during paediatric deep hypothermic circulatory 
arrest: deep hypothermia, slow rewarming and normothermia. The authors measured in all cell 
lines the cytotoxicity and the production of IL-6 as a marker for neuroprotection and 
regeneration. While steroid administration did not affect the normothermic treated cells, in the 
 
2 Deep hypothermic circulatory arrest (DHCA) is a surgical technique that involves cooling the body 
temperature (with the help of the CPB machine) to 14 to 20 degrees Celsius followed by complete cessation of 




deep hypothermia treated cells methylprednisolone increased cell survival but decreased the 
protective IL-6 (Schmitt et al. 2006).  
Langley et al. randomised two groups of 8 piglets to placebo and methylprednisolone 
30 mg/kg, intramuscularly, given 8h and 2 hours before induction. All piglets underwent 
cooling to 180C, 60 minutes of circulatory arrest and 60 minutes of reperfusion and rewarming. 
The steroid arm had a significantly higher recovery of the cerebral blood flow and cerebral 
oxygen metabolism (Langley et al. 2000). In a later study, Schubert and colleagues randomised 
two groups of 7 neonatal piglets to methylprednisolone (30 mg/kg), intravenous, given earlier, 
at 24 hours before surgery and placebo. The piglets were then cooled to a lower temperature - 
150C and had a more extended period of DHCA – 120 minutes and rewarming for 40 minutes. 
The authors conducted quantitative histological studies in the various brain regions: 
hippocampus, cortex, cerebellum and caudate nucleus. The steroid arm had more neuronal cells 
death and neuronal apoptosis in the dentate gyrus and hippocampus.  
The neuroprotective potential of corticosteroids in cases of paediatric heart surgery with 
the use of deep hypothermic circulatory arrest has been the least studied. The current evidence 
is contradictory, and the results from the available animal studies highlight the need for human 




I found no clear evidence that the anti-inflammatory effect of corticosteroids does 
translate into better clinical outcomes. Most randomized studies in the literature report too few 
patients, different endpoints and use various steroid types, doses and regimens. A trial on 
neonates found a potential benefit of steroids in new-borns undergoing palliative procedures. 




populations, they are limited by their retrospective design. The effect of corticosteroids on 
clinical outcomes will need to be clarified by a large, multicentre, randomised controlled trial 
with clear agreed methodology and aims. Our knowledge about the basic physiology of the 
hypothalamic-pituitary axis during surgery remains limited, and it is unclear how to define 
adrenal insufficiency in the context of paediatric heart surgery and if corticosteroids do play a 
role. Such an understanding of the dynamic, pulsatile cortisol secretion can be gained from 
studies that use frequent time-point measurements in patients not receiving corticosteroids. 
Finally, the neuroprotective effect of corticosteroids during deep hypothermic circulatory arrest 



















10.2 Corticosteroids and Other Anti-Inflammatory Strategies in Paediatric Heart 
Surgery: A National Survey of Practice 
 
Sections 10.2.1 to 10.2.4 were largely taken from an original article published in the 
World Journal for Pediatric and Congenital Heart Surgery (D. P. Fudulu, Schadenberg, et al. 
2018). The authors contributions were the following: Daniel Fudulu - conception and design 
of the analysis; collection of the data; the analysis and writing of the paper; Alvin Schadenberg 
- collection of the data, revision; Ben Gibbison -revision; Ian Jenkins - conception and design 
of the analysis; Stafford Lightman, Gianni Angelini - supervision, revision; Serban Stoica - 
supervision, revision and collection of the data. 
 
10.2.1 Introduction  
As seen in the previous chapter, there is a lack of evidence and even consensus on the 
utility of steroids for heart surgery with the use of CPB. This lack of consensus was also 
reflected locally, in the Bristol Children’s Hospital, which was the first recruitment centre for 
the Peacock study (see next chapter). Some of the consultants were reluctant in omitting 
steroids for the patient recruited in the Peacock Study. Therefore, we decided to design a 
national survey to assess current preferences consultant anaesthetists in the UK to administer 
steroids in paediatric heart surgery with the use of CPB. As a secondary objective, we also 
surveyed the use of other anti-inflammatory strategies including modified ultrafiltration, 
aprotinin and heparin-coated circuits.  
 
10.2.2 Material and Methods 
A 19-question survey was distributed to the Congenital Cardiac Anaesthetic Network 




2015-November 2016 period, and several iterations were conducted until an adequate response 
from all units was received. Results were collected using the Survey Monkey Inc. platform, 
San Mateo, California, USA and analysed using Graph Pad Prism version 7.00 for Windows, 












The survey was sent to 60 consultants from all 12 National Health Service (NHS) units 
across the UK and Ireland performing paediatric heart surgery. We received 37 responses 
(61.7%) with an average of 3 responses per centre (ranging from 1 to 5 responses). In 5 out of 
the 12 centres, the practice of administering steroids varied between consultants within that 
centre (Figure 23 B). Out of the 37 respondents from the UK and Ireland: 24 (64.8 %) reported 
the use of CS while 13 (35.1%) do not use CS at all. Seven (7/24, 29.1%) anaesthetists 
administer CS in every case while 17 (17/24, 70.8%) in selected cases only (Figure 23 A).  
There were 29 indications cited for steroid use in total, ranging from 1 to 6 indications 
per respondent (n=17). The most common indications for corticosteroid administration was  
surgery in neonates (9, 31%), surgery with use of DHCA (9, 31%), re-do cases (2, 6.9%), the 
Norwood operation (2, 6.9%), high perioperative inotrope requirement (2, 6.9%), complex 
atrial/ventricular septal defects (2, 6.9%), switch operation (1, 3.4%), long CPB time (1, 3.4%) 
and surgery in infants (1, 3.4%)  
The most widely used corticosteroid was dexamethasone; used by 17 consultants 
(17/24, 70.8%) followed by methylprednisolone used by 4 (4/24, 16.7%) and hydrocortisone 
used by 3 consultants (3/24, 12.5%). Almost all consultants (23/24, 95.8 %,) administer a single 
dose of steroid at induction, and only one (1/24, 4.2%) administers a two-dose regimen (dose 
at induction and one at 6 hours from the first dose). Dexamethasone doses ranged from 
0.5mg/kg to 1 mg/kg, methylprednisolone dose ranged from 20mg/kg to 30mg/kg, and 
hydrocortisone was administered at a dose of 4mg/kg. If we calculate the equivalent anti-
inflammatory dose of dexamethasone for the rest of CS administered, there is a further variation 




 Most consultants (24/37, 65.9%) use modified ultrafiltration3 after CPB. Seven 
consultants (7/24, 29.25%) use ultrafiltration in children up to 6kg, 13 (13/24, 54.2%) in 
children up to 10 kg and 4 consultants (4/24, 16.7%) in children over 10 kg. Out of the 32 
respondents: 15 (15/32, 46.9%) consultants use aprotinin and only 3 (3/24, 9.4%) heparin-





3 Modified ultrafiltration is a technique that tackles the capillary leak syndrome associated with the paediatric 
cardiopulmonary bypass and that results in increased content of water in the tissue. The technique is applied immediately after 















Corticosteroid N % Dose range (mg/kg) Dexamethasone equivalence (mg/kg) 
Dexamethasone 17 71% 0.5 - 1 0.5 – 1 
Methylprednisolone 4 17% 20 - 30 4 -6 




10.2.4 Discussion  
Across the UK and Ireland, approximately 4500 paediatric heart operations involving 
CPB are performed every year(“CCAD - Congenital Analysis - Summary Data - By Year” 
n.d.). Therefore, understanding the impact of steroids on clinical outcomes is a significant 
health issue. In contrast to previous surveys (Allen et al. 2009; P. A. Checchia et al. 2005), we 
have also assessed the preference of steroid administration not only between centres but also 
within centres. In the survey by Checchia et al. 36 responses were returned from each centre 
representative (P. A. Checchia et al. 2005), and in the survey, by Allen et al. (Allen et al. 2009) 
only 12 responses were returned in total from centre representatives. Neither study looked at 
variation within centres. In our survey, we found variation in steroid preferences within five 
centres. This suggests the lack of local consensus between consultants and a lack of protocols 
in individual centres.  
More than half of consultant anaesthetists use CS in paediatric heart surgery (65%) in 
some form. However, we noticed a trend in reduced CS use compared to an international survey 
by Chechia et al.(P. A. Checchia et al. 2005) from 2005 (97%) and an older UK survey by 
Allen et al. (Allen et al. 2009) (80%). Out of the consultants that use CS, the majority 
administer them in selected cases only (71%) compared to 60% and 58% in the previous 
surveys of practice (P. A. Checchia et al. 2005; Allen et al. 2009). This trend towards reserving 
CS for selected cases reflects the ongoing lack of consensus and need for further evidence in 
the “high risk” patient groups.  
We found variability in the indications of CS use. The most common indications for 
steroid use were surgery in neonates (31%) and use of DHCA (31%). Indeed, we know very 
little about the stress response in neonates. The immaturity of their HPA axis means they are 
less likely to cope with the stress of surgery (Green and Koch 2012). We conducted a recent 




2016). The use of CS for neuroprotection in cases with use DHCA is another unanswered 
question. The available studies assessing the effect on brain protection used piglet CPB models. 
A study by Langley et al. suggested cerebral protection if methylprednisolone (MP) is given 
early: 8 to 12 hours pre-operatively (Langley et al. 2000). 
On the other hand, a study by Schubert et al. (Schubert et al. 2005) showed no benefit 
for MP 24-hour pre-treatment. Other indications for CS were aimed at the high-risk procedure 
groups. There are a few studies in this group, and the evidence is again conflicting. In a small 
RCT of 20 neonates undergoing arterial switch, pre-treatment with MP reduced the expression 
of myocardial and plasma cytokines that translated in lower inotrope requirement and 
decreased myocardial damage(Heying et al. 2012). A large retrospective analysis of 549 
neonates who underwent the Norwood procedure found intraoperative steroid administration 
was not associated with improvement in outcome. 
Furthermore, steroid non-recipients had better hospital survival but longer intensive 
care and hospital stays (Elhoff et al. 2016). With regards to inotrope requirements, there is 
some evidence that so-called “rescue” steroids improve hemodynamically and lower inotrope 
requirement (Neunhoeffer et al. 2015). In an RCT of 40 neonates by Roberto et al. the use of a 
prophylactic postoperative steroid infusion reduced inflammation, improved fluid balance and 
urine output and allowed a faster wean from catecholamines or vasopressin(Robert et al. 2015). 
Similar to our survey of prophylactic steroid administration, a recent survey by Flores et al. 
(Flores et al. 2017) found significant variability in the indications for corticosteroid 
administration in patients with severe low cardiac output syndrome.  
We found variation in both the type of steroid used and in terms of the doses 
administered. This is a similar finding to previous surveys of practice (Allen et al. 2009; P. A. 
Checchia et al. 2005). Almost all consultants give one dose at anaesthesia induction, and only 




A few studies on piglet CPB models found some benefit of early CS administration on 
pulmonary function (Lodge et al. 1999) and brain protection (Langley et al. 2000).  
In contrast to US practice, where steroids are administered in the majority of the cases 
in the CPB prime solution (the fluid that is in the CPB prior to going on “bypass”) (Ungerleider 
2005), in our survey we noted that steroids are given most of the time pre-operatively, at 
anaesthetic induction. A three-arm RCT of 45 children evaluated the effect of 
methylprednisolone administration in CPB prime versus intravenously (at anaesthetic 
induction) during cardiac surgery. There was no difference in terms of clinical outcomes 
between the three groups. However, steroids given at induction were superior in terms of anti-
inflammatory effect compared to the CPB prime route(Keski-Nisula et al. 2015).  
Modified ultrafiltration use in paediatric heart surgery can remove the excess of water 
and inflammatory mediators during CPB. The impact on the postoperative course is 
haemoconcentration, reduced need for transfusions, and improvement of cardiac and 
respiratory function (Wang, Palanzo, and Ündar 2012). According to previous surveys, its use 
amongst paediatric heart surgery centres ranged from 75-80% (P. A. Checchia et al. 2005; 
Allen et al. 2009). In the current survey, fewer centres used MUF (e.g. 66%). This could be 
explained by the emergence of low prime volume extracorporeal circuits, avoidance of severe 
haemodilution or efficient use of conventional ultrafiltration that no longer justifies the use of 
MUF and its associated risks (Jonas 2017). Aprotinin is a potent anti-fibrinolytic but also has 
anti-inflammatory properties that could be advantageous in paediatric heart surgery. However, 
its safety profile in both adult and paediatric patients remains a matter of debate (Goobie 2014). 
This is reflected in the current survey, where about half of the consultants reported its use.  
There are no studies to date investigating the combined effect of the various anti-
inflammatory modalities. The strengths of this survey are the analysis of steroid variation 




response rate of only 61.7 %. However, this compares to previous surveys on this topic (P. A. 
Checchia et al. 2005; Allen et al. 2009). Another source of bias could be steroid administration 
by other healthcare professionals, including surgeons, intensivists or perfusionists. However, 
within the UK, the prophylactic, perioperative steroid administration is usually governed by 
the paediatric cardiac anaesthetist. 
The current survey offers the following observations. The use of prophylactic 
corticosteroids in paediatric heart surgery remains a matter of intense debate. We found 
variations in steroid administration both within centres and between centres. Most consultant 
anaesthetists give steroids in selected cases. However, there was heterogeneity in the cited 
indications, dose and type of steroid used. Of those that used steroids, almost all administer a 
single dose of CS preoperatively at induction. These results reflect the lack of evidence from 
placebo-controlled randomised trials of CS versus placebo, powered to look at the impact on 
clinical outcomes. In the context of the low mortality and morbidity associated with paediatric 
heart surgery, the obstacle to conducting such research is the recruitment of a sufficiently large 
sample size to detect any effect. This also implies that the effect size of corticosteroid use is 
small across a population or may be limited to selected pathologies. This survey also highlights 
the need to investigate the role of steroids in the “vulnerable” patient groups such as neonates 











11 THE PEACOCK STUDY – A DETAILED CHARACTERISATION 
OF THE HYPOTHALAMIC-PITUITARY ADRENAL PHYSIOLOGY 
DURING AND AFTER PAEDIATRIC HEART SURGERY 
 
“There is no more difficult art to acquire than the art of observation, and for some 
men it is quite as difficult to record an observation in brief and plain language” 
William Osler 
 
11.1 Introduction  
11.1.1 The knowledge gaps  
There is little research into the basic physiology of the HPA axis in children undergoing 
heart surgery. As shown in the previous chapters, no study to date has examined ultradian 
rhythms and therefore, pulsatile patterns of cortisol in children. Because of this knowledge gap, 
there is an ongoing debate around the modulation of the HPA axis function perioperatively to 
improve outcomes. Surgery with CPB is a potent activator of the systemic inflammatory 
response and hence of the HPA axis. It is believed that this activation is augmented in the 
paediatric population (D. P. Fudulu, Gibbison, et al. 2018).   
Our first difficulty in elucidating the role of steroids in paediatric CPB is our lack of 
understanding of the systemic inflammatory response to surgery and the difficulties of 
detecting a significant treatment effect in the context of a low mortality or morbidity results of 
contemporary paediatric heart surgery. As shown in the previous chapter, there is a lack of 
HPA axis physiology understanding. This stems from the difficulty of measuring plasma 
cortisol frequently enough due to the limitations of multiple blood samples taken from a small 
circulating volume - particularly in low weight babies. Indeed, an accurate assessment of the 




have measured cortisol at a few time points over long periods (D. P. Fudulu, Gibbison, et al. 
2018). Another common limitation of these studies is that they have attempted to assess HPA 
axis function after potent corticosteroids have been given pre-operatively (Gajarski et al. 2010; 
Mackie et al. 2011; Bangalore et al. 2014; Maeda et al. 2016a; Garcia et al. 2010; Wald et al. 
2011a; Schiller et al. 2013; Crawford et al. 2017; Verweij et al. 2012; Sasser et al. 2012; 
Teagarden and Mastropietro 2016; Anand, Hansen, and Hickey 1990) (Figure 24). Finally, 
defining abnormal HPA axis physiology by using limited points of cortisol or synthetic adreno-
corticotropic-hormone stimulation tests is inaccurate in the context of the dynamic cortisol 
release. 
The Peacock Study aimed to gain some understanding of the HPA axis physiology in 
children of various ages, not receiving perioperative steroids and undergoing various cardiac 
procedures. This was achieved by using a novel automated tissue microdialysis system that 
allows very frequent and cortisol measurements that allows the dynamic, pulsatile nature of the 
system to be seen. I this chapter I will discuss our methods, the study protocol and data from 






Figure 24 Limitations of our understanding of the paediatric HPA axis stress 
response to surgery in children 
 
11.2 Hypothesis and aims 
 
The following hypotheses were tested: 
1. The use of an automated microdialysis system is a feasible method of measuring 
cortisol profiles in children; 
2. Children display a dynamic, pulsatile cortisol response in response to surgery 
3. The cortisol patterns vary according to the: 
a. Age of the child 
b. The underlying heart defect (e.g. cyanotic vs acyanotic defects) 
c. Pubertal state (pre- and post-pubertal) 
d. Type of procedure (open heart surgery with the use of CPB versus 





Furthermore, the aims of the thesis are reported as the following: 
1. To assess the performance of an automated tissue microdialysis system in 
measuring cortisol in children undergoing heart surgery and cardiac procedures; 
2. To measure tissue cortisol and cortisone profiles in children undergoing heart 
surgery and cardiac procedures recruited in the various patient groups set up in 
the study protocol; 
3. To measure serum cortisol, ACTH, CBG, cytokines and sex hormones at the 
various time-points set up in the protocol; 
4. To record various clinical outcomes for correlation with the hormone profiles 




11.3.1 Overview of the 24-hours automated microdialysis system structure 
 
The principle of microdialysis involves the insertion of a small microdialysis catheter 
in the tissue that allows continuous monitoring of the tissue chemistry. A physiological, 
isotonic solution is slowly pumped through a semipermeable membrane and this solution is 
equilibrated with the surrounding tissue fluid (extracellular fluid). This allows an accurate 
measurement without the need o blood sampling.  
The ideal measurement of cortisol measurement in children has to be acceptable for 
patients, parents and staff. Specifically, it must be reliable and automatic to facilitate a frequent 
cortisol measurement and must also have minimal impact on the circulating blood volume of 
the child. This is crucial, especially in neonates, that are in a critical state perioperatively and 




transfusions. Our research group has described a similar automated 24-hour sampling system 
for the measurement of tissue free cortisol in healthy adult volunteers (Bhake et al. 2013. The 
structure of this system has already been described in detail (R. C. Bhake et al. 2013). Briefly, 
the system is made from 3 parts (Figure 1): (1) microdialysis pump (CMA 107 pump, 
MDialysis, Sweden); (2) microdialysis catheter (66 linear microdialysis catheter, MDialysis, 
Sweden), (3) sample collector/fractioner (Designworks, Windsor, UK) (Figure 25). These 
components are interconnected by delicate tubing connectors that are assembled at the time of 
insertion. The original design has undergone several modifications to allow successful 
application in the operating theatre environment, where the catheter tubing is prone to kink or 
disconnect during surgery or patient transfer and as a result of clinical time pressures. Notably, 
the connections were reinforced by silicone tube wrapping, and most of the components are 
preassembled to reduce the insertion time.  
 









11.3.2 The pump 
 
The microdialysis pump (CMA 107, Mdialysis, Sweden) (Figure 26) is set to perfuse 
fluid 1microL/min for 20-minute sampling. The fluid is pushed into the microdialysis catcher 
(MD 66 linear, Mdialysis, Sweden).  
 
Figure 26 The Microdialysis pump 
 
11.3.3 The microdialysis catheter 
The microdialysis catheter has a 3-cm dialysis membrane that is placed subcutaneously 
via which the dialysis of cortisol in the perfusion fluid occurs. The dialysate is then pushed 
from the catheter, via FEP 20 cm cut tube into the sampling device (Figure 27).  
 







11.3.4 The sampler  
The sampler contains the sample store (e.g. the spool) and the mechanism that allows 
separation of the column of fluid that the sampler receives. This includes a pressure sensor, a 
servo pump, bubble pump and control electronics. A detailed description of the structure of the 
device can be found in Bhake et al. (R. C. Bhake et al. 2013) (Figure 28). 
 




11.3.5 The FEP tubing 
The FEP (Fluorinated Ethylene Propylene) tubing is attached to the microdialysis 
catheter via so-called “pink-green” connector and the FEP tubing to the sampler device via a 
pink connector (Figure 29).  
 





11.3.6 The pink and the pink-green connectors 
These set of connectors are pre-dilated in 100% alcohol prior to insertion into the 
tubing. The pink connector is used to secure the FEP tubing to the sampler (metal manifold) 
and the pink-green connector to secure the microdialysis tubing (Figure 30 and Figure 31). 
 
Figure 30 "Pink-Green" connector 
 
Figure 31 Figure to illustrate how the pink and pink-green connectors are used to 
assemble the microdialysis system. The dotted line represents the flow of fluid from the 












11.3.7 The spool 
 
We used the newest version of the sampling device that enables collection up to 30 
hours without changing the spool. The device delivers air bubble every 20 minutes to separate 





Figure 32 The spool. 
 
 
11.3.8 Particularities of sampling of children undergoing heart surgery  
 
Children undergoing heart surgery tend to be very mobile post-extubation (turning off 
sedation and removal of the breathing tube). Some patients will be extubated very early either 
on the operating table or in the intensive care unit (ICU) as part of enhanced recovery protocols. 
This practice increases the chances of the microdialysis tube disconnections. Moreover, during 
patient transfers, the tubing system is particularly vulnerable. To overcome this, our research 
group (Dr Thomas Upton) has designed silicone covers for the connectors. These are pre-
dilated in petroleum-ether then applied to the connector. In contact with the air, these tubes 






Figure 33 The Upton-Kershaw connector protector 
 
 
11.3.9 The “FEP first” approach  
Because of time pressure during theatre insertion, one essential modification of the 
technique was to pre-fit the FEP tube to the sampler. This minimises the time of connection of 
the FEP to the sampler but also time for the insertion of the silicon protector. This modification 
has resulted in an increase in the number of samples since its introduction. (Figure 34).  
 
 





11.3.10 Insertion  
 
Insertion was carried out after the patient has been anaesthetised, and all catheters 
(central or arterial) have been inserted. This was done under aseptic technique, in the operating 
theatre. Insertion was in the left lower abdominal wall. Compared to the studies on healthy 
volunteers (Upton et al., Ultradian Study, ultradian.blogs.bristol.ac.uk/), we did not dispose of 
the first samples. This is because we wanted to record cortisol pulsatility during the critical 
period of surgery (i.e. from knife to skin time). Figure 35 depicts the equipment necessary prior 













Figure 36 The microdialysis system in situ. The zoomed-in picture depicts the removal 
of the microdialysis membrane from the subcutaneous tissue 
 
11.3.11 Disconnection  
If the patient completed a 24-hour cycle of sampling, the catheter was disconnected 
according to the following sequence: (1) pump disconnection, (2) sampler disconnection and 




11.3.12 Collection of samples 
 
The spool was disconnected from the sampler after approximately 3 hours – this allowed for 
the pressures within the spool tubing to equalize. After the spool unwinds, this was secured on 
a metal plate using magnets (the Fudulu and Upton modification) to keep in place during 
sectioning of the samples (Figure 37). Each sample was marked, and photos were taken to be 
able to retrospectively analyse the quality of the spool/samples or re-interpret the time-points 
(Figure 38).  
The samples were then cut and pushed in small Eppendorf tubes (Figure 38, 1) using 
an air syringe (Figure 38, 2), and then 10 microliters of the sample (Figure 38, 3) were pipetted 
in the 96 well plates (Figure 38,4). The cortisol levels were determined in each the sample 
using automated on-line solid-phase extraction-liquid chromatography-tandem mass 
spectrometry (SPE-LC–MS/MS) by our collaborators from the University of Groningen (see 






































Figure 37 Twenty-four-hour sampling. The spool is opened and secured with 




11.3.13 Tissue cortisol and cortisone analysis  
 
After the end of the 24-hour sampling period, the fluid samples (20 microliters/per 
sample), separated by air bubbles, were collected inside of a 4,5 m tubing that was rolled onto 
a spool. The spool was opened, and careful recording of the timing and separation of each 
sample was undertaken (Figure 38, 1). The samples were then pipetted in plates for further 
analysis.  
The samples are isolated by cutting the tubing (between the air bubbles) (Figure 38,1). 
This can be a very tricky step because the plastic tubing has memory and acts as spring that 
throws the samples out. Therefore, we have implemented a metal board with magnets to 
stabilise the spool once this is unrolled. The samples are then pushed out of the sectioned tubing 
into small Eppendorf tubes using and air-filled syringe. From the Eppendorf containing 20 µL 
of the sample, half of this volume (10 µL) is pipetted into the 96-well plate (Waters) for further 
analysis. The samples are sent to Groningen, the Netherlands for analysis.   
 
Cortisol and cortisone were measured in the microdialysate by isotope dilution liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) using cortisol-13C3 and cortisone-
D7 as an internal standard. In brief, 10 µL dialysate was pipetted into a 96-well plate (Waters), 
50 µL of internal standard and 90µL distilled water were added. The plate was mixed for ten 
minutes, and 2 µL was injected on the UPLC (Acquity) system equipped with a Kinetex 
Phenyl-Hexyl, 100 x 2.1 mm, 1.7 µm column (Phenomenex) in combination with a Xevo TQ-
s with electrospray ionisation in selective reaction monitoring mode (Waters). For cortisol and 
cortisone, intra- and inter-assay variability were below 6% and 5%, respectively. Limit of 

































11.4 Study Protocol 
 
11.4.1 Study design  
 
11.4.1.1 The cardiac surgery cohort  
This is a two-centre, descriptive study of the ultradian rhythms of cortisol that occur in 
neonates, infants and children. Forty-eight patients undergoing cardiac surgery will have 24-
hour tissue cortisol/cortisone microdialysis sampling after induction of anaesthesia up to 24 
hours (). Also, serum cortisol adrenocorticotrophic hormone (ACTH), interleukin 1 (IL-1), 
interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 9 (IL8), interleukin-10 (IL-10) and tumour 
necrosis factor-alpha (TNF-α) will be measured at 7-time points for infants and older children. 
The time points are pre-op assessment clinic blood, anaesthesia induction sample, pre-CPB, 
post-CPB, 6 hours post anaesthesia induction, 12 hours post anaesthesia induction and 24 hours 
post anaesthesia induction (Figure 39). In neonates, due to circulating blood volume limits, we 
will measure the above variables at 6 time-points only (the post-CPB sample is excluded). 
Cortisol binding globulin (CBG) will be measured at 4 time points only: pre-op assessment 
clinic blood, anaesthesia induction sample, 6 hours post anaesthesia induction and 24 hours 
post anaesthesia induction. The cohort will be further split into 4 groups (Figure 40). Neonates 
(6 cyanotic and 6 acyanotic heart disease), infants (6 cyanotic and 6 acyanotic heart disease), 
6 children aged 1-5 and, 18 patients aged 10-16. Acyanotic defects are classified based on pre-
op oxygen saturation > 89% (on room air) while cyanotic heart defects based on a pre-op 
oxygen saturation ≤ 89% on room air.  
 For the 10-16 year’s age group, we will recruit only the patients operated in the 
morning. This group will be further split into three subgroups. The pre-pubertal group (6 




either pubertal or post-pubertal group based on clinical criteria (e.g. presence of breast buds, 
periods, in girls and a testis volume greater than 4 mL in boys). The pre- and post-pubertal 
groups (18 patients) will have one morning sample of follicle-stimulating hormone (FSH), 






Figure 39 Sampling timepoints for the cardiac surgery cohort 




11.4.1.2 The cardiac investigation cohort 
We will also recruit a cardiac investigation cohort of 30 children (no neonate group). 
In this group, we will recruit six infants and six children (1-5-year-old). We will also recruit 
18 patients in the age group of 10-16 years. In this group, we will recruit six patients for the 
pre-pubertal group and 12 patients in the post-pubertal group (e.g. six males and six females) 
(Figure 41). 
Similarly, to the cardiac surgery cohort, all patients have / will undergo continuous 
tissue microdialysis sampling for cortisol and cortisone after anaesthesia induction up to 24 
hours, postoperatively. The cardiac investigation cohort patients will have only one basal pre-
op sample via the cannula inserted for anaesthesia and microdialysis sampling for 24 hours or 
until the patient is discharged. From this sample, we will measure serum cortisol, CBG, ACTH 
and the same interleukins measured in the surgical groups (Figure 42). 
 
 













Figure 42 Sampling time points for the cardiac catheter cohort 
 
11.4.2 Inclusion and exclusion criteria    
 
11.4.2.1  Inclusion criteria for the cardiac surgery cohort 
Participant may enter the study if ALL the following apply 
1. Age 0-5 or 10-16 years  
2. Undergoing cardiac surgery using CPB;  
3. Weight above 2 kg for neonate patients.  
We aim to recruit patients in each of the following categories: 
• Neonates 
• Infants 
• Age 1-5 
• Age 10-16 
11.4.2.2 Exclusion criteria for the cardiac surgery cohort 
Participant may not enter the study if ANY of the following apply: 




2. Current or recent (within 3 months) use of glucocorticoids 
3. Disorders of the HPA axis 
4. Thyroid disease 
11.4.2.3 Inclusion criteria for the cardiac investigation cohort 
Participant may enter the study if ALL of the following apply 
1. Age 0-5 or 10-16 years 
2. Undergoing minimally invasive cardiac investigation with anaesthesia. 
3. Weight above 2 Kg. 
We aim to recruit patients in each of the following categories: 
• Infants 
• Age 1-5 
• Age 10-16 
11.4.2.4 Exclusion criteria for the cardiac investigation cohort 
Participant may not enter the study if ANY of the following apply: 
1. Emergency investigation 
2. Current or recent (within 3 months) use of glucocorticoids 
3. Disorders of the HPA axis 
4. Thyroid disease 
 
11.4.3 Primary and secondary outcomes 
 
11.4.3.1 Primary outcome 
The primary outcome is the subcutaneous cortisol profile during the 24-hour 




• Tissue cortisol levels in all subjects are measured using subcutaneous 
microdialysis. For the surgical cohort, total serum cortisol will also be measured at 7 time 
points (pre-op assessment, pre-operative – before anaesthesia induction, pre CPB, post CPB, 
at 6, 12 and 24 hours postop) for infants and pre- and post-pubertal children and at 6 time points 
for neonates (post-CPB sample excluded). These will be correlated with tissue cortisol levels 
obtained by microdialysis over 24 hours.  
• For the cardiac investigation cohort, serum cortisol will be measured pre-
procedure (1-time point) for all age groups.    
• Pulsatility and interaction of cortisol and ACTH as assessed using a bespoke 
algorithm developed by our group. 
11.4.3.2 Secondary outcomes 
For the surgical cohort: 
- Adreno-corticotropic hormone (ACTH) Measured at seven-time points (pre-op 
assessment, pre-operative, pre CPB, post-CPB, at 6, 12 and 24 hours postop) for infants and 
pre- and post-pubertal children and at six-time points for neonates (post-CPB sample 
excluded). 
- Cortisol Binding Globulin (CBG) measured at four-time points (pre-op 
assessment, induction, at 6, and 24 hours postop) for. all age groups. 
- IL-1, IL-4, IL-6, IL8, IL10 and TNF-alpha measured at seven time-points (pre-
op assessment, pre-operative, pre CPB, post-CPB, at 6, 12 and 24 hours postop) for infants and 
pre- and post-pubertal children at and six-time points for neonates (post-CPB sample 
excluded). 
- FSH, LH and testosterone or oestradiol for 10-16-year olds only (pre-operative 
– before anaesthesia induction) 





b. Preoperative biventricular function; 
c. Cardiac arrest; 
d. Extracorporeal membrane oxygenation use; 
e. Renal insufficiency (creatinine more than two times normal); 
f. Hepatic insufficiency; 
g. Duration of mechanical ventilation post-cardiac surgery; 
h. Inotrope and vasopressors use 
i. Intensive care unit stay;  
j. Hospital Stay; 
k. Infection; 
l. Insulin use; 
m. Fluid retention (daily weights) 
For the cardiac investigation cohort:  
- Adreno-corticotropic hormone (ACTH) measured at 1 timepoint (pre-operative) 
- Cortisol Binding Globulin (CBG) measured at 1 timepoint (pre-operative) 
- . IL-1, IL-4, IL-6, IL8, IL10 and TNF-alpha measured at 1 timepoint (pre-
operative) 
- FSH, LH and testosterone or oestradiol for 10-16-year olds only (pre-operative 
- before anaesthesia induction)  
- Measure the following clinical outcomes to correlate with cortisol rhythms:  
a. Death; 
b. Preoperative biventricular function; 
c. Cardiac arrest; 




e. Hepatic insufficiency; 
f. Hospital Stay; 
g. Infection; 
h. Insulin use. 
 
11.4.4 Sample size calculation 
 
The lack of previous studies does not allow power calculation on the expected 
variations in ultradian rhythmicity of the HPA axis in children. However, the use of multiple 
samples from the microdialysis provides high discriminatory power and recent investigations 
from our group demonstrated very marked changes in pulse characteristics in a group of 20 
adult patients undergoing CABG compared to healthy individuals (Ben Gibbison et al. 2015). 
Furthermore, a study of 10 patients with obstructive sleep apnoea pre- and post- continuous 
positive airway pressure demonstrated significant changes in ACTH/cortisol ultradian patterns 
(David E Henley et al. 2009). 
 
11.4.5 Research procedures 
 
The cardiac surgery cohort will have blood sampling for serum cortisol, ACTH, CBG. 
IL-1, IL-4, IL-6, IL-8, IL10 and TNF-alpha. 
To minimise patient distress, we will synchronise a preoperative, basal, sample in the 
preoperative assessment clinic and before anaesthesia induction, along with other routine 
preoperative blood samples.   
Intraoperatively, samples will be collected from the arterial or central line, pre-CPB 




Postoperatively, blood samples will be spaced at 6, 12 and 24 hours postoperatively.  
Infants, pre- and post-pubertal children: At each time point, we will measure serum 
cortisol, ACTH and interleukins. CBG will be measured at 3-time points over 24 hours. 
(induction, 6 hours and 24 hours only). This results in a total blood volume of 1.3mL per draw 
for time points, including CBG sampling and 1.0ml for time points without CBG. If we 
measure at six-time points within 24 hours (e.g. we exclude the pre-assessment clinic sample), 
this results in a cumulative, perioperative blood volume draw of 6.9 mL. Previous policies and 
recommendations reported the safe limits of blood sampling for research in healthy children 
and the proposed study is well within limits (Howie 2011). Most guidelines quote a maximum 
cumulative draw volume ranging from 5-10 % of the total circulating volume, 50 mL total over 
8 weeks (whichever is less) and the lowest volume quoted is of 3mL/kg in critically ill children.  
Neonates: Neonates with cardiac disease are by their nature smaller than children 
without cardiac disease and therefore constitute a particular case. Hazinski et al. (Hazinski 
2012)  reported the circulating volumes at various ages from which we can calculate the 
circulating volume depending on weight, and calculate the maximum 5 % cumulative blood 
volume. For example, the circulating volume of a 2 kg neonate is 180 mL (90mL kg x 2), and 
5 % of this volume is 9 mL. However, to be within all guidelines, we will use the 3mLs/kg 
limit.  This would result in 3 x 2=6 mL maximum blood volume for measurements. This means 
that we would have to limit the weight in neonates to 2 kg and reduce the number of sampling 
time-points within the 24 hours from 6 to 5. In this case, we will omit the post CPB sample 
(see Figure 7) in order to be within the safety limits of all guidelines. This results in a 
cumulative blood volume for 24 hours of 5.9 mL, which is below the 6 mL lowest limit of the 
guideline.    
For the cardiac investigation cohort, blood sampling for serum cortisol, ACTH, CBG 




operatively. For this group, the weight limit can be lowered because of the need for only 1 
sample (1.3 mL total draw). Therefore, blood sampling will be theoretically possible in the 
cardiac cohort in neonates with a weight above 0.33 kg (although few, if any babies are likely 
to be as small as this).  
Modified ultrafiltration with CPB is commonly used in paediatric cardiac surgery to 
haemoconcentrate patients but also to reduce the systemic inflammatory response to CPB. 
Several studies demonstrated a decrease in the levels of specific pro-inflammatory cytokines 
such as IL6, IL8 or TNFα (Ziyaeifard, Alizadehasl, and Massoumi 2014). Although this could 
alter the levels of IL6 that will be measured in the blood, we believe that the free cortisol 
measured by subcutaneous microdialysis will not be affected because of the lipophilic nature 
of its molecule and a large volume of distribution.  
It is common for paediatric surgery patients to receive blood products such as red blood 
cell packs, fresh frozen plasma or Cryoprecipitate perioperatively. We were also planning to 
assay cortisol and ACTH in 10 units each of fresh frozen plasma or Cryoprecipitate, to 
determine the level of hormones in these blood products and any impact it may have on our 
analyses. However, we have not done after a discussion with NHS Blood and Transplant that 
advised us there is no cortisol in these blood products.  
 
11.4.6 Serum cortisol analysis  
 
The serum cortisol samples were analysed by the University of Bristol NHS Foundation 






11.4.6.1 Principle and Method of the Procedure Used for the Examination 
 
We used the Elecsys Cortisol II assay that makes use of a competition test principle 
using a monoclonal antibody which is directed explicitly against cortisol. Endogenous cortisol 
which has been liberated from binding proteins with danazol competes with exogenous cortisol 
derivative in the test which has been labelled with ruthenium complex for the binding sites on 
the biotinylated antibody (Morgan 2019). 
 
11.4.6.2 Test principle 
Competition principle. The total duration of the assay: 18 minutes (Morgan 2019). 
• 1st incubation: 10 μL of sample is incubated with a cortisol-specific biotinylated 
antibody, and a ruthenium complex labelled cortisol derivative. Depending on 
the concentration of the analyte in the sample and the formation of the respective 
immune complex, the labelled antibody binding site is occupied in part with 
sample analyte and in part with ruthenylated hapten. 
• 2nd incubation: After addition of streptavidin-coated microparticles, the 
complex becomes bound to the solid phase via interaction of biotin and 
streptavidin. 
• The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the electrode. 
Unbound substances are then removed with ProCell/ProCell M. Application of 
a voltage to the electrode then induces chemiluminescent emission which is 




• Results are determined via a calibration curve which is an instrument 
specifically generated by 2-point calibration and a master curve provided via 
the reagent barcode or e-barcode. 
11.4.6.3 Reportable Intervals 
• 3-1750 nmol/L (defined by the lower detection limit and the maximum of the 
master curve) (Morgan 2019). 
11.4.6.4 Results outside Reportable Intervals  
Values below the lower detection limit are reported as <3.0 nmol/L. Values above the 
measuring range are reported as >1750 nmol/L (Morgan 2019). 
 
11.4.7 Serum ACTH analysis 
 
The serum ACTH samples were analysed by the University of Bristol NHS Foundation 
Trust, Department of Biochemistry. 
11.4.7.1 Principle and Method of the Procedure Used for the Examination 
All blood ACTH samples were handled on ice. The Elecsys ACTH assay was used. 
This assay employs two monoclonal antibodies specific for ACTH and for the C-terminal 
region. Due to common antigenic structure, the antibodies recognise intact biologically active 
ACTH and the ACTH precursors: pro-opiomelanocortin (POMC) and pro-ACTH (Morgan. 
2019). 
11.4.7.2 Test principle 
Sandwich principle: Total duration of assay=18 minutes (Morgan. 2019). 
• 1st incubation: 50μL of the sample, a biotinylated monoclonal ACTH-specific 
antibody, and a monoclonal ACTH-specific antibody labelled with a ruthenium 




▪ 2nd incubation: after addition of streptavidin-coated microparticles, the complex 
becomes bound to the solid phase via interaction of biotin and streptavidin. 
The reaction mixture is aspirated into the measuring cell where the microparticles are 
magnetically captured onto the surface of the electrode. Unbound substances are then removed 
with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission 
which is measured by a photomultiplier. Results are determined via a calibration curve which 
is instrument-specifically generated by 2-point calibration and a master curve provided via the 
reagent barcode. 
 
11.4.7.3 Limits and ranges 
Measuring range: 
• 1.0-2000 ng/L (defined by the lower detection limit and the maximum of the 
master curve). Values below the lower detection limit are reported as < 1.00 
ng/L or. Values above the measuring range are reported as > 2000 ng/L. 
The lower detection limit is 1.00 ng/L. The lower detection limit represents the lowest 
measurable analyte level that can be distinguished from zero. It is calculated as the value lying 
two standard deviations above that of the lowest standard (master calibrator, standard 1 + 2 
SD, repeatability study, n = 21) (Morgan. 2019). 
 
11.4.8 Serum and tissue cortisol: levels to expect and correlations between blood and tissue 
compartments 
One pertinent question for the Peacock study is what levels of serum and tissue cortisol 
measurement we would expect. There is no study to date in children that investigated the 
correlation between blood cortisol and tissue cortisol. However, Cohen et al. (Cohen et al. 




plasma cortisol (total and free) in blood and the interstitial (tissue) cortisol using microdialysis 
in the burn and non-burn tissue. The authors used a Cortisol analysis was by ELISA for cortisol 
analysis. The mean total plasma cortisol was 8.8 +/- 3.9 mcg/ dL (242.7 +/- 107.6 nmol/L) and 
mean free plasma cortisol was 1.7 +/- 1.1 mcg/ dL (46.9 +/- 30.3 nmol/L). The corresponding 
tissue cortisol level measured by microdialysis was 0.80 +/- 0.31 mcg/dL (22 +/-  8.5 nmol/L) 
in the burn areas and 0.74 +/- 0.41 mcg/dL (20.4 +/- 11.3 nmol/L) in the non-burn areas with 
no significant difference between burn and non-area p=0.8). In a recent study by Bhake et al. 
(R. Bhake et al. 2019) on healthy volunteers correlated the total and free blood cortisol with 
tissue microdialysis cortisol after 250 µg Synacthen or 1 mg dexamethasone. They measured 
simultaneously cortisol in blood and tissue, every 10 minutes using automated devices. There 
was a good correlation between tissue and blood cortisol with no significant delay (e.g. less 
than 5 minutes).  For example, in one of their experiments, the median serum total cortisol pre-
Synacthen was 321 nmol/l (range 188-773) and at the peak was 973 nmol/l (range 778-1369) 
between 2 and 3 hours post-Synacthen. The corresponding median subcutaneous tissue cortisol 
levels obtained by microdialysis were 11.5 nmol/l (range 2.3-38.5) pre-Synacthen and at peak 
67.4 nmol/l (18.7-101.5) between 1-3.25 hours post-Synacthen. 
 
11.4.9 CBG assays  
 
The CBG was analysed using a commercially available kit (Kip1809) DiaSource 
Louvain-La-Neuve, Belgium.  
Method 
A fixed amount of 125I labelled CBG competes with the CBG present in the sample or in the 
calibrator for a fixed amount of anti-CBG antibody sites, which are bound to the goat anti-




room temperature, an aspiration step terminates the completion reaction. The tubes are then 
washed with 2ml of working wash solution and aspirated again. A calibration curve is plotted, 
and the CBG concentrations of the samples are determined by dose interpolation from the 
calibration curve (DIAsource ImmunoAssays 2019). 
Reagents 
• Calibrators: Reconstitute the zero calibrators with 3 ml distilled water and the 
other calibrators with 1 ml distilled water. 
• Controls: Reconstitute the controls with 0.5 ml distilled water. 
• Working Wash solution: Prepare an adequate volume of Working Wash 
solution by adding 69 volumes of distilled water to 1 volume of Wash Solution 
(70x) (2ml+138ml, 3ml+207ml). Use a magnetic stirrer to homogenise. Discard 
unused Working Wash solution at the end of the day. 
Specimen collections and preparation 
• Serum samples were kept at 2-8°C. 
• If the test is not run within 48 hrs, storage at -20°C was recommended. 
• Freeze-thaw cycles should be and were avoided 
• After thawing, the samples should be mixed and centrifuged. 
• The samples must be diluted 25 times in Dilution Buffer. 
• Recommended procedure: 100 μl serum + 2.4 ml Dilution Buffer. Use LP4 
tubes. 
Procedure 
1. Label coated tubes in DUPLICATE for each calibrator, control and sample. For the 
determination of total counts, label 2 standard tubes. 
2. Briefly vortex calibrators, controls and diluted samples and dispense 100μl of each 




3. Dispense 100 μl of 125Iodine labelled CBG into each tube, including the tubes for 
total counts. 
4. Dispense 100 μl of CBG antiserum into each tube (except total counts). 
5. Shake the tube rack gently by hand to liberate any trapped air bubbles. 
6. Incubate for 2 hours at room temperature with continuous shaking at 300 rpm. 
7. Aspirate (or decant) the content of each tube (except total counts). Be sure that the 
plastic tip of the aspirator reaches the bottom of the coated tube in order to remove all the 
liquid. 
8. Wash tubes with 2 ml Working Wash solution (except total counts) and aspirate. 
Avoid foaming during the addition of the Working Wash solution. 
9. Let the tubes stand upright for two minutes and aspirate the remaining drop of liquid. 
10. Count tubes in a gamma counter for 60 seconds. 
Calculation of Results 
The concentrations read on the calibration curve for the samples and controls must be 
multiplied by 25 (dilution factor) (DIAsource ImmunoAssays 2019). 
 
 
11.4.10 Cytokine analysis  
 
Cytokine analysis was performed in duplicate using MILLIPLEX® MAP multiplex kits 
on Luminex MAGPIX® system. The assay uses a mix of fluorescent-coded magnetic beads, 
each set coated with a specific capture antibody. Corresponding analytes (IL-1β, IL-4, IL-6, 
IL-8, IL-10 and TNFα) are bound to the bead during an overnight incubation with patient serum 




incubation with Streptavidin-PE conjugate reporter molecule. Each bead is identified, and a 
fluorescent reporter signal measured by the MAGPIX® system. 
 
11.4.11 Participant recruitment 
 
Patients undergoing non-emergency heart surgery and cardiology catheter were and 
will be invited to participate.  
 
11.4.11.1 Consent +/- assent will be obtained according to patient age:  
 
• 0-5 years: Parents/guardians of patients are expected to read and understand the 
parent/guardian information leaflet and (with the assistance of a member of the 
clinical team) explain the purposes and consequences of the study to the patient 
at a level suitable for their age, if appropriate. Parents/guardians are required to 
provide full, written, informed consent. 
 
• 10-15 years: Patients who can read and understand will be provided with a PIL, 
and parents/guardians will be provided with a parent/guardian information 
leaflet. Parental consent must be obtained for enrolment to be valid. In parallel, 
where appropriate, the patients will be given a suitable form to provide written 
informed assent to participate in the study. Failure to complete and sign this 






• 16 years: Patients aged 16 years are legally responsible for providing their own 
consent and will be provided with their own information leaflet and consent 
form. Parental signed consent can be taken besides using the parent/guardian 
consent form; however; this is not a necessity and alone is not sufficient for 
enrolment.  
 
Patients can be formally enrolled, and consent/assent obtained at various points 
preoperatively.  
Details of all patients approached for the study and reason(s) for non-participation (e.g. 
reason for being ineligible or patient refusal) were documented. 
 
11.4.11.2 Patients waiting at home  
 
During the first outpatient clinic, the parents/guardians of patients considered eligible 
for the study will be provided with an information leaflet. Following their meeting with the 
consultant surgeon, a member of the research team explained the details of the study in person 
and provided answers to any questions that might be raised. At this time, patients were also 
provided with a Patient Information Leaflet (PIL) suitable for their age group. Approaching 
parents/guardians and patients during their first clinic, ensured maximum time is given to 
consider participation. All information leaflets were approved by the Research Ethics 
Committee (REC).  
Consent/assent will be requested at the pre-assessment clinic (1-2 weeks prior to 
procedure). If consent/assent has not been sought before the patient’s arrival at the hospital for 
surgery, parents/guardians/patients have the opportunity to provide signed consent/assent up to 




On the rare occasions where parents/guardians/patients cannot be seen during pre-
operative clinics, the procedure for patients waiting in-hospital will be followed.  
Information leaflets may occasionally be sent directly to the patient’s home address 
with an invitation letter if a patient does not attend the outpatient clinic, or if they cannot be 
approached during the clinic visit. 
 
11.4.11.3 Patients waiting in-hospital  
 
The parents/guardians of patients considered eligible for the study will be given a 
parent/guardian information leaflet when the patient is transferred to a ward at the hospital. The 
patients will also be given a PIL suitable to their age group at this time.  
 
Admission/transfer to the hospital is usually the day before their procedure. 
Parents/guardians and patients should, therefore, have a minimum of 24 hours to read and 
consider the information and to ask questions before being asked to decide whether they are 
willing to consent/assent.  
 
On occasions, this time interval may be as little as (but never less than) 4 hours, for 
example for patients admitted for same-day surgery without prior notification. It is essential to 








11.4.12 Ethical considerations 
 
11.4.12.1 Review by an NHS Research Ethics Committee  
Ethical approval was obtained from a UK National Research Ethics Service (NRES) 
Research Ethics Committee, South West – Frenchay Research Committee, REC reference: 
11/H0107/9.   
Any amendments to these documents, after a favourable opinion from the REC has 
been given, were submitted to the REC for approval before implementation. 
 
11.4.13 Risks and anticipated benefits  
 
11.4.13.1 Potential benefits to participants: 
There are no direct benefits to participants. 
11.4.13.2 Potential harms to participants:    
 
The only anticipated harms to participants would be from taking blood samples and 
potential risk for superficial infection associated with the microdialysis catheter. This volume 
of blood taken, however, is small and would not make the difference between needing and not 
needing a blood transfusion. A critical care patient in the intensive care unit would expect up 
to half this amount of blood taken per day for clinical blood tests. 
The potential risk of infection at the site of subcutaneous catheter insertion is extremely 
low, and we shall minimise this even further by adherence to a rigorous aseptic, non-touch 
technique and keeping the catheter in for only 24 hours.  
Over the last 6 years during which we have undertaken many studies both inpatients 




keeping with this a study by Poca et al. (M.A. et al. 2006)  on 97 neurocritical adult patients 
who underwent percutaneous brain microdialysis catheter insertion, reported a 0% infection 
rate. Furthermore, in a literature review by Hack et al. (Hack et al. 2005) of subcutaneous 
microdialysis in paediatric patients, including neonates with extremely low birth weight, no 
infections were reported.   
Despite this very low risk, we will regularly monitor the insertion site for any signs of 
infection throughout catheter insertion. 
11.4.13.3 Possible adverse effects of each intervention: 
 
The risk of taking the blood samples at 7 time points from existing in situ lines is virtually 
nil.  
The risk of superficial infection at the site of subcutaneous microdialysis catheter insertion.  
 
11.5 Statistical analysis  
 
Graph Pad Prism version 7.00 (Graph Pad Software, La Jolla, CA, USA) was used for statistical 
analysis and data graphing. For the grouped analyses, all data are expressed as mean ± SEM. 
Calculation of the AUC for cortisol and per hour was done using a specific formula calculation 
in Microsoft Office Excel 365 (e.g. the sum of the area of all trapezoids that can be drawn 
beneath the curve) (Microsoft Corporation, Redmond, Washington, United States).  
If values on the x-axis are inputted in column A starting from row 1 and the values 
corresponding to the y-axis are inputted in column B the formula input in column C was C1 
“=(B1+B2)/2*(A2-A1)”. The area under the curve between certain time points was deducted 




Total AUC for Cortisol was crosschecked with AUC calculation done in Graph Pad prism. 
Since the distribution of the AUC for cortisol within the groups was skewed, we used 
nonparametric tests for between-group comparisons (Mann Whitney test or one-way ANOVA 
test followed by Kruskal-Wallis test for the post hoc analysis). The preliminary analysis of 
CBG and cytokine data was done using a two-way ANOVA test followed by a Tuckey’s 
multiple comparisons test. Statistical significance was set for all statistical tests at P<0.05. 
 
11.6 Results  
11.6.1 Overview of recruitment 
 
The study started recruitment in 14/09/2017. To date, a total of 69 children (61/78, 84 
% of recruitment target) consented to take part in the study (49 surgical and 20 catheters). 
Bristol Children’s Hospital recruited a total of 53 patients (53 surgical and 17 catheters) while 
16 patients (15 from the surgical group and one from the catheter group) consented to take part 
in the study at Royal Brompton Hospital, London, UK. Out of 69 children that underwent 
sampling, we obtained complete data for 45 patients (45/78, 64%% of the original recruitment 
target). The rest of the sampled patients (N=24)  were withdrawn due to various reasons: (1) 
accidental early disconnection (below threshold of 8 hours) (N=13); (2) system failure (N=4), 
(3) administration of glucocorticoids during sampling (N=3), (3) sampling), (4) no surgeon to 
insert the catheter (N=2)  and (5) damage during transport of samples from London to Bristol 











































11.6.2 Preoperative patient characteristics 
 






P1 11 days 3.5 <30 days Transposition of great arteries repair 4 94 
P2 12 days 3.5 <30 days Transposition of great arteries repair 3 88 
P3 13 days 5 <30 days Transposition of great arteries repair 3 78 
P4 12 days 3 <30 days Right ventricle to pulmonary artery 
conduit 
3 87 
P5 8 days 3.1 <30 days Interrupted aortic arch repair 3 89 
P6 3 months 4.5 30 days -1 year Ventricular septal defect repair 2 92 
P7 5 months 6 30 days -1 year Tetralogy of Fallot Repair 3 92 
P8 3 months 6.6 30 days -1 year Aortic valve repair 3 98 
P9 5 months 6 30 days -1 year Left atrioventricular valve repair 3 100 
P10 4 months 5.1 30 days -1 year Tetralogy of Fallot Repair 3 79 
P11 4 months 5.1 30 days -1 year Glenn shunt and diaphragm plication 2 76 
P12 7 months 5.3 30 days -1 year Glenn shunt 2 86 
P13 6 months 4.9 30 days -1 year Tetralogy of Fallot Repair 2 100 
P14 7 months 6.2 30 days -1 year Ventricular septal defect repair 2 99 
P15 11 months 6 30 days -1 year Damus-Kaye-Stansel anastomosis, 
Glenn shunt and atrial septectomy 
6 88 
P16 4 months 4.4 30 days -1 year Norwood operation  6 79 
P17 1 year 11 
months 
10.6 1-5 years Ventricular septal defect repair 1 90 
P18 2 years 
1months 
11.2 1-5 years Ventricular septal defect repair 2 75 
P19 1 year 3 
months 
10.3 1-5 years Ventricular septal defect repair 2 100 
P20 4 years 6 
months 
16.9 1-5 years Fontan operation 3 83 
P21 1 year 2 
months 
7.1 1-5 years Glenn shunt 2 72 
P22 16 years 5 
months 
57.7 10-16 years Mitral valve repair 3 98 
P23 15 years 2 
months 
55.6 10-16 years Aortic valve repair 3 100 
P24 15 years 4 
months 
39.4 10-16 years Aortic valve repair 3 99 
P25 10 years 3 
months 
31.6 10-16 years Resection of subaortic membrane  2 100 
P26 14 years 57.7 10-16 years Pulmonary valve replacement 2 96 
P27 13years 
11months 
47 10-16 years Ventricular septal defect repair 2 98 
P28 15 years 6 
months 
31.6 10-16 years Aortic valve repair/replacement  3 98 
Table 7 Table to summarise pre-operative characteristics of the surgical group: age, weight at 
operation, recruitment group, type of surgical procedure, RACHS risk category and preoperative 
oxygen saturation (on room air).*RACHS-1 categorises the risk of hospital mortality according to 
the type of procedure. The categories range from 1 from (low-risk procedures with mortality of 






Table 8 Table to summarise patient characteristics for the catheter group: age, weight, 













Patient Age Weight 
(kg) 









study and ablation 
96 





study and ablation 
98 














































Table 9 Table to summarise the surgical procedure times, the aortic cross-clamp and CPB times, the 











Temperature end of 
CPB (Celsius) 
Aortic cross clamp 
(degrees Celsius)  
P1 <30 days Transposition of great arteries 
repair 
6:54 206 134 36.6 33.7 
P2 <30 days Transposition of great arteries 
repair 
6:35 209 123 36.4 30 
P3 <30 days Transposition of great arteries 
repair 
6:45 193 113 36.7 36.6 
P4 <30 days Right ventricle to pulmonary 
artery conduit 
4:05 66 no cross 
clamp 
36.3 36.3 
P5 <30 days Interrupted aortic arch repair 6:23 120 59 37 18.9 
P6 30 days -
1 year 
Ventricular septal defect repair 6:20 171 119 36.6 32.9 
P7 30 days -
1 year 
Tetralogy of Fallot Repair 4:20 125 75 36.1 34.1 
P8 30 days -
1 year 
Aortic valve repair 4:50 106 55 36.7 34.8 
P9 30 days -
1 year 
Left atrioventricular valve repair 3:40 52 35 36.5 36.5 
P10 30 days -
1 year 
Tetralogy of Fallot Repair 5:13 120 77 36.1 36.1 
P11 30 days -
1 year 
Glenn shunt and diaphragm 
plication 
1:45 77 no cross 
clamp 
36.3 - 
P12 30 days -
1 year 
Glenn shunt 5:00 54 9 36.7 - 
P13 30 days -
1 year 
Tetralogy of Fallot Repair 4:28 60 40 - 36.5 
P14 30 days -
1 year 
Ventricular septal defect repair 5:10 132 113 36.7 36.6 
P15 30 days -
1 year 
DKS anastomosis, Glenn shunt 
and atrial septectomy 
7:09 164 78 36.7 28 
P16 30 days -
1 year 
Norwood operation  9:48 200 85 36.2 18.9 
P17 1-5 years Ventricular septal defect repair 5:00 104 89 36.4 34.9 
P18 1-5 years Ventricular septal defect repair 6:52 163 129 36.5 33 
P19 1-5 years Ventricular septal defect repair 3:40 83 64 36.5 36.5 
P20 1-5 years Fontan operation 5:27 110 no cross 
clamp 
- - 
P21 1-5 years Glenn shunt 6:03 159 25 36.9 - 
P22 10-16 
years 
Mitral valve repair 5:20 68 46 36 36.4 
P23 10-16 
years 
Aortic valve repair 5:52 124 99 36.7 35.5 
P24 10-16 
years 
Aortic valve repair 6:03 128 83 35 - 
P25 10-16 
years 
Resection of subaortic membrane  3:20 40 27 36.9 34.9 
P26 10-16 
years 





Ventricular septal defect repair 3:35 63 47 36.6 36.6 
P28 10-16 
years 




Table 10 Table to summarise the procedures times for the catheter group 
 
Table 11 Use of vasopressors and inotropes by age group for surgery patients
Patient Group Procedure Procedure time (hours) 
P29 10-16 years Electrophysiology study and ablation 1:35 
P30 10-16 years Electrophysiology study and ablation 1:46 
P31 10-16 years Electrophysiology study 4:11 
P32 10-16 years Electrophysiology study 2:26 
P33 10-16 years Electrophysiology study 2:48 
P34 10-16 years Electrophysiology study 3:00 
P35 10-16 years Electrophysiology study  2:30 
P36 10-16 years Ventricular septal defect closure 2:30 
Patient Group Procedure Adrenaline Noradrenaline Dopamine Milrinone 















P4 <30 days Right ventricle to pulmonary 
artery conduit 
   
✓ 




P6 30 days -1 year Ventricular septal defect repair 
   
✓ 





P8 30 days -1 year Aortic valve repair 
    
P9 30 days -1 year Left atrioventricular valve repair 
   
✓ 
P10 30 days -1 year Tetralogy of Fallot Repair 
  
✓ ✓ 




P12 30 days -1 year Glenn shunt 
  
✓ ✓ 
P13 30 days -1 year Tetralogy of Fallot Repair 
  
✓ ✓ 
P14 30 days -1 year Ventricular septal defect repair 
  
✓ ✓ 
P15 30 days -1 year Damus-Kaye-Stansel, Glenn 
shunt and atrial septectomy 
  
✓ ✓ 
P16 30 days -1 year Norwood operation  ✓ 
 
✓ ✓ 
P17 1-5 years Ventricular septal defect repair 
  
✓ ✓ 
P18 1-5 years Ventricular septal defect repair 
  
✓ ✓ 
P19 1-5 years Ventricular septal defect repair 
   
✓ 
P20 1-5 years Fontan operation 
  
✓ ✓ 
P21 1-5 years Glenn shunt 
  
✓ ✓ 




P23 10-16 years Aortic valve repair 
  
✓ ✓ 
P24 10-16 years Aortic valve repair 
  
✓ ✓ 
P25 10-16 years Resection of subaortic 
membrane  
    
P26 10-16 years Pulmonary valve replacement 
    
P27 10-16 years Ventricular septal defect repair 
    


























P1 <30 days 5 days 5 hrs 15 mins  133 111 38 64 68% 7 10 Alive 
P2 <30 days 4 days 3 hrs 48 mins  175 122 43 51 19% 5 12 Alive 
P3 <30 days 8 days 4 hrs 20 mins  147 130 45 73 62% - - Alive 
P4 <30 days 6 days 5 hrs 0 mins  82 118 27 53 96% 9 13 Alive 
P5 <30 days 12 days 3 hrs 5 mins  154 137 38 67 76% 14 35 Alive 
P6 30 days -1 
year 
1 day 4 hrs 39 mins  101 106 16 23 44% 2 2 Alive 
P7 30 days -1 
year 
2 days 2 hrs 31 mins  134 110 23 30 30% 3 5 Alive 
P8 30 days -1 
year 
1 day 4 hrs 40 mins  117 129 23 28 22% 3 
 
Alive 
P9 30 days -1 
year 
5 hrs 10 mins  111 140 22 23 5% 1 6 Alive 
P10 30 days -1 
year 
7 days 2 hrs 31 mins  124 105 24 101 321% 8 14 Alive 
P11 30 days -1 
year 
24 days 5 hrs 40 mins  144 117 23 20 13% 36 113 Alive 
P12 30 days -1 
year 
11 hrs 34 mins  130 123 22 21 5% 3 21 Alive 
P13 30 days -1 
year 
21 hrs 53 mins  113 80 31 41 32% 2 15 Alive 
P14 30 days -1 
year 
3 days 3 hrs 25 mins  112 106 29 39 34% 4 10 Alive 
P15 30 days -1 
year 



















Table 12 Table to summarise the relevant clinical outcomes of the different age groups duration of mechanical ventilation, perioperative Hb 
measurements, perioperative creatinine, PICU stay, the total duration of admission and hospital mortality. Missing data are marked as “- “. 
 
 

















P16 30 days -1 
year 
11 days 22 hrs 9 mins  162 120 25 25 0% 38 43 Alive 
P17 1-5 years 2 days 12 hrs 7 mins  158 131 27 62 130% 2 7 Alive 
P18 1-5 years 1 day 8 hrs 8 mins  144 92 32 68 113% 37 98 Alive 
P19 1-5 years 0 days 10 hrs 55 mins  130 113 23 28 22% 2 6 Alive 
P20 1-5 years 6 day 13 hrs 6 mins  189 117 44 60 36% 8 34 Alive 
P21 1-5 years 1 day 20 hrs 0 mins  169 106 24 24 0% 2 6 Alive 
P22 10-16 years  6 hrs 5 mins  154 108 87 94 8% 1 6 Alive 
P23 10-16 years  4 hrs 32 mins  152 94 60 78 30% 3 12 Alive 
P24 10-16 years  4 hrs 5 mins  133 101 58 57 2% 2 5 Alive 
P25 10-16 years 4 hrs 20 mins  140 94 39 48 23% 1 5 Alive 
P26 10-16 years 4 hrs 32 mins  133 109 60 65 8% 1 7 Alive 
P27 10-16 years 4 hrs 5 mins  136 100 58 70 21% 1 4 Alive 





11.6.3 Individual cortisol profiles  
 
In this chapter, I have included cortisol profiles of 34 patients. These profiles are 
grouped by age group.  In the end, I have also included two more profiles that were withdrawn 
from the study due to the administration of glucocorticoids during the sampling period but, are 





Figure 44 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 45 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 46 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 47 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife off skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 48 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 






Figure 49 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 50 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 51 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 52 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 53 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 






Figure 54 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 55 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 56 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 57 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 58 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 59 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 60 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 61 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 62 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 63 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 64 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 65 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 66  Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 67 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 68 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 69 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 70 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In 
dotted green lines are illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum 
concentration taken at the reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue 
line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point 





Figure 71 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary 
by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). The 
blue line denotes the tissue cortisol and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each 






Figure 72 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 73 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 74 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 75 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 76 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 77 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 





Figure 78 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 79 Cortisol and cortisone microdialysis profiles of a child undergoing a catheter procedure. Abbreviations: KTS: knife to skin; CPB: 
cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time – end of the operation. The green shaded box denotes the operative time (from 
KTS to KOS). The green dot denotes the serum cortisol level taken at the reference time point. The purple dot line denotes the ACTH serum concentration 
taken at the reference time point. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 80 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery who received intravenous Dexamethasone during sampling. 
The yellow line marks the time of intravenous administration.  Abbreviations: KTS: knife to skin; CPB: cardiopulmonary by-pass time (red dotted area). 
KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In dotted green lines are illustrated 
the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum concentration taken at the reference 
time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the 
red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol 






Figure 81 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery who received intravenous Hydrocortisone during sampling. 
The yellow line marks the time of intravenous hydrocortisone administration. The cortisol profile after IV glucocorticoid administration is depicted in the 
next graph (for better understanding) Abbreviations: KTS: knife to skin; CPB: cardiopulmonary by-pass time (red dotted area). KOS – knife of skin time 
– end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In dotted green lines are illustrated the serum cortisol levels 
taken at the reference time points (seven). The purple dotted line denotes the ACTH serum concentration taken at the reference time points (seven) is 
illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol and the red line the tissue 
cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one tissue cortisol sample collected 





Figure 82 Cortisol and cortisone microdialysis profiles of a child undergoing heart surgery who received intravenous Hydrocortisone during sampling. 
The yellow line marks the time of intravenous hydrocortisone administration. Abbreviations: KTS: knife to skin; CPB: cardiopulmonary by-pass time (red 
dotted area). KOS – knife of skin time – end of the operation. The red shaded box denotes the operative time (from KTS to KOS). In dotted green lines are 
illustrated the serum cortisol levels taken at the reference time points (seven). The purple dotted line denotes the ACTH serum concentration taken at the 
reference time points (seven) is illustrated. On the right Y-axis, the serum cortisol/ACTH concentration is depicted. The blue line denotes the tissue cortisol 
and the red line the tissue cortisone levels taken every 20 minutes using the automated microdialysis system. Each point on the X-axis represents one 




11.6.4 Overview of Cortisol/Cortisone changes by age group 
 
Figure 83 Cortisol and cortisone profiles of neonates undergoing surgery. The cortisol area is marked in blue. The cortisone response that overlaps the 





Figure 84 Cortisol and cortisone profiles of children aged >30 days-1 year undergoing surgery. The cortisol area is marked in blue. The cortisone 









Figure 85 Cortisol and cortisone profiles of children aged >30 days-1 year undergoing surgery (continued). The cortisol area is marked in blue. The 





Figure 86 Cortisol and cortisone profiles of children aged 1-5 year undergoing surgery. The cortisol area is marked in blue. The cortisone response that 







Figure 87 Cortisol and cortisone profiles of children aged 10-16 year undergoing surgery. The cortisol area is marked in blue. The cortisone response 





Figure 88 Cortisol and cortisone profiles of children aged 10-16 year undergoing catheter procedures. The cortisol area is marked in blue. The cortisone 














Cortisol: Cortisone  
P1 <30 days Surgery 2431 2599 0.935359754 
P2 <30 days Surgery 1649 3819 0.431788426 
P3 <30 days Surgery 4538 1871 2.425440941 
P4 <30 days Surgery 1197 1175 1.018723404 
P5 <30 days Surgery 1013 960.3 1.054878684 
P6 30 days -1 year Surgery 4741 1444 3.283240997 
P7 30 days -1 year Surgery 1567 548.3 2.857924494 
P8 30 days -1 year Surgery 3147 1579 1.993033566 
P9 30 days -1 year Surgery 2017 448.6 4.496210432 
P10 30 days -1 year Surgery 978.2 247.1 3.958721166 
P11 30 days -1 year Surgery 286.5 327.6 0.874542125 
P12 30 days -1 year Surgery 78.66 94.6 0.831501057 
P13 30 days -1 year Surgery 1186 435.6 2.722681359 
P14 30 days -1 year Surgery 2114 453.5 4.661521499 
P15 30 days -1 year Surgery 970.1 368.8 2.630422993 
P16 30 days -1 year Surgery 5605.4 1275.6 4.39432424 
P17 1-5 years Surgery 2412 810.8 2.974839665 
P18 1-5 years Surgery 158.4 39.44 4.016227181 
P19 1-5 years Surgery 1134 396.2 2.862190813 
P20 1-5 years Surgery 2501 533.7 4.68615327 
P21 1-5 years Surgery 1933 571.5 3.382327209 
P22 10-16 years Surgery 1373 313.5 4.379585327 
P23 10-16 years Surgery 398 173.1 2.299248989 
P24 10-16 years Surgery 252.8 166.1 1.521974714 
P25 10-16 years Surgery 213.2 43.75 4.873142857 
P26 10-16 years Surgery 294.6 117.3 2.511508951 
P 27 10-16 years Surgery 1031 521 1.978886756 
P28 10-16 years Surgery 1725 480.6 3.589263421 
P29 10-16 years Catheter 144.3 176.5 0.817563739 
P30 10-16 years Catheter 124.2 70 1.774285714 
P31 10-16 years Catheter 225.3 259.1 0.869548437 
P32 10-16 years Catheter 549.2 236.7 2.320236586 
P33 10-16 years Catheter 76.81 88.44 0.868498417 
P34 10-16 years Catheter 371.6 289.1 1.285368385 
P35 10-16 years Catheter 43.14 32.55 1.325345622 




11.6.5 Grouped cortisol analysis 
All cortisol profiles were pulsatile. There was no patient that had a suppressed 
endogenous cortisol response. The tissue cortisol levels increased significantly at a variable 
interval from the procedure. The majority of the surgical patient had up to 100-fold increase or 
more in their cortisol levels from basal while the cortisol peaks in the catheter patients were 
less pronounced (10-20-fold increase). Table 13 summarises the total AUC for all patients by 
recruitment group and age.   
11.6.6 Changes in AUC for cortisol and cortisone by age  
There was a significant effect of age of children undergoing cardiac procedures on the 
changes in the AUC for cortisol (P=0.0045), AUC for cortisone and in the ratio of AUC for 
cortisol to AUC cortisone (P=0.0097) (Figure 89). In the post hoc analysis, the AUC for cortisol 
in neonates was significantly larger than the 10-16 years patients (P=0.0363). Similarly, the 
AUC for cortisol in infants (age 1-5) was significantly larger than the 10-16 years (P=0.0242) 
(Figure 89 A).  The AUC for cortisone was significantly larger in neonates compared to 10-16 
years group (P=0.0003), and there was a trend towards a larger area in infants compared to 10-
16 years older patients (P=0.0539) (Figure 89 B). The ratio of the AUC for cortisol to cortisone 
was significantly lower in neonates compared to 1-5 years old children (P=0.0214) (Figure 89 
C).  
11.6.7 Changes in AUC for cortisol and cortisone by type of procedure  
The AUC for cortisol (Figure 90 A) and cortisone (Figure 90 B) were significantly 
larger (P<0.0001 and P=0.0017, respectively) in the patients undergoing surgery compared to 
the patients undergoing catheter procedures. The ratio of cortisol to cortisone ratio was 




11.6.8 Procedure specific changes in AUC  
I cannot make any solid statements regarding the procedure specific changes as the 
numbers within each procedure were too small. However, the increases in AUC for cortisol 
were broadly consistent with the complexity of the operation (Figure 91). For example, 
Norwood procedures4 followed by arterial switch procedures had the highest recorded AUC. 
This fitted well with RACHS scoring.  In contrast, catheter procedures had the lowest AUC for 
cortisol.  
11.6.9 Changes in AUC for cortisol and cortisone by type of underlying heart defect.   
 
We found no significant difference in the AUC for cortisol (P=0.3791) (Figure 92, A), 
for cortisone (P=0.1281) (Figure 92, B) and the ratios of AUC for cortisol to AUC for cortisone 
(P=0.9604) (Figure 92, B) in patients with a acyanotic heart defects (pre-op oxygen saturation 
> 89%) versus cyanotic heart defect (pre-op oxygen saturation ≤ 89%).  
 
4 The Norwood procedure is probably one of the most complex operations in congenital heart surgery and in heart surgery in 
general. It is the first surgery out of three staged heart operations that aims to create new systemic circulation (univentricular) in patients born 





Figure 89 Changes in AUC cortisol/cortisone by age group. Data are mean of AUC 
per age group ±SEM; data were analysed by one-way ANOVA followed by Kruskal-
Wallis post-hoc-test; * P<0.05,**<P0.005; A - AUC for cortisol, B- AUC for cortisone, 







Figure 90 Changes in AUC cortisol/cortisone according to type procedure (surgery vs 
catheter). Data are mean of AUC per procedure group ±SEM; data were analysed 
using the Mann-Whitney test; * P<0.05, **<P0.005; A - AUC for cortisol, B- AUC for 


















Figure 92 Changes in AUC cortisol/cortisone according to underlying congenital heart 
defect (acyanotic vs cyanotic). Data are mean of AUC per procedure group ±SEM; 
data were analysed using the Mann-Whitney test; A - AUC for cortisol, B- AUC for 






11.6.10 Analysis of the changes in the AUC for cortisol and cortisone by hour  
 
11.6.10.1 Overall AUC per hour analysis for cortisol, cortisone and cortisol to cortisone 
ratio 
 
In my analysis, I have also looked at the changes in the AUC per hour. We have 
excluded the last 2 hours of the 24-hour interval (e.g. the 23rd and 24th hours) because few 
patients achieved sampling up to this interval. Therefore, the analysis deals with the 1 to 22-
hour sampling interval.  
In the overall analysis, we found that the AUC for cortisol in the first hour was significantly 
lower compared to the AUC per hour measured in the interval 4 to 22 hours. This difference 
was highly significant later, from 6 hours up to 22 hours of sampling (P<0.0001). The AUC 
for cortisol at 2 hours from the start of sampling, were significantly lower compared to the 
AUC per hour measured in the interval 10-21 hours. This difference was highly significant 
between 15 and 21 hours of sampling (P<0.001) (Figure 93).   
 
11.6.10.2 Analysis of the ratio of AUC for cortisol to cortisone per hour stratified by 
age, procedure and oxygen saturation 
 
The two-way ANOVA analysis of the change of the ratio of AUC for cortisol to 
cortisone per hour showed an overall significant effect of the age (p<0.0001) and procedure 
(p<0.0001) but there was no significant effect of the ratio of AUC for cortisol to cortisone 
change per hour nor a significant interaction. In the posthoc analysis, there were no significant 
differences between age groups or procedure groups in the ratios of AUC for cortisol to 
cortisone per hour.  There was no effect of oxygen saturation (cyanotic/acyanotic heart defect) 





Figure 93 AUC per hour for cortisol (A), cortisone (B) and the ratio of AUC cortisol 
to cortisone per hour (C). Data are mean of AUC per hour ±SEM. Data were analysed 








Figure 94 Ratios of AUC per hour by age group (A), procedure type (B) and type of 













11.6.11Changes in serum ACTH and cortisol  
 
The catheter patients had only one baseline serum ACTH and cortisol measurement. 
The serum ACTH, serum cortisol and ration of ACTH to cortisol are found in Table 14. 
Figure 95 A depicts the changes in serum ACTH and cortisol. We could not do a 
stratified analysis by age, procedure and type of defect (cyanotic/acyanotic) due to missing 
ACTH and Cortisol data for the various subgroups. Therefore, the data is analysed overall in 
20 children that underwent cardiac surgery (1 neonate, 8 infants, 5 children aged 1-5 and 6 
teenagers). The ANOVA analysis showed a significant effect of sampling timepoint on the 
ACTH to cortisol ratio change (P<0.0001). In the posthoc analysis, we compared the change 
in the ACTH to Cortisol ratio to the baseline time point (the before skin incision sampling time 
point). The analysis revealed a significant increase at the post CPB sampling time point 
compared to baseline (P=0.0050). Also, the ACTH to cortisol ratio was significantly lower at 
the 6-24 hours sampling time point compared to the before skin incision timepoint (P=0.0076) 









Table 14 Serum ACTH, serum cortisol and ACTH to cortisol ratio for the catheter 
patients at the baseline sampling time-point 
 
Patient  Cortisol 
(nmol/L) 




P22 598 216.7451975 54.3 0.250 
P23 375 135.9188112 74.1 0.545 
P24 221 80.10148605 36.1 0.450 
P25 303 109.8223994 31.4 0.285 
P26 203 73.57738311 16.9 0.229 
P27 449 162.7401232 58.5 0.359 
P28 536 194.2732874 18.2 0.093 





Figure 95 A - Changes of the serum ACTH in relation to serum cortisol (N=20). Data 
are mean of serum cortisol (nmol/L) ±SEM and serum ACTH (ng/L); B - Data are mean 
of ACTH to cortisol ratios (ng/µg) ±SEM; data were analysed using a one-way ANOVA 




11.6.12Changes in the CBG perioperatively 
 
11.6.12.1 Overall Analysis  
The CBG concentrations were measured at a 1-time point in the catheter patients (Table 
15. We had CBG data for 26 surgical patients. In the overall analysis, we found that the CBG 
concentration significantly decreased at the 6 hours (P<0.0001) and the 24-hour time point (P 
<0.0001) compared to the preoperative measurements (Figure 96). Similarly, the CBG 
concentrations at 6 hours (P= 0.0008) and 24 hours (P= 0.0003) were significantly lower. We 
analysed the CBG perioperative changes by age and type of congenital heart defect in surgical 
patients.  
























Figure 96 Overall changes in the CBG perioperatively. A –Data are mean of CBG 
measurements (ng/mL) ±SEM; data were analysed using the one-way ANOVA test 
followed by a post hoc analysis using Tuckey’s multiple comparisons test; *P<0.001, 
*p<0.0001, B – the spread of the data at the 4 sampling time points.   
 
11.6.12.2 CBG analysis by age  
 
In the two-way ANOVA analysis, we found a significant effect of age (P<0.0001) and 
sampling time (P<0.001) on the CBG concentration. There was a significant interaction 
between the time of sampling and age (P=0.0054). In the post hoc analysis, we found that the 
CBG was significantly lower in neonates compared to the rest of the groups at preoperative 




significantly lower at 6 hours compared to 1-5 years old children (P=0.0079) and 10-16 years 
old children (P=0.0036). Similarly, at 24 hours, the CBG concentration in neonates were lower 
compared to 1-5 years old children (P=0.0031) and 10-16 years old children (P=0.0017). At 6 
hours sampling timepoint, the CBG concentration was significantly lower for children aged 30 
days-1 years compared to 1-5 years old children (P=0.0134) and 10-16 years old children 
(P=0.0051). At induction, the 30 days – 1years old children had significantly lower CBG 
concentration (P=0.0216) compared to children aged 1-5 years while the CBG concentration 




Figure 97 Perioperative changes in the CBG concentration by age group (N=26). Data 
are mean of CBG measurements (ng/mL) ±SEM; data were analysed using the two-way 
ANOVA test followed by the Tuckey’s multiple comparisons tests; a – P<0.0001, <30 
days old children compared to rest of the age groups; b – P<0.01, <30 days old 
children compared to 1-5 years old and 10-16 years old; c – P<0.05, 30-days old 
children versus 1-5 years old and 10-16 years old children; d – P<0.05, 30 days-1 
years versus 1-5 years old children, e – P<0.05 1-5 years old children versus 10-16 










11.6.12.3 CBG analysis by saturations 
 
We found a highly statistically significant effect of oxygen saturation (P<0.0001) on the CBG 
concentrations measured at 6 and 24 hours (P<0.0001). In the post hoc analysis, the CBG 
concentrations of cyanotic children (oxygen saturation  ≤ 89%) were significantly lower at 6 
hours (P<0.0151) and 24 hours (P<0.0129) compared to the acyanotic groups (oxygen 
saturation> 89%) (Figure 98).  
 
Figure 98 Pre-operative changes in the CBG concentration by acyanotic versus 
acyanotic heart defects (N=26). Data are mean of CBG measurements (ng/mL) ±SEM; 
data were analysed using the two-way ANOVA test followed by the Sidaks’s multiple 
comparisons tests; * P<0.05 acyanotic versus cyanotic.   
 
11.6.13Preliminary cytokine analysis 
This analysis is based on the data available to date (for the surgery group only). This includes 
cytokine data for one neonate and data for most of the infants, aged 1-5 years and teenagers’ 





11.6.13.1 Cytokine response by age  
 
Analysis of IL-10 showed a significant effect of time of sampling (P<0.0001) and a 
trend towards an effect of age (P=0.081) with no significant interaction. In the posthoc analysis, 
post-CPB, the IL-10 was significantly elevated in the 1-5 years group (P<0.0001) compared to 
the 0, 1, 2- and 24-hours sampling time points. Similarly, IL-10 in the 30 days-1-year groups 
was significantly higher (P<0.05) compared to the 0, 1, 2- and 24-hours sampling time points. 
Post-CPB, we noted significant age-specific responses. The IL-10 in the 1-5 years group was 
significantly higher compared to the teenager’s group (P<0.05) (Figure 99, A). We found no 
significant changes in the IL-1β response by age (Figure 99, B). There was highly significant 
age-specific IL-4 response (P=0.003) with trends towards a lower production of IL-4 in the 30-
days to 1 year compared to older children (1-5 years and teenagers) (Figure 99, C). Analysis 
of IL-6 showed a significant effect of time (P<0.001) but no significant effect on the posthoc 
analysis (Figure 99, D). Analysis of IL-8 showed a significant of time (P<0.001) and age 
(P=0.004) but no significant interaction (P=0.6121) and no significant age-specific differences 
in the posthoc analysis (Figure 99, E).  We found a highly significant age-related (P<0.0001) 
TNFα response with a significant of time of sampling (P=0.0013). At sampling time points 0 
up to 24 hours, we found a significant increase in TNFα, in the 30 days to 1-year group 
compared to 10-16 years group (P<0.0005). Similarly, the TNFα production was significantly 
higher in the 1-5 years group versus teenagers, between sampling time point 0 to 3 (post-CPB) 
(P<0.05). We have also found a higher TNFα response in 30days – 1-year group compare to 






Figure 99 Changes in cytokine perioperatively depending on age group. Data are mean of cytokine 
concentrations (pg/mL) ±SEM; Data were analysed using two-way ANOVA test followed by a posthoc 
Tuckey’s multiple comparisons test. A – Changes in IL-10, ** P<0.0001 versus time points 0, 1, 2 and 6 
in same age group, *<P0.05; *P<0.05 versus time points 0, 1, 2 and 6 in same age group; ^ P<0.001 age 
1-5 versus 30 days- 1year group; Changes in IL-1β, IL-4, IL-6 and IL-8 (B-E); F -Changes in TNFα 
concentrations; **P<0.0001, 30-days-1 year versus 10-16 years, *P<0.0005, 30-days-1 year versus 10-










11.6.13.2 Cytokine responses by cyanotic versus acyanotic heart disease  
 
We found a highly significant effect of cyanotic heart disease on the production of IL-
10 (P<0.0001) and a significant effect of time (P<0.0001) with highly a significant interaction 
(P= 0.0001). In the posthoc analysis the IL-10 peaked significantly post CPB in the cyanotic 
group (at sampling time point 3) compared to sampling time point 0, 1, 2, 5 and 6 (P in same 
age group (P<0.0001). This peak at time point 3 was higher for the cyanotic group compared 
to the acyanotic group (P<0.0001) (Figure 100, A). The analysis of IL-1β showed no significant 
effect of cyanotic heart disease (Figure 100, B). We have also found a significant effect of 
cyanotic disease on IL-4 production (P=0.0016). However, this was not significant in the 
posthoc analysis for the various sampling time points (Figure 100, C). The IL-6 production was 
significantly higher for the cyanotic group compared acyanotic patients at the sampling time 
points 5 (P= 0.0385) and 6 (P=0.0069). For the cyanotic group, there were significant increases 
in IL-6 production at time points 4 to 6 compared to the time point 0 and 1 (Figure 100, D). A 
similar pattern was found for IL-8 that peaked significantly between time points 4 to 5 
(P<0.007) compared to time points 0, 1 and 2 (Figure 100, E). This increase was significantly 
higher in the cyanotic group compared to acyanotic group at time point 5 (P=0.0165). We found 





Figure 100 Changes in cytokine perioperatively depending on acyanotic (O2 saturation>89%) versus cyanotic 
heart disease (O2 saturation ≤80%). Data are mean of cytokine concentrations (pg/mL) ±SEM; Data were 
analysed using two-way ANOVA test followed by a posthoc Tuckey’s multiple comparisons test. A – Changes in 
IL-10, ** P<0.0001 versus time points 0, 1, 2, 5and 6 time point in same age group, * P<0.001 versus time points 
0, 1, 2 and 6; ^ P<0.0001 cyanotic versus acyanotic group. Changes in IL-1β, IL-4 (B and C); D -Changes in IL6 
concentrations; **P<0.0001 versus time 0 and 1, *P<0.005 versus time 0 and 1, +P=0.005 versus timepoint 2, ^ 
P<0.05 acyanotic versus acyanotic group. E – Changes in IL-8; ** P≤0.0007 versus time 0, 1 and 2; *P<0.05 




11.6.14 Discussion  
 
11.6.14.1 Automated tissue microdialysis cortisol measurement in children is feasible 
 
These 36 successful cortisol profiles demonstrate that our automated microdialysis 
system is a feasible method for the assessment of the HPA axis in children. As outlined before, 
this method overcomes the limitations of the circulating blood volume in small weight babies 
and allows measurement of the free active cortisol fraction. Therefore, in the Peacock study, 
tissue microdialysis was used for the first time to assess the HPA axis response during surgery 
and it is the first study of this kind in the paediatric population. This allowed us to obtain high-
resolution cortisol profiles with up to 70 samples collected every 20 minutes for 24 hours. Even 
in the patients that were disconnected earlier, we were able to collect more cortisol samples 
than the previous studies that measured up to a maximum of 10 samples over 48 hours (Table 
16).  
 
 The main technical disadvantages of the system are (1) the fragility of the microdialysis 
tubing (2) the microdialysis pump that occasionally malfunctions (3) the long learning curve. 
All of these issues could be overcome by an improved design and Design Works Ltd (the 
current manufacturers) is currently working on a new design taking our experience into 
account. Furthermore, the method can prove feasible to measure multiple steroid hormones (all 
in the same sample) other hormones such as catecholamines and peptide hormones, 




















and Stárka 1986)  
1986 24 children Observational  no data 6 1 time-point day before 
surgery, 4 time-points 
days of surgery and 1 
timepoint 8th day of 
surgery 
Anand et al.(Anand, 
Hansen, and Hickey 
1990) 
1990 15 neonates Observational  no  7 pre-op, pre-CPB, during 
DHCA, end of the 
operation, 6 hours, 12 
hours and 24 hours.  
Gajarski et 
al.(Gajarski et al. 
2010) 
2010 58 children Observational  yes 10 before surgery, after 
surgery, 6, 12, 18, 24, 30, 
36, 42 and 48 hours 
Garcia et al.(Garcia 
et al. 2010)  
2010 21 neonates Retrospective yes 2 basal and post ACTH test 
Mackie et 
al.(Mackie et al. 
2011)  
2011 38 neonates Observational  yes 3 preoperative, at 24 hours 
and 48 hours post-surgery 
Wald et al.(Wald et 
al. 2011a)  
2011 52 children Observational  yes 2 pre - and postoperative 
Verweij et 
al.(Verweij et al. 
2012) 
2012 62 children with 
low cardiac 
output 
Retrospective yes 1 basal cortisol 
Schiller et 
al.(Schiller et al. 
2013)  
2013 119 children Observational  yes 2 before and 18 hours after 
surgery 
Banaglore et 
al.(Bangalore et al. 
2014)  
2014 33 neonates Observational  yes 3 day 0 (after intensive care 
unit admission); day 1 
(first morning of 
surgery), day 2 (second 
morning of surgery) 
Crow et al.(Crow et 
al. 2014b) 
2014 32 infants  Observational  yes 7 after anaesthesia 
induction, after CPB, 
after intensive care unit 
(ICU) arrival, and 4, 8, 12 
and 24 hours after surgery 
Teagarden et 
al.(Teagarden and 
Mastropietro 2016)  
2016 24 patients < 21 
years 
Retrospective yes 1 pre-hydrocortisone 
treatment serum cortisol 
Maeda et al.(Maeda 
et al. 2016b)  
2016 32 neonates Retrospective yes 3 baseline and at 30 and 60 
minutes after the 
tetracosactide stimulation 








11.6.14.2 The relevance of point cortisol tests in the context of the pulsatile cortisol 
release – a paradigm shift?  
 
One important finding is that some individual subcutaneous cortisol profiles display a 
pulsatile pattern. Therefore, the use of single-point cortisol measurements or other tests based 
on limited time point cortisol measurements (e.g. ACTH stimulation tests) to diagnose the so-
called “relative adrenal insufficiency” are difficult to interpret. Therefore, all the body of 
literature that guides the administration of glucocorticoids based on the current definitions of 
abnormal adrenal function perioperatively is questionable. These findings also question the 
relevance of any previous attempts to correlate clinical outcomes with what is believed to be 
relative adrenal insufficiency.  
 
11.6.14.3 The endogenous cortisol release after surgery 
 
 Looking at the cortisol profiles obtained so far, in most cases, the massive release of 
cortisol that occurs does so several hours after surgery. Firstly, there is an almost hundred-fold 
increase in the tissue cortisol levels from baseline. This confirms that children do have a 
significant endogenous cortisol reserve that they can mount during and after the stress of 
surgery. This makes us question again whether adrenal insufficiency after cardiac surgery does 
exist (D. P. Fudulu, Gibbison, et al. 2018; D. Fudulu, Lightman, et al. 2018). Furthermore, it 
also makes us question the concept in many centres that all children should be supplemented 
with exogenous steroids at the cost of multiple short-term and long-term effects (D. Fudulu, 
Lightman, et al. 2018). We have not noticed any suppressed cortisol profiles in the patients 
sampled so far. It was also evident that the cortisol release is proportional to the type of 




surgical incision (midline sternotomy) and exposure to the non-self CPB circuit compared to 
catheter patients. This is clear on the individual cortisol profiles and the calculation of the AUC 
by type of procedure (Figure 40-75 and Figure 86). 
In the surgical group, we have also observed that the most complex procedures such as 
Norwood procedures or arterial switch operations were associated with the largest AUC for 
cortisol. Furthermore, these procedures were performed in neonates, where CPB times were 
longer compared to older children (Table 9) and therefore the inflammatory stimulus is 
expected to be greater. When analysed by age group, the teenagers had significantly lower 
AUC for cortisol than neonates and infants (Figure 85 A). This could be the reflection of the 
more complicated surgery performed in this group or an age-specific response related to the 
maturation of the HPA axis.  
Secondly, there is a delayed cortisol release in most surgical patients, after the 
discontinuation of CPB. The cause of this delay in the cortisol surge of several hours is unclear. 
It is, however, similar to the adult cardiac surgical plasma cortisol data by Gibbison et al. (Ben 
Gibbison et al. 2015). This delay is longer than would be expected simply due to the need for 
cortisol to be manufactured de novo. This could reflect the fact that activation of the HPA axis, 
in this situation, is secondary to cytokine release (see cytokine discussion). It is unclear, 
however, why other patients have a cortisol peak that coincides with surgery or begins just 
immediately after surgery (Section 11.6.13: P1, 3, 4, 6, 7, 14, 19, 23, 26, 27, 28). A potential 








11.6.14.4 Overview of the cortisol to cortisone relation during stress 
 
This equilibrium between cortisol and biologically inactive cortisone is maintained by 
the 11ß-HSD enzyme system (Figure 101). The 11ß-HSD enzyme type 2 (dehydrogenase 
enzyme) converts the active cortisol into cortisone in the kidney, colon, placenta, fetus, salivary 
glands) while the type 1 11ß-HSD (a reductase) regenerates cortisone back to active cortisol in 
tissues such liver, adipose tissue, lung. During normal physiological conditions, the system 




Figure 101 11ß-HSD isoenzyme system 
 
At the conception of the study, we did not plan to measure cortisone in addition to 
cortisol in the microdialysate. Because the very sensitive cortisol analysis done in collaboration 
with Groningen permitted us to measure this too, on relatively small volume per sample, we 
decided to add cortisone levels as a measure of the activity of the 11β-Hydroxysteroid 
dehydrogenase system (11ß-HSD). Interestingly we noticed a dynamic change in the ratio of 
cortisol to cortisone over time and in p particular an increase in the cortisol to cortisone ratio 
following major secretory episodes of cortisol. 
This suggests that the increased cortisol to cortisone tissue ratio could either be due to 
saturation of the 11ß-HSD type 2 system by the massive release of cortisol or it could be due 




type 1 (mainly in the liver) or inactivation of the 11ß-HSD type 2 (mainly in the kidneys) could 
alter the cortisol to cortisone ratio in this way. 
In our data, catheter procedures were associated with lower total AUC cortisol to 
cortisone ratios compared to surgery. This suggests that in the context of the massive release 
of cortisol during surgery, the 11ß-HSD is overwhelmed and does not convert as efficiently 
cortisol to cortisone (Figure 90, C).  
Several studies have demonstrated a similar increase in the cortisol to cortisone ratios 
in the days after surgery (Vogeser et al. 2003; Heckmann et al. 2014). An earlier study by 
Vogeser et al. (Vogeser et al. 1999) that measured the urinary cortisol and cortisone metabolites 
pointed towards a reduced cortisol inactivation (e.g. inhibition of the dehydrogenase enzyme 
isoform). Reduced reduction of the 4,5-double bond of the A-ring of cortisol and cortisone 
(predominantly by the liver) was found to play a role in the critically ill patient(Heckmann et 
al. 2014). However, it is unlikely that this plays a role in the acute response. If we hypothesise 
that during the acute phase of the stress response, there is inhibition of the 11ß-HSD type 2 in 
the kidney, this mechanism can have huge implications in the perioperative retention of fluid 
(Figure 102). If this is the case, this means that some children could develop perioperatively a 
so-called syndrome of apparent mineralocorticoid excess as has been described by Weber in 
1974. This causes a severe form of low-renin, low-aldosterone hypertension as a result of a 
mutation in the HSD11B2 gene, causing  11ß-HSD type 2 deficiency(Ferrari and Krozowski 
2000). The pathophysiology of this syndrome has been well described (Ferrari and Krozowski 
2000).  
Cortisol circulates at a 100- to 1000-fold higher level than aldosterone. Both cortisol 
and aldosterone compete for the mineralocorticoid receptor. The role of the 11ß-HSD type II 
in the kidney is to selectively convert cortisol to inactive cortisone so that aldosterone can 




activity is saturated at such high levels of cortisol, then cortisol will exert a mineralocorticoid 
effect resulting in fluid retention (retention of Na+ and excretion of K+) in the absence of raised 
renin. The syndrome could be reversed by treatment with MR antagonist – spironolactone. 
This has enormous implications for clinical practice because it was always thought that the 
fluid retention, we encounter in the postoperative patient is related to an activation of the renin-
angiotensin system. It is well known that fluid retention after paediatric heart surgery with the 
use of CPB is associated with worse outcomes (Hassinger, Wald, and Goodman 2014; Jonas et 
al. 2003). 
 
Figure 102 Effect of the 11ß-HSD type 2 in the kidney 
 
 
11.6.14.5 Patterns of cortisol and cortisone release depending on the age of the patient, 
type of surgery and type of congenital heart defect 
 
The patterns of cortisol and cortisone release were different in neonates (Figure 89) 
compared to older children in that neonates had higher ratios of cortisol to cortisone. This 
finding suggests a higher ability of neonates to convert cortisol to cortisone. The mechanism 
can be explained, as outlined in the previous section, either by increased activity of the (1) 11ß-
HSD-2 enzymes, or (2) reduced activity of 11ß-HSD-1 or both. Several mechanisms can be 
responsible for these changes in the new-born (Figure 103). Not only the placenta is rich is in 




cortisone (Cottrell et al. 2014) but fetal tissues are also rich in 11ß-HSD 2 enzyme (Chapman, 
Holmes, and Seckl 2013). Another contributing mechanism is that the activity of the 11ß-HSD 
1 is switched on later in the life of the baby and after birth there is not much activity of the 
enzyme (Speirs, Seckl, and Brown 2004) This is contained mainly in the liver and due to its 
high organ mass could be mainly responsible for the increased conversion to cortisol later in 
life. Finally, we did not have enough data show that a distinct cytokine response in neonates 
compared to older children (please see Cytokine discussion section). However, several studies 
have shown that the activity of type 1 11ß-HSD is enhanced by inflammatory cytokines such 




Figure 103 11ß-HSD 1 and 2 in the fetus 
 
11.6.14.6 ACTH and serum cortisol data 
 
Another aspect that is worth discussing is the correlation of the ACTH and cortisol 




we have measured ACTH and serum cortisol at only a few reference time-points. However, 
some profiles display no apparent correlation between plasma and tissue cortisol levels 
(Section 11.6.13: P9, P10, P16, P19, P23, P24, P26). If we look at the plasma ACTH and serum 
and tissue cortisol, the data is similar to Gibbison et al. (Ben Gibbison et al. 2015) studies 
where after the initial ACTH increase, the cortisol remains elevated while the ACTH  levels 
are reduced. This possibly suggests an increased sensitivity of the adrenal gland to ACTH in 
children as seen in adults. This is reflected in the analysis of the ACTH to cortisol ratio, where 
we found the ratio to be significantly increased at CPB compared to pre-surgery and 
significantly decreased to pre-surgery levels up to 24 hours.  
 
11.6.14.7 Plasma CBG concentrations 
 
In the overall analysis, the CBG levels dropped significantly postoperatively (at 6 and 
24 hours) compared to levels measured at induction (Figure 96). This finding is similar to 
previous studies in adults (Ben Gibbison et al. 2015; Roth-Isigkeit, Dibbelt, and Schmucker 
2000) and children (Mcmaster et al. 2010) and most likely the cause is haemodilution (Roth-
Isigkeit, Dibbelt, and Schmucker 2000). However, in the context of major surgery, this could 
also be due to variation in temperature, neutrophil count or pH  (Cameron et al. 2010; D.E. 
Henley and Lightman 2011; Hammond et al. 1990). Due to the finite ability of CBG to bind 
cortisol in plasma (Ballard 1979) and in the context of a pulsatile secretion, this results in vast 
swings of free, available, cortisol that can act on the GR receptor. However, one interesting 
finding is the influence of age on CBG concentrations of patients having surgery. Neonates 
displayed significantly lower levels of CBG compared to older, at all-time points. We noted 
further age-related differences, with a trend towards lower CBG levels the younger the age 




received more intravenous fluid or this could be an age-specific response. Moreover, in the 
analysis by cyanotic versus acyanotic heart disease, the CBG levels were significantly lower 
in the cyanotic patients at 6- and 24-hour time points compared to the acyanotic patients (Figure 
98). In the study by Wald et al. (Wald et al. 2011b), the authors noted the significant variation 
of CBG levels across a cohort of 51 patients with ages ranging from 0.4 to 6.5 years and this 
could have been the effect of the age and the underlying congenital heart defect.  
 
11.6.14.8 Characterisation of the inflammatory response  
 
The paediatric inflammatory response to CPB has been studied more than the adrenal 
response. However, as stated before, its relation to clinical outcomes is unclear (D. Fudulu, 
Lightman, et al. 2018; D. P. Fudulu, Gibbison, et al. 2018). Furthermore, the relation of the 
cytokine response to HPA axis function during and after paediatric heart surgery is not well 
understood. This will be a direction of the analysis once recruitment has finalised. On the 
preliminary analysis of the cytokine by age and underlying congenital disability, we noted 
significant changes in IL-10, IL-6, IL-8 and TNFα levels and this in keeping with previous 
studies (Madhok et al. 2006; Alcaraz et al. 2002; 2005). We noted a significant increase of the 
IL-10 immediately post CPB in age groups 30 days-1-year-old children and 1-5 years old 
children. This increase was the most significant in the 1-5 years old group. In this preliminary 
analysis, we excluded the neonate for whom we had cytokine data; hence, it is difficult to draw 
any comparisons with other age groups.  
A limitation of the study is not measuring cytokines in neonates at the post-CPB 
timepoint, where we noted most changes IL-10 to occur. However, Alcaraz et al. (Alcaraz et 
al. 2002) showed that this immediate increase is more profound in neonates that secrete more 




is to temper the inflammatory response post-by-pass. Interestingly, in the analysis by oxygen 
saturation, the IL-10 was significantly more increased post-bypass in the cyanotic children 
compared to the acyanotic children. Hövels-Gürich et al. (Hövels-Gürich et al. 2002) found 
that the levels Il-10 were lower pre-operatively in infants with hypoxemia owing to intracardiac 
right-to-left shunt compared to infants with heart failure because of an intracardiac left-to-right 
shunt. We found no difference at baseline in our study. The maximal rise of IL-10 occurred 
post-CPB immediately in our study, and this was similar to the above study where the maximal 
rise was at the protamine administration (i.e. termination of CPB) time-point. All in all, these 
findings suggest that IL-10 is rapidly secreted post-CPB to attenuate the inflammatory 
response. This is more pronounced in the most vulnerable groups: younger children and 
cyanotic patients. We found no significant changes in IL-1β, which were similar to previous 
studies (Madhok et al. 2006). There is not much literature investigating the effect on the pro-
inflammatory cytokine IL-4. However, we noted an effect of age of the child with a trend 
towards higher levels in older children and lower levels in the cyanotic patients compared to 
acyanotic. We also noted that the pro-inflammatory cytokine levels for IL-6 and IL-8 started 
to rise post CPB, with a peak for IL-6 at 12 hours and at 6 hours for IL-8. This suggests that 
the pro-inflammatory cytokine IL-10 rises immediately after by-pass and then returns to 
baseline while the pro-inflammatory cytokine response is more delayed and kicks in several 
hours after surgery. We found no effect on age on IL-6 and IL-8 however, both cytokines were 
significantly more elevated in the cyanotic patients. Alcaraz et al. found the same peak of IL-
6 and IL-8 to occur immediately post-CPB (Alcaraz et al. 2005). In addition, neonates had a 
distinctive response in that they secreted higher levels of IL-8 compared to older children. In 
the same study, IL-8 levels were significantly correlated with postoperative morbidity 
(pulmonary dysfunction, days on inotropic support and days of PICU stay). Moderate increases 




1997; Alcaraz et al. 2005) with a higher response in the neonates (Alcaraz et al. 2005). Again, 
we included in the preliminary analysis only one neonate; however, we noted a strong effect 
of age on the pattern of TNFα release in that younger children (infants and 1-5 years old) 
produced higher levels than teenagers. 
  
Finally, we have to acknowledge several limitations in the evaluation of the cytokine response. 
Firstly, it will always be challenging to discern the magnitude of the effect of surgery on the 
individual cytokine release from an age-specific response. Secondly, some of the children had 
modified ultrafiltration at the end of CPB; hence, this is known to affect the levels of specific 
cytokines (mainly TNFα) (Brancaccio et al. 2005).  
Interleukin 1, TNFα and IL-6 are known to activate the HPA axis  (Turnbull and Rivier 
1995). On our preliminary data, IL-1β had no significant changes, and the increases in TNFα 
were modest and non-significant compared to pre-op levels. However, we noted significant 
increases in IL-6 at post CPB at 6, 12 and 24 hours from the start of the operation. As discussed 
in the previous chapters, IL-6 is known to be a potent activator of the HPA axis (Bethin, Vogt, 
and Muglia 2000) This coincides with the cortisol peaks that we noted to occur within several 
hours after the end of surgery. This fits with previous hypotheses that suggest a delayed HPA 
axis activation mediated by cytokines (B Gibbison et al. 2015), but we were unable to 










11.6.15 Considerations on microdialysis cortisol profiles of glucocorticoid recipients. 
 
Two patients received glucocorticoids during microdialysis sampling and were 
withdrawn (Figure 80, Figure 81, Figure 82). One patient was a 4 years old boy that had 
bidirectional Glenn shunt and double aortic arch division (P 37) and received dexamethasone 
(0.25mg/kg, IV) to prevent airway oedema post-extubation because of pre-operative bilateral 
vocal cord palsy (Figure 80). The other child was a 3-week-old boy (P38) that underwent 
arterial switch procedure and atrial septal defect closure for transposition of great arteries. He 
had hydrocortisone (2 mg/kg, IV) for low cardiac output syndrome and increased vasopressor 
requirement.  Pre glucocorticoid administration, there was no suppression of the tissue cortisol 
response to surgery in both patients. The dexamethasone recipient displayed suppression of the 
ACTH level post dexamethasone administration with a remarkable lack or delay of suppression 
of cortisol, suggesting autonomous activation of cortisol release. (Figure 80). The 
hydrocortisone recipient had a steep, supraphysiological increase of the tissue cortisol levels 
(peak level of 1839 from a basal level of 1.08) and suppressed ACTH levels (Figure 81 and 
Figure 82) . This patient is currently alive; however, he had a ventilation time of 6 days and a 
long admission of approximately 1 month. The postoperative recovery was complicated by 
acute kidney injury for which he required peritoneal dialysis in PICU. The time of 
administration (on the prescription) correlated very well with the time we recorded the tissue 
cortisol increase from the start of the device. This demonstrates again good correlation of 







11.6.16 Conclusions  
 
The preliminary data from the Peacock Study firstly demonstrates that automated tissue 
microdialysis sampling method was feasible to measure cortisol in children of various ages. 
We have shown that tissue cortisol levels display a pulsatile pattern throughout the 
perioperative period. This confirms the inappropriateness of single point cortisol tests. 
Neonates were a distinct group by the pattern for cortisol to cortisone release. The data suggests 
that they have a higher ability to convert cortisol to cortisone. Probably, this reflects a higher 
activity of the 11- HSD type 2 enzyme and/or immaturity of the 11β-HSD type 1. As expected, 
we found patients undergoing heart surgery had higher levels of cortisol compared to catheter 
patients with lower cortisol to cortisone ratios suggesting substrate overload of 11- HSD type 
2 enzyme. There was no significant effect of cyanosis on cortisol secretion. 
Similar to adult studies, the serum ACTH and cortisol levels suggest an increased 
adrenal sensitivity to ACTH. Overall, the CBG levels were reduced perioperatively in line with 
previous studies in adult and children. However, we found variations in CBG concentration by 
age and type of defect (cyanotic/acyanotic). Younger children and cyanotic patients had lower 
levels of CBG, suggesting a higher availability of free cortisol in these patient groups. We 
found age-related and cyanosis related changes in cytokine secretion patterns during and after 
surgery.   
 
11.6.17 Suggestions for future work 
 
The short-term objectives are to finalise recruitment in the Peacock study. To date, there 
are nine more surgical patients (10-16 years group) 18 more catheter patients (mostly 30 years-




A more in-depth analysis of all the data is needed. A possible approach is to use 
machine learning techniques to deal with this amount of data. If the time-series data is aligned 
in a meaningful way, this can allow identifying repeated features and potential anomalies. 
These can be further classified using clustering and decision tree analysis. Ideally, the model 
would integrate the dynamic microdialysis data with all the serum measurements (serum 
ACTH, cortisol, cytokines) and the clinical outcome data to predict how children of various 
age groups would respond to surgery.  
A more long-term objective would be to understand the 11β-HSD enzyme interplay 
responsible for the cortisol to cortisone ratio increase, and this would ideally involve 
measurement of type 1 and type 2 enzyme 11β -HSD enzyme activity in children, particularly 
in neonates or in an animal translation model (pig). This could be investigated by measuring 
plasma cortisol and cortisone concentration, urinary cortisol, cortisone and specific metabolites 
















12 OVERALL DISSCUSSION, CONCLUSIONS AND LIMITATIONS  
 
12.1 Overall discussion  
To understand the HPA axis response of children of various ages, I have used the stress 
model of paediatric heart surgery. The results of my thesis highlight how complex the 
paediatric HPA axis regulation is during acute stress and how little we know about this subject. 
Children display an endogenous cortisol response proportional to the stress insult. Paediatric 
cardiac surgery with the use of CPB resulted in a more profound cortisol release compared to 
the lower invasive catheter procedures. The cortisol patterns were pulsatile, and this suggests 
that single point cortisol tests are not accurate in defining perioperative adrenal dysfunction. In 
the context of acute stress, the adrenal regulation is not only modulated by pituitary inputs. As 
shown in my in vitro work, the immune cells exert a local control and can change the activity 
of the steroidogenic pathway. These local mechanisms are likely complementing the HPA axis 
activation during stress. Furthermore, this local interaction can be directly modulated by the 
effect of glucocorticoids.  
My data shows significant postoperative changes in CBG concentration. This can further 
have profound changes in the availability of free plasma cortisol during the stress response to 
surgery.  
The changes in the cortisol to cortisone ratios we have noted are likely the effect of a 
change in the 11-β-HSD enzyme system activity. This finding highlights that the availability 
of cortisol during stress is also regulated to a great extent at the tissue level. This regulation 
appears to be age and procedure-related. Neonates are a distinct physiological group because 
of a higher conversion of cortisol to cortisone. Furthermore, the cytokine response patterns are 




anti-inflammatory steroids are indicated in children undergoing heart surgery, a “one-size-fits-
all” approach is likely not to be useful. 
  
12.2 Overall conclusions  
 
I demonstrate that our basic understanding of the physiology of the hypothalamic-
pituitary-adrenal axis of children undergoing paediatric heart surgery is very limited. 
Therefore, by using an automated tissue microdialysis system in children, I show that cortisol 
is released in a pulsatile manner during and after surgery. Furthermore, I found a change in 
tissue cortisol metabolism, suggesting an involvement of the 11 β-hydroxysteroid 
dehydrogenases.  The cortisol release was also accompanied by an early systemic release of 
anti-inflammatory cytokines and a more delayed release of proinflammatory cytokines. By 
using a novel co-culture model, I also demonstrate how a local adrenal crosstalk between the 
immune and adrenal cells can modulate the expression of adrenal cytokines and the activity of 
the steroidogenic pathway during acute stress.   
 
12.3 Limitations  
 
My PhD thesis has several limitations I would like to acknowledge in this section.  
With regards to the in vitro work, the cell lines used originated from adult rats and 
human adults, respectively. Hence, we could not study the changes in immune-adrenal 
interactions according to the age of the cells. Another limitation of using this in vitro model is 
that we do not understand to what extent these observations apply to the in-vivo immune-




Concerning the Peacock Study, the main technical disadvantages of the system are (1) 
the fragility of the microdialysis tubing (2) the microdialysis pump that occasionally 
malfunctions and (3) the long learning curve. All of these can be overcome by an improved 
design and DesignWorks Ltd (the current manufacturers) are currently working on a new 
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